AMINOQUINOLINE COMPOUNDS AND THEIR APPLICATIONS

Abstract

Provided herein are compounds of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, wherein R1, R2, Ring A, L, R6, R7, R8, R9, and R10 are as defined elsewhere herein. Also provided are methods of preparing compounds of formula (I). Also provided herein are methods of modulating TDP-43 and methods of treating a disease or condition mediated by TDP-43 in an individual in need thereof.

Description

[0001] Attorney Docket No.: 185992002240 AMINO QUINOLINE COMPOUNDS AND USES THEREOFCROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority benefit of United States Provisional PatentApplication No. 63 / 618,189 filed January 5, 2024, which is hereby incorporated herein byreference in its entirety.FIELD OF THE INVENTION Aspects of the invention generally relate to amino quinoline compounds, pharmaceutical compositions, kits comprising the same, their use as biomolecular condensate modifying drugs (c-mods), and their use in the treatment of a disease or condition. BACKGROUND OF THE INVENTION TAR DNA-binding protein 43 (TDP-43) is a highly conserved and ubiquitously- expressed RNA / DNA-binding protein involved in RNA processing. Cytoplasmic aggregates of TDP-43 occur in >97% of amyotrophic lateral sclerosis (ALS) cases. Stress-induced formation of cytoplasmic TDP-43 biological condensates represent an intermediate, reversible, pre-pathological state in neurons. Over time, TDP-43-containing condensates losetheir fluid-like properties and potentially convert into irreversible, toxic aggregates [Ling, etal., Neuron 79, 416–438 (2013); Markmiller, et al. Cell Reports 36, 109685 (2021); and Lu etal. Nat Cell Biol 1–16 (2022)].The role of condensate dysfunction in ALS pathogenesis is supported by thediscovery of condensate genes as genetic modifiers of ALS (e.g., TAF15, EWSR1, TIA1,HNRNPA1, HNRNPA2B1), as well as co-localization of C9ORF72 ALS G4C2expansion- derived dipeptide repeats (DPRs) and stress granule proteins with TDP-43 inclusions in preclinical models. Nuclear depletion of TDP-43 into cytoplasmic condensates leads to toxic loss of splicing function in motor neurons. Small molecule condensate modifying drugs (c-mods) that directly modulate TDP-43 condensates can treat diverse forms of ALS. [Chew, J.et al., Mol. Neurodegener. 14, 9 (2019); and Taylor, J. P., et al., Nature 539, 197–206(2016)]. Attorney Docket No.: 185992002240 BRIEF SUMMARY OF THE INVENTION In one aspect, provided herein is a compound of formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, orsolvate of any of the foregoing, whereinR1and R2are each independently C1-6alkyl, C2-6alkenyl, -C(=O)R14, -C(=O)OR14, - C(=O)N(R13)(R14), -S(=O)2R14, -S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 12-memberedheterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl whereinthe C1-6alkyl of R1 or R2 is optionally substituted with one or more R1a,the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to10-membered heteroaryl of R1 or R2 is optionally substituted with one or more R1b,and optionally, two substituents of the C1-6alkyl, C2-6alkenyl, -C(=O)R14, -C(=O)OR14, -C(=O)N(R13)(R14), -S(=O)2R14, -S(=O)2N(R13)(R14), or C3-8cycloalkyl group of R1or R2are taken together with the atoms to which they are attached to form a C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl,or 5- to 10-membered heteroaryl is optionally substituted with one or moreR1b;or R1 and R2 are taken together with the N to which they are attached to form a 3- to 12-membered heterocyclyl, wherein the 3- to 12-membered heterocyclyl or 5- to 10-membered heteroaryl of R1 and R2 isoptionally substituted with one or more R3; each R3is independently halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, oxo, -OR12, -SR12, -SF5, -N(Rx)(Ry), -NO2, -CN, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, - OC(=O)R14, -OC(=O)N(R13)R14, -OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), -C(=O)OR14, -C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, - Attorney Docket No.: 185992002240 N(R13)S(=O)2R14, -S(=O)R14, -S(=O)N(R13)R14, -S(=O)OR14, -S(=NR15)R14, - S(=NR15)N(R13)R14, -S(=NR15)OR14, -S(=O)2R14, -S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C1-6alkyl of R3is optionally substituted with one or more R3a, and optionally, two substituents of R3are taken together with the atoms to which they are attached form a C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10- membered aryl, or 5- to 10-membered heteroaryl is optionally substituted one or more R3b; Ring A is 4- to 12-membered cycloalkenyl, 4- to 12-membered unsaturated heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the 4- to 12-membered cycloalkenyl, 4- to 12-membered unsaturated heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of Ring A is optionally substituted by one or more R4, and the 4- to 12-membered unsaturated heterocyclyl or 5- to 10-membered heteroaryl of Ring A comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S; each R4is independently halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, -OR12, -SR12, -SF5, - N(Rx)(Ry), -NO2, -CN, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, - OC(=O)R14, -OC(=O)N(R13)R14, -OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), - C(=O)OR14, -C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, - N(R13)S(=O)2R14, -S(=O)R14, -S(=O)N(R13)R14, -S(=O)OR14, -S(=NR15)R14, - S(=NR15)N(R13)R14, -S(=NR15)OR14, -S(=O)2R14, -S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C1-6alkyl of R4is optionally substituted by one or more R4a, the C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of R4is optionally substituted with one or more R4b, and the 3- to 8-membered heterocyclyl of R4comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S; L is a bond, C1-6alkyl, -O-(C1-6alkyl)-, -S-(C1-6alkyl)-, or -N(R5)(C1-6alkyl)-, wherein the C1-6alkyl, -O-(C1-6alkyl)-, -S-(C1-6alkyl)-, or -N(R5)(C1-6alkyl)- is optionally substituted by one or more RL; each RLis independently halo, -N(Rx)(Ry), -OR12, -SR12, -SF5, -NO2, -CN, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, -OC(=O)R14, -OC(=O)N(R13)R14, - Attorney Docket No.: 185992002240 OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), -C(=O)OR14, C3-8cycloalkyl, 3- to 8- membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, or two RLare taken together along with the atoms to which they are attached to form a C3-8cycloalkyl or 3- to 8-membered heterocyclyl; R5is H, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, -C(=O)R14, -S(=O)2R14, -S(=O)2N(R13)(R14), or C3-8cycloalkyl, wherein the C1-6alkyl of R5is optionally substituted with one or more halo, -N(Rx)(Ry), -OR12, -SR12, -SF5, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, - OC(=O)R14, -OC(=O)N(R13)R14, -OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), - C(=O)OR14, -C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, - N(R13)S(=O)2R14, -S(=O)R14, -S(=O)N(R13)R14, -S(=O)OR14, -S(=NR15)R14, - S(=NR15)N(R13)R14, -S(=NR15)OR14, -S(=O)2R14, or -S(=O)2N(R13)(R14), and the C3-8cycloalkyl is optionally substituted with one or more R5b; R6is H, halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, -OR12, -O-(3- to 12-membered N- containing heterocyclyl), -O-(5- to 6-membered N-containing heteroaryl), -SR12, -SF5, - N(Rx)(Ry), -NO2, -CN, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, - OC(=O)R14, -OC(=O)N(R13)R14, -OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), - C(=O)OR14, -C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, - N(R13)S(=O)2R14, -S(=O)R14, -S(=O)N(R13)R14, -S(=O)OR14, -S(=NR15)R14, - S(=NR15)N(R13)R14, -S(=NR15)OR14, -S(=O)2R14, -S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C1-6alkyl of R6is optionally substituted by one or more R6a, the C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, 5- to 10- membered heteroaryl, -O-(3- to 12-membered N-containing heterocyclyl), or -O-(5- to 6-membered N-containing heteroaryl) of R6is optionally substituted with one or more R6b, -C(=O)R14, -C(=O)N(R13)(R14), or -C(=O)OR14, and the 3- to 8-membered heterocyclyl of R6comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S, and optionally, two substituents of R6are taken together with the atoms to which they are attached form a C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R6b; Attorney Docket No.: 185992002240 R7, R8, R9, and R10are each independently H, halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, - OR11, -OR12, -SR12, -SF5, -N(Rx)(Ry), -NO2, -CN, -N(R13)C(=O)R14, - N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, -OC(=O)R14, -OC(=O)N(R13)R14, - OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), -C(=O)OR14, -C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, -N(R13)S(=O)2R14, -S(=O)R14, -S(=O)N(R13)R14, - S(=O)OR14, -S(=NR15)R14, -S(=NR15)N(R13)R14, -S(=NR15)OR14, -S(=O)2R14, - S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C1-6alkyl of R7, R8, R9, or R10is optionally substituted by one or more R7a, the 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of R7, R8, R9, or R10is optionally substituted with one or more R7b, and the 3- to 8-membered heterocyclyl of R7, R8, R9, or R10comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S, and optionally, two substituents of R7, R8, R9, or R10are taken together with the atoms to which they are attached form a C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R7b; each R1a, R3a, R4a, R6a, or R7ais independently halo, -N(Rx)(Ry), -OR12, -SR12, -SF5, -NO2, - CN, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, -OC(=O)R14, - OC(=O)N(R13)R14, -OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), -C(=O)OR14, - C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, -N(R13)S(=O)2R14, - S(=O)R14, -S(=O)2R14, -S(=O)N(R13)R14, -S(=O)OR14, -S(=NR15)R14, -S(=NR15)N(R13)R14, - S(=NR15)OR14, -S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10- membered aryl, or 5- to 10-membered heteroaryl, wherein the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of R1a, R3a, R4a, R6a, or R7ais optionally substituted with one or more R1b, and the 3- to 12-membered heterocyclyl of R1a, R3a, R4a, R6a, or R7acomprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S; each R1b, R3b, R4b, R5b, R6b, or R7bis independently halo, C1-6alkyl, -OR11, -N(Rx)(Ry), oxo, - CN, C3-8cycloalkyl, or 3- to 8-membered heterocyclyl, wherein Attorney Docket No.: 185992002240 the C1-6alkyl of R1b, R3b, R4b, R5b, R6b, or R7bis optionally substituted by -OR12, - N(Rx)(Ry), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl; each R11is independently H, C1-6alkyl, C2-6alkenyl, C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C1-6alkyl of R11is optionally substituted with 6- to 10-membered aryl, or 5- to 10- membered heteroaryl, wherein the 6- to 10-membered aryl, or 5- to 10-membered heteroaryl is optionally substituted with halo, C1-3alkyl, C1-3alkoxy, or -N(Rx)(Ry), and the 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of R11is optionally substituted with halo, C1-3alkyl, C1-3alkoxy, -N(Rx)(Ry), or 3- to 12-membered heterocyclyl; each R12is independently H, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, 3- to 8- membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C1-6alkyl of R12is optionally substituted with one or more halo, deuterium, C1-6alkoxy, -N(Rx)(Ry), or 3- to 8-membered heterocyclyl; each R13is independently H, C1-6alkyl, or C3-8cycloalkyl; each R14is independently H, C1-6alkyl, C2-6alkenyl, C3-8cycloalkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, or 3- to 12-membered heterocyclyl, wherein the C1-6alkyl of R14is optionally substituted by one or more halo, -OH, -O(C1-6alkyl), -SH, -S(C1-6alkyl), -(C=O)NH2, -(C=O)OH, -O(C=O)C1-8alkyl), -NH(C=NH)NH2, - N(Rx)(Ry), C3-8cycloalkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, or 3- to 12-membered heterocyclyl, wherein the 6- to 10-membered aryl is optionally substituted by -OH, and the C3-8cycloalkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, or 3- to 12-membered heterocyclyl of R14is optionally substituted with halo, C1-6alkyl, -OH, or -N(Rx)(Ry); each R15is independently H or C1-6alkyl; and each Rxand Ryis independently H, C1-6alkyl, C3-8cycloalkyl, -C(=O)(C1-6alkyl), or - C(=O)O(C1-6alkyl), wherein the C1-6alkyl of Rxor Ryis optionally substituted with halo, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -NH2, NH(C1-6alkyl), or -N(C1-6alkyl)(C1-6alkyl), and the C1-6alkyl of -C(=O)(C1-6alkyl) or -C(=O)O(C1-6alkyl) is optionally substituted with -O(C=O)C1-8alkyl). Attorney Docket No.: 185992002240 In some embodiments, the compound of formula (I) is a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Any embodiments provided herein of a compound of formula (I), or a stereoisomer ortautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate of any of theforegoing, apply where applicable to any other formula detailed herein, the same as if each and every embodiment were specifically and individually listed. Thus, it is understood and described that each embodiment provided herein of a compound of formula (I), or astereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate ofany of the foregoing, such as embodiments related to R1, R2, R3, Ring A, R4, L, R5, R6, R7,R8, R9, R10, R1a, R3a, R6a, R7a, R1b, R3b, R4b, R5b, R6b, R7b, R11, R12, R13, R14, R15, Rx, and Ry,apply to formula (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B),(IV), or (IV-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt,hydrate, or solvate of any of the foregoing, the same as if each and every embodiment werespecifically and individually listed. It is also understood and described that all such embodiments may be used in any of the pharmaceutical compositions, methods, kits, uses, orother aspects detailed herein.In one aspect, provided is a pharmaceutical composition comprising a compound offormula (I) or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, ora pharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, and one ormore pharmaceutically acceptable excipients. This aspect in some embodiments may employa compound of any of formulas (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or a stereoisomer or tautomer thereof, or a pharmaceuticallyacceptable salt, hydrate, or solvate of any of the foregoing. In another variation, provided is apharmaceutical composition comprising a compound of formula (I) or any variation orembodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptablesalt of any of the foregoing, and one or more pharmaceutically acceptable excipients. Thisaspect in some embodiments may employ a compound of any of formulas (II), (II-A), (II-B),(II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or a stereoisomer ortautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In one aspect, provided is a method for treating a disease or condition mediated byTDP-43, comprising administering to an individual in need thereof a compound of formula(I) or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or apharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, or a Attorney Docket No.: 185992002240pharmaceutical composition comprising a compound of formula (I) or any variation orembodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptablesalt, hydrate, or solvate of any of the foregoing, and one or more pharmaceutically acceptableexcipients. This aspect in some embodiments may employ a compound of any of formulas(II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or astereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate ofany of the foregoing. In another variation, provided is a method for treating a disease orcondition mediated by TDP-43, comprising administering to an individual in need thereof acompound of formula (I) or any variation or embodiment thereof, or a stereoisomer ortautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate of any of theforegoing, or a pharmaceutical composition comprising a compound of formula (I) or anyvariation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptableexcipients. This aspect in some embodiments may employ a compound of any of formulas(II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or astereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In one aspect, provided herein is a method of modulating TDP-43, comprisingcontacting a cell with an effective amount of a compound of formula (I), or a stereoisomer ortautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate of any of theforegoing. This aspect in some embodiments may employ a compound of any of formulas(II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or astereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate ofany of the foregoing. In another variation, provided herein is a method of modulating TDP-43, comprising contacting a cell with an effective amount of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of theforegoing. This aspect in some embodiments may employ a compound of any of formulas(II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or astereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In one aspect, provided herein is a method of modulating TDP-43 target geneexpression levels, comprising contacting a cell with an effective amount of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt,hydrate, or solvate of any of the foregoing. This aspect in some embodiments may employ a Attorney Docket No.: 185992002240compound of any of formulas (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or a stereoisomer or tautomer thereof, or a pharmaceuticallyacceptable salt, hydrate, or solvate of any of the foregoing. In another variation, providedherein is a method of modulating TDP-43 target gene expression levels, comprisingcontacting a cell with an effective amount of a compound of formula (I), or a stereoisomer ortautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. This aspect insome embodiments may employ a compound of any of formulas (II), (II-A), (II-B), (II-C),(II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or a stereoisomer or tautomerthereof, or a pharmaceutically acceptable salt of any of the foregoing. In one aspect, provided herein is a compound of formula (I), or a stereoisomer ortautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate of any of theforegoing, or a pharmaceutical composition comprising a compound of formula (I) or anyvariation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceuticallyacceptable salt, hydrate, or solvate of any of the foregoing, and one or more pharmaceuticallyacceptable excipients, for use in the treatment of a disease or condition mediated by TDP-43.This aspect in some embodiments may employ a compound of any of formulas (II), (II-A),(II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or astereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate ofany of the foregoing. In another variation, provided herein is a compound of formula (I), or astereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of theforegoing, or a pharmaceutical composition comprising a compound of formula (I) or anyvariation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, and one or more pharmaceutically acceptable excipients, for use in the treatment of a disease or condition mediated by TDP-43.This aspect in some embodiments may employ a compound of any of formulas (II), (II-A),(II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or astereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In one aspect, provided herein is the use of a compound of formula (I), or astereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate ofany of the foregoing, or a pharmaceutical composition comprising a compound of formula (I) or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or apharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, and one or morepharmaceutically acceptable excipients, in the manufacture a medicament for the treatment of Attorney Docket No.: 185992002240a disease or condition mediated by TDP-43. This aspect in some embodiments may employ acompound of any of formulas (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or a stereoisomer or tautomer thereof, or a pharmaceuticallyacceptable salt, hydrate, or solvate of any of the foregoing. In another variation, providedherein is the use of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical compositioncomprising a compound of formula (I) or any variation or embodiment thereof, or astereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, and one or more pharmaceutically acceptable excipients, in themanufacture a medicament for the treatment of a disease or condition mediated by TDP-43.This aspect in some embodiments may employ a compound of any of formulas (II), (II-A),(II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or astereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In one aspect, provided herein is a kit, comprising (i) a compound of formula (I), or astereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate ofany of the foregoing, and (ii) instructions for use in treating a TDP-43 mediated disease orcondition in an individual in need thereof. This aspect in some embodiments may employ acompound of any of formulas (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or a stereoisomer or tautomer thereof, or a pharmaceuticallyacceptable salt, hydrate, or solvate of any of the foregoing. In another variation, providedherein is a kit, comprising (i) a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) instructions foruse in treating a TDP-43 mediated disease or condition in an individual in need thereof. Thisaspect in some embodiments may employ a compound of any of formulas (II), (II-A), (II-B),(II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or a stereoisomer ortautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. All pharmaceutical compositions, methods, kits, uses, or other aspects described herein with reference to formula (I), or stereoisomer or tautomer thereof, or apharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, are also herebydescribed and embraced for any one of the other formulas detailed herein such as formula(II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), thesame as if each and every embodiment were specifically and individually listed. Attorney Docket No.: 185992002240 DETAILED DESCRIPTION OF THE INVENTION “Individual” refers to mammals and includes humans and non-human mammals. Examples of individuals include, but are not limited to, mice, rats, hamsters, guinea pigs, pigs, rabbits, cats, dogs, goats, sheep, cows, and humans. In some embodiments, individual refers to a human. As used herein, “about” a parameter or value includes and describes that parameter or value per se. For example, “about X” includes and describes X per se. “Treatment” or “treating” is an approach for obtaining beneficial or desired results including clinical results. Beneficial or desired results may include one or more of the following: decreasing one or more symptom resulting from the disease or condition; diminishing the extent of the disease or condition; slowing or arresting the development of one or more symptom associated with the disease or condition (e.g., stabilizing the disease or condition, preventing or delaying the worsening or progression of the disease or condition); and relieving the disease, such as by causing the regression of clinical symptoms (e.g., ameliorating the disease state, enhancing the effect of another medication, delaying the progression of the disease, increasing the quality of life, and / or prolonging survival). As used herein, “delaying” development of a disease or condition means to defer, hinder, slow, retard, stabilize and / or postpone development of the disease or condition. Thisdelay can be of varying lengths of time, depending on the history of the disease and / orindividual being treated. As is evident to one skilled in the art, a sufficient or significant delay can, in effect, encompass prevention, in that the individual does not develop the disease or condition. As used herein, the term “therapeutically effective amount” or “effective amount” intends such amount of a compound of the disclosure or a pharmaceutically salt thereof sufficient to effect treatment when administered to an individual. As is understood in the art, an effective amount may be in one or more doses, e.g., a single dose or multiple doses may be required to achieve the desired treatment endpoint. An effective amount may be considered in the context of administering one or more therapeutic agents, and a single agent may be considered to be given in an effective amount if, in conjunction with one or more other agents, a desirable or beneficial result may be or is achieved. As used herein, “unit dosage form” refers to physically discrete units, suitable as unit dosages, each unit containing a predetermined quantity of active ingredient, or compound, which may be in a pharmaceutically acceptable carrier. Attorney Docket No.: 185992002240 As used herein, by “pharmaceutically acceptable” is meant a material that is not biologically or otherwise undesirable, e.g., the material may be incorporated into a pharmaceutical composition administered to an individual without causing significant undesirable biological effects. The term “alkyl”, as used herein, refers to an unbranched or branched saturated univalent hydrocarbon chain. As used herein, alkyl has 1-20 carbons (i.e., C1-20alkyl), 1-16 carbons (i.e., C1-16alkyl), 1-12 carbons (i.e., C1-12alkyl), 1-10 carbons (i.e., C1-10alkyl), 1-8 carbons (i.e., C1-8alkyl), 1-6 carbons (i.e., C1-6alkyl), 1-4 carbons (i.e., C1-4alkyl), or 1-3 carbons (i.e., C1-3alkyl). Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, pentyl, 2-pentyl, iso-pentyl, neo-pentyl, hexyl, 2-hexyl, 3-hexyl, and 3-methylpentyl. When an alkyl residue having a specific number of carbons is named by chemical name or molecular formula, all positional isomers having that number of carbon atoms may be encompassed—for example, “butyl” includes n-butyl, sec-butyl, iso-butyl, and tert-butyl; and “propyl” includes n-propyl and iso- propyl. Certain commonly used alternative names may be used and will be understood by those of ordinary skill in the art. For instance, a divalent group, such as a divalent “alkyl” group, may be referred to as an “alkylene”. The term “alkenyl”, as used herein, refers to a branched or unbranched univalent hydrocarbon chain comprising at least one carbon-carbon double bond. As used herein, alkenyl has 2-20 carbons (i.e., C2-20alkenyl), 2-16 carbons (i.e., C2-16alkenyl), 2-12 carbons (i.e., C2-12alkenyl), 2-10 carbons (i.e., C2-10alkenyl), 2-8 carbons (i.e., C2-8alkenyl), 2-6 carbons (i.e., C2-6alkenyl), 2-4 carbons (i.e., C2-4alkenyl), or 2-3 carbons (i.e., C2-3alkenyl). Examples of alkenyl include, but are not limited to, ethenyl, prop-1-enyl, prop-2-enyl 1,2- butadienyl, and 1,3-butadienyl. When an alkenyl residue having a specific number of carbons is named by chemical name or molecular formula, all positional isomers having that number of carbon atoms may be encompassed—for example, “propenyl” includes prop-1- enyl and prop-2-enyl. Certain commonly used alternative names may be used and will be understood by those of ordinary skill in the art. For instance, a divalent group, such as a divalent “alkenyl” group, may be referred to as an “alkenylene”. The term “alkynyl”, as used herein, refers to a branched or unbranched univalent hydrocarbon chain comprising at least one carbon-carbon triple bond. As used herein, alkynyl has 2-20 carbons (i.e., C2-20alkynyl), 2-16 carbons (i.e., C2-16alkynyl), 2-12 carbons (i.e., C2-12alkynyl), 2-10 carbons (i.e., C2-10alkynyl), 2-8 carbons (i.e., C2-8alkynyl), 2-6 carbons (i.e., C2-6alkynyl), 2-4 carbons (i.e., C2-4alkynyl), or 2-3 carbons (i.e., C2-3alkynyl). Attorney Docket No.: 185992002240 Examples of alkynyl include, but are not limited to, ethynyl, prop-1-ynyl, prop-2-ynyl, but-1- ynyl, but-2-ynyl, and but-3-ynyl. When an alkynyl residue having a specific number of carbons is named by chemical name or molecular formula, all positional isomers having that number of carbon atoms may be encompassed—for example, “propynyl” includes prop-1- ynyl and prop-2-ynyl. Certain commonly used alternative names may be used and will be understood by those of ordinary skill in the art. For instance, a divalent group, such as a divalent “alkynyl” group, may be referred to as an “alkynylene”. The term “alkoxy”, as used herein, refers to an -O-alkyl moiety. Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, and 1,2-dimethylbutoxy. The term “aryl”, as used herein, refers to a fully unsaturated carbocyclic ring moiety. The term “aryl” encompasses monocyclic and polycyclic fused-ring moieties. As used herein, aryl encompasses ring moieties comprising, for example, 6 to 20 annular carbonatoms (i.e., 6- to 20-membered aryl), 6 to 16 annular carbon atoms (i.e., 6- to 16-memberedaryl), 6 to 12 annular carbon atoms (i.e., 6- to 12-membered aryl), or 6 to 10 annular carbonatoms (i.e., 6- to 10-membered aryl). Examples of aryl moieties include, but are not limitedto, phenyl, naphthyl, fluorenyl, and anthryl. The term “cycloalkyl”, as used herein, refers to a saturated or partially unsaturated carbocyclic ring moiety. The term “cycloalkyl” encompasses monocyclic and polycyclic ring moieties, wherein the polycyclic moieties may be fused, branched, or spiro. Cycloalkyl includes cycloalkenyl groups, wherein the ring moiety comprises at least one annular double bond. Cycloalkyl includes any polycyclic carbocyclic ring moiety comprising at least one non-aromatic ring, regardless of the point of attachment to the remainder of the molecule. As used herein, cycloalkyl includes rings comprising, for example, 3 to 20 annular carbon atoms (i.e., a C3-20cycloalkyl), 3 to 16 annular carbon atoms (i.e., a C3-16cycloalkyl), 3 to 12 annular carbon atoms (i.e., a C3-12cycloalkyl), 3 to 10 annular carbon atoms (i.e., a C3-10cycloalkyl), 3 to 8 annular carbon atoms (i.e., a C3-8cycloalkyl), 3 to 6 annular carbon atoms (i.e., a C3-6cycloalkyl), or 3 to 5 annular carbon atoms (i.e., a C3-5cycloalkyl). Monocyclic cycloalkyl ring moieties include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic groups include, for example, bicyclo[2.2.1]heptanyl, bicyclo[2.2.2]octanyl, adamantyl, norbonyl, decalinyl, 7,7-dimethyl -bicyclo [2.2.1]heptanyl, and the like. Still further, cycloalkyl also includes spiro cycloalkyl ring moieties, for example, spiro[2.5]octanyl, spiro[4.5]decanyl, or spiro [5.5]undecanyl. Attorney Docket No.: 185992002240 The term “halo”, as used herein, refers to atoms occupying groups VIIA of The Periodic Table and includes fluorine (fluoro), chlorine (chloro), bromine (bromo), and iodine (iodo). Additionally, terms such as “haloalkyl” are meant to include monohaloalkyl and polyhaloalkyl. For example, the term “C1-4haloalkyl” is mean to include trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, difluoromethyl, and the like. The term “heteroaryl”, as used herein, refers to an aromatic (fully unsaturated) ringmoiety that comprises one or more annular heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur. The term “heteroaryl” includes both monocyclic and polycyclic fused-ring moieties. As used herein, a heteroaryl comprises, forexample, 5 to 20 annular atoms (i.e., a 5- to 20-membered heteroaryl), 5 to 16 annular atoms(i.e., a 5- to 16-membered heteroaryl), 5 to 12 annular atoms (i.e., a 5- to 12-memberedheteroaryl), 5 to 10 annular atoms (i.e., a 5- to 10-membered heteroaryl), 5 to 8 annular atoms(i.e., a 5- to 8-membered heteroaryl), or 5 to 6 annular atoms (i.e., a 5- to 6-memberedheteroaryl). Any monocyclic or polycyclic aromatic ring moiety comprising one or more annular heteroatoms is considered a heteroaryl, regardless of the point of attachment to the remainder of the molecule (i.e., the heteroaryl moiety may be attached to the remainder of the molecule through any annular carbon or any annular heteroatom of the heteroaryl moiety). Examples of heteroaryl groups include, but are not limited to, oxazolyl, thiazolyl, pyridinyl, pyrimidinyl, and pyridazinyl. The term “heterocyclyl”, as used herein, refers to a saturated or partially unsaturated cyclic moiety that encompasses one or more annular heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur. The term “heterocyclyl” includes both monocyclic and polycyclic ring moieties, wherein the polycyclic ring moieties may be fused, bridged, or spiro. Any non-aromatic monocyclic or polycyclic ring moiety comprising at least one annular heteroatom is considered a heterocyclyl, regardless of the point of attachment to the remainder of the molecule (i.e., the heterocyclyl moiety may be attached to the remainder of the molecule through any annular carbon or any annular heteroatom of the heterocyclyl moiety). Further, the term heterocyclyl is intended to encompass any polycyclic ring moiety comprising at least one annular heteroatom wherein the polycyclic ring moiety comprises at least one non-aromatic ring, regardless of the point of attachment to the remainder of the molecule. As used herein, a heterocyclyl comprises, for example, 3 to 20annular atoms (i.e., a 3- to 20-membered heterocyclyl), 3 to 16 annular atoms (i.e., a 3- to 16-membered heterocyclyl), 3 to 12 annular atoms (i.e., a 3- to 12-membered heterocyclyl), 3 to10 annular atoms (i.e., a 3- to 10-membered heterocyclyl), 3 to 8 annular atoms (i.e., a 3- to Attorney Docket No.: 185992002240 8-membered heterocyclyl), 3 to 6 annular atoms (i.e., a 3-6 membered heterocyclyl), 3 to 5annular atoms (i.e., a 3- to 5-membered heterocyclyl), 5 to 8 annular atoms (i.e., a 5- to 8-membered heterocyclyl), or 5 to 6 annular atoms (i.e., a 5- to 6-membered heterocyclyl).Examples of heterocyclyl groups include, e.g., azetidinyl, piperidinyl, piperazinyl,pyrrolidinyl, pyrazolidinyl, thiazolidinyl, tetrahydrofuryl, or tetrahydropyranyl. Examples ofspiro heterocyclyl rings include, but are not limited to, bicyclic and tricyclic ring systems, such as 2-oxa-7-azaspiro[3.5]nonanyl, 2-oxa-6-azaspiro[3.4]octanyl, and 6-oxa-1-azaspiro[3.3]heptanyl. Examples of fused heterocyclyl rings include, but are not limited to,5,6,7,8-tetrahydropyrido[4,3-d]pyrimidinyl, 6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidinyl, 5,7- dihydrofuro[3,4-d]pyrimidinyl, and 5,7-dihydrothieno[3,4-d]pyrimidinyl, where theheterocyclyl can be bound via either ring of the fused system.The term “oxo”, as used herein, refers to a =O moiety. The terms “spiro”, “spirocycle” and “spirocyclic”, as used herein, refer to a polycyclic moiety in which two of the rings share one atom in common. The terms “spiro”, “spirocycle”and “spirocyclic” may refer to a saturated or partially unsaturated carbocycle, or a saturatedor partially unsaturated heterocycle.The term “fused”, as used herein, refers to a polycyclic moiety in which two of therings share two adjacent atoms in common. The term “fused” may refer to a saturated orpartially unsaturated carbocycle, or a saturated or partially unsaturated heterocycle.The term “bridged”, as used herein, refers to a polycyclic moiety in which two of the rings share three or more atoms in common, and the bridgehead atoms are separated by at least one atoms. The term “bridged” may refer to a saturated or partially unsaturatedcarbocycle, or a saturated or partially unsaturated heterocycle.The terms “optional” and “optionally”, as used herein, mean that the subsequently described event or circumstance may or may not occur and that the description includes instances where the event or circumstance occurs and instances where it does not. Accordingly, the term “optionally substituted” infers that any one or more (e.g., 1, 2, 1 to 5, 1 to 3, 1 to 2, etc.) hydrogen atoms on the designated atom or moiety or group may be replaced or not replaced by an atom or moiety or group other than hydrogen. By way of illustration and not limitation, the phrase “methyl optionally substituted with one or more chloro”encompasses -CH3, -CH2Cl, -CHCl2, and -CCl3 moieties.It is understood that aspects and embodiments described herein as “comprising” include “consisting of” and “consisting essentially of” embodiments. Attorney Docket No.: 185992002240 The term “pharmaceutically acceptable salt”, as used herein, of a given compound refers to salts that retain the biological effectiveness and properties of the given compound and which are not biologically or otherwise undesirable. “Pharmaceutically acceptable salts” include, for example, salts with inorganic acids, and salts with an organic acid. In addition, if the compounds described herein are obtained as an acid addition salt, the free base can be obtained by basifying a solution of the acid salt. Conversely, if the product is a free base, an addition salt, particularly a pharmaceutically acceptable addition salt, may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds. See, e.g., Handbook of Pharmaceutical Salts Properties, Selection, and Use, International Union of Pure and Applied Chemistry, John Wiley & Sons (2008), which isincorporated herein by reference in its entirety. Those skilled in the art will recognize varioussynthetic methodologies that may be used to prepare nontoxic pharmaceutically acceptable addition salts. Pharmaceutically acceptable acid addition salts may be prepared from inorganic or organic acids. Salts derived from inorganic acids include, e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Salts derived from organic acids include, e.g., acetic acid, propionic acid, gluconic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluene-sulfonic acid, salicylic acid, trifluoroacetic acid, and the like. Likewise, pharmaceutically acceptable base addition salts can be prepared from inorganic or organic bases. Salts derived from inorganic bases include, by way of example only, sodium, potassium, lithium, aluminum, ammonium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines. Specific examples of suitable amines include, by way of example only,isopropylamine, trimethyl amine, diethyl amine, tri(iso-propyl) amine, tri(n-propyl) amine,ethanolamine, 2-dimethylaminoethanol, piperazine, piperidine, morpholine, N- ethylpiperidine, and the like. Isotopically labeled forms of the compounds depicted herein may be prepared. Isotopically labeled compounds have structures depicted herein, except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as2H,3H,11C,13C,14C,13N,15N,15O,17O,18O,31P,32P,35S,18F,36Cl,123I, and125I, respectively. In some Attorney Docket No.: 185992002240embodiments, a compound of formula (I) is provided wherein one or more hydrogen isreplaced by deuterium or tritium. Some of the compounds provided herein may exist as tautomers. Tautomers are in equilibrium with one another. By way of illustration, amide containing compounds may exist in equilibrium with imidic acid tautomers. Regardless of which tautomer is shown and regardless of the nature of the equilibrium among tautomers, the compounds of this disclosure are understood by one of ordinary skill in the art to comprise both amide and imidic acid tautomers. Thus, for example, amide-containing compounds are understood to include their imidic acid tautomers. Likewise, imidic-acid containing compounds are understood to include their amide tautomers. Also provided herein are prodrugs of the compounds depicted herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvatethereof. In some embodiments, provided herein are prodrugs of the compounds depictedherein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof. Prodrugs are compounds that may be administered to an individual and release, in vivo, a compound depicted herein as the parent drug compound. It is understood that prodrugs may be prepared by modifying a functional group on a parent drug compound in such a way thatthe modification is cleaved in vitro or in vivo to release the parent drug compound. See, e.g.,Rautio, J., Kumpulainen, H., Heimbach, T. et al. Prodrugs: design and clinical applications.Nat Rev Drug Discov 7, 255–270 (2008), which is incorporated herein by reference in itsentirety. The compounds of the present disclosure, or their pharmaceutically acceptable salts,hydrates, or solvates may include an asymmetric center and may thus give rise toenantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms ofabsolute stereochemistry, as (R)- or (S)- (or as (D)- or (L)- for amino acids). The presentdisclosure is meant to include all such possible isomers, as well as their racemic and opticallypure forms and mixtures thereof in any ratio. Optically active (+) and (-), (R)- and (S)-, or(D)- and (L)- isomers may be prepared using chiral synthons or chiral reagents, or may beresolved using conventional techniques, for example, chromatography and / or fractional crystallization. Conventional techniques for the preparation / isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or the resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC), and chiral supercritical fluid chromatography (SFC). When the compounds described herein contain olefinic double bonds or other centers Attorney Docket No.: 185992002240 of geometric asymmetry, unless specified otherwise, it is intended that the present disclosureincludes both E and Z geometric isomers. Likewise, cis- and trans- are used in theirconventional sense to describe relative spatial relationships. A “stereoisomer” refers to a compound made up of the same atoms bonded by the same bonds, but having different three-dimensional structures, which are not interchangeable.The present disclosure contemplates various stereoisomers, or mixtures thereof, and includes“enantiomers,” which refers to two stereoisomers whose structures are non-superimposable mirror images of one another. “Diastereomers” are stereoisomers that have at least two asymmetric atoms, but which are not mirror images of each other. Where enantiomeric and / or diastereomeric forms exist of a given structure, flat bonds indicate a mixture of stereoisomeric forms of the depicted structure may be present, e.g., the composition is made up of at least 90%, by weight,dashes or wedges with or without the presence of an “(S)” or “(R)” designation indicate asingle enantiomer or diastereomer with known relative or absolute stereochemistry, e.g., . COMPOUNDS In one aspect, provided herein is a compound of formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, orsolvate of any of the foregoing, wherein Attorney Docket No.: 185992002240 R1and R2are each independently C1-6alkyl, C2-6alkenyl, -C(=O)R14, -C(=O)OR14, - C(=O)N(R13)(R14), -S(=O)2R14, -S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl wherein the C1-6alkyl of R1or R2is optionally substituted with one or more R1a, the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of R1or R2is optionally substituted with one or more R1b, and optionally, two substituents of the C1-6alkyl, C2-6alkenyl, -C(=O)R14, -C(=O)OR14, - C(=O)N(R13)(R14), -S(=O)2R14, -S(=O)2N(R13)(R14), or C3-8cycloalkyl group of R1or R2are taken together with the atoms to which they are attached to form a C3- 8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10- membered heteroaryl, wherein the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R1b; or R1and R2are taken together with the N to which they are attached to form a 3- to 12- membered heterocyclyl or 5- to 10-membered heteroaryl, wherein the 3- to 12-membered heterocyclyl or 5- to 10-membered heteroaryl of R1and R2is optionally substituted with one or more R3; each R3is independently halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, oxo, -OR12, -SR12, -SF5, - N(Rx)(Ry), -NO2, -CN, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, - OC(=O)R14, -OC(=O)N(R13)R14, -OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), - C(=O)OR14, -C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, - N(R13)S(=O)2R14, -S(=O)R14, -S(=O)N(R13)R14, -S(=O)OR14, -S(=NR15)R14, - S(=NR15)N(R13)R14, -S(=NR15)OR14, -S(=O)2R14, -S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C1-6alkyl of R3is optionally substituted with one or more R3a, and optionally, two substituents of R3are taken together with the atoms to which they are attached form a C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10- membered aryl, or 5- to 10-membered heteroaryl is optionally substituted one or more R3b; Attorney Docket No.: 185992002240 Ring A is 4- to 12-membered cycloalkenyl, 4- to 12-membered unsaturated heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the 4- to 12-membered cycloalkenyl, 4- to 12-membered unsaturated heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of Ring A is optionally substituted by one or more R4, and the 4- to 12-membered unsaturated heterocyclyl or 5- to 10-membered heteroaryl of Ring A comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S; each R4is independently halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, -OR12, -SR12, -SF5, - N(Rx)(Ry), -NO2, -CN, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, - OC(=O)R14, -OC(=O)N(R13)R14, -OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), - C(=O)OR14, -C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, - N(R13)S(=O)2R14, -S(=O)R14, -S(=O)N(R13)R14, -S(=O)OR14, -S(=NR15)R14, - S(=NR15)N(R13)R14, -S(=NR15)OR14, -S(=O)2R14, -S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C1-6alkyl of R4is optionally substituted by one or more R4a, the C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of R4is optionally substituted with one or more R4b, and the 3- to 8-membered heterocyclyl of R4comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S; L is a bond, C1-6alkyl, -O-(C1-6alkyl)-, -S-(C1-6alkyl)-, or -N(R5)(C1-6alkyl)-, wherein the C1-6alkyl, -O-(C1-6alkyl)-, -S-(C1-6alkyl)-, or -N(R5)(C1-6alkyl)- is optionally substituted by one or more RL; each RLis independently halo, -N(Rx)(Ry), -OR12, -SR12, -SF5, -NO2, -CN, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, -OC(=O)R14, -OC(=O)N(R13)R14, - OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), -C(=O)OR14, C3-8cycloalkyl, 3- to 8- membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, or two RLare taken together along with the atoms to which they are attached to form a C3-8cycloalkyl or 3- to 8-membered heterocyclyl; R5is H, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, -C(=O)R14, -S(=O)2R14, -S(=O)2N(R13)(R14), or C3-8cycloalkyl, wherein the C1-6alkyl of R5is optionally substituted with one or more halo, -N(Rx)(Ry), -OR12, -SR12, -SF5, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, - OC(=O)R14, -OC(=O)N(R13)R14, -OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), - C(=O)OR14, -C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, - Attorney Docket No.: 185992002240 N(R13)S(=O)2R14, -S(=O)R14, -S(=O)N(R13)R14, -S(=O)OR14, -S(=NR15)R14, - S(=NR15)N(R13)R14, -S(=NR15)OR14, -S(=O)2R14, or -S(=O)2N(R13)(R14), and the C3-8cycloalkyl is optionally substituted with one or more R5b; R6is H, halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, -OR12, -O-(3- to 12-membered N- containing heterocyclyl), -O-(5- to 6-membered N-containing heteroaryl), -SR12, -SF5, - N(Rx)(Ry), -NO2, -CN, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, - OC(=O)R14, -OC(=O)N(R13)R14, -OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), - C(=O)OR14, -C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, - N(R13)S(=O)2R14, -S(=O)R14, -S(=O)N(R13)R14, -S(=O)OR14, -S(=NR15)R14, - S(=NR15)N(R13)R14, -S(=NR15)OR14, -S(=O)2R14, -S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C1-6alkyl of R6is optionally substituted by one or more R6a, the C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, 5- to 10- membered heteroaryl, -O-(3- to 12-membered N-containing heterocyclyl), or -O-(5- to 6-membered N-containing heteroaryl) of R6is optionally substituted with one or more R6b, -C(=O)R14, -C(=O)N(R13)(R14), or -C(=O)OR14, and the 3- to 8-membered heterocyclyl of R6comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S, and optionally, two substituents of R6are taken together with the atoms to which they are attached form a C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R6b; R7, R8, R9, and R10are each independently H, halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, - OR11, -OR12, -SR12, -SF5, -N(Rx)(Ry), -NO2, -CN, -N(R13)C(=O)R14, - N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, -OC(=O)R14, -OC(=O)N(R13)R14, - OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), -C(=O)OR14, -C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, -N(R13)S(=O)2R14, -S(=O)R14, -S(=O)N(R13)R14, - S(=O)OR14, -S(=NR15)R14, -S(=NR15)N(R13)R14, -S(=NR15)OR14, -S(=O)2R14, - S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C1-6alkyl of R7, R8, R9, or R10is optionally substituted by one or more R7a, Attorney Docket No.: 185992002240 the 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of R7, R8, R9, or R10is optionally substituted with one or more R7b, and the 3- to 8-membered heterocyclyl of R7, R8, R9, or R10comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S, and optionally, two substituents of R7, R8, R9, or R10are taken together with the atoms to which they are attached form a C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R7b; each R1a, R3a, R4a, R6a, or R7ais independently halo, -N(Rx)(Ry), -OR12, -SR12, -SF5, -NO2, - CN, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, -OC(=O)R14, - OC(=O)N(R13)R14, -OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), -C(=O)OR14, - C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, -N(R13)S(=O)2R14, - S(=O)R14, -S(=O)2R14, -S(=O)N(R13)R14, -S(=O)OR14, -S(=NR15)R14, -S(=NR15)N(R13)R14, - S(=NR15)OR14, -S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10- membered aryl, or 5- to 10-membered heteroaryl, wherein the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of R1a, R3a, R4a, R6a, or R7ais optionally substituted with one or more R1b, and the 3- to 12-membered heterocyclyl of R1a, R3a, R4a, R6a, or R7acomprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S; each R1b, R3b, R4b, R5b, R6b, or R7bis independently halo, C1-6alkyl, -OR11, -N(Rx)(Ry), oxo, - CN, C3-8cycloalkyl, or 3- to 8-membered heterocyclyl, wherein the C1-6alkyl of R1b, R3b, R4b, R5b, R6b, or R7bis optionally substituted by -OR12, - N(Rx)(Ry), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl; each R11is independently H, C1-6alkyl, C2-6alkenyl, C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C1-6alkyl of R11is optionally substituted with 6- to 10-membered aryl, or 5- to 10- membered heteroaryl, wherein the 6- to 10-membered aryl, or 5- to 10-membered heteroaryl is optionally substituted with halo, C1-3alkyl, C1-3alkoxy, or -N(Rx)(Ry), and Attorney Docket No.: 185992002240 the 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of R11 is optionallysubstituted with halo, C1-3alkyl, C1-3alkoxy, -N(Rx)(Ry), or 3- to 12-memberedheterocyclyl;each R12 is independently H, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl,wherein the C1-6alkyl of R12is optionally substituted with one or more halo, deuterium, C1-6alkoxy, -N(Rx)(Ry), or 3- to 8-membered heterocyclyl;each R13 is independently H, C1-6alkyl, or C3-8cycloalkyl;each R14 is independently H, C1-6alkyl, C2-6alkenyl, C3-8cycloalkyl, 6- to 10-membered aryl,5- to 10-membered heteroaryl, or 3- to 12-membered heterocyclyl, whereinthe C1-6alkyl of R14 is optionally substituted by one or more halo, -OH, -O(C1-6alkyl),-SH, -S(C1-6alkyl), -(C=O)NH2, -(C=O)OH, -O(C=O)C1-8alkyl), -NH(C=NH)NH2, -N(Rx)(Ry), C3-8cycloalkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, or3- to 12-membered heterocyclyl, whereinthe 6- to 10-membered aryl is optionally substituted by -OH, andthe C3-8cycloalkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, or 3- to12-membered heterocyclyl of R14 is optionally substituted with halo, C1-6alkyl, -OH,or -N(Rx)(Ry); each R15is independently H or C1-6alkyl; andeach Rx and Ry is independently H, C1-6alkyl, C3-8cycloalkyl, -C(=O)(C1-6alkyl), or -C(=O)O(C1-6alkyl), wherein the C1-6alkyl of Rx or Ry is optionally substituted with halo, 6- to 10-membered aryl,5- to 10-membered heteroaryl, -NH2, NH(C1-6alkyl), or -N(C1-6alkyl)(C1-6alkyl), andthe C1-6alkyl of -C(=O)(C1-6alkyl) or -C(=O)O(C1-6alkyl) is optionally substituted with-O(C=O)C1-8alkyl). In some embodiments of the above, the compound is a compoundof formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments of formula (I),R1and R2are each independently C1-6alkyl, C2-6alkenyl, -C(=O)R14, -C(=O)OR14, - C(=O)N(R13)(R14), -S(=O)2R14, -S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 12-memberedheterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl whereinthe C1-6alkyl of R1 or R2 is optionally substituted with one or more R1a, Attorney Docket No.: 185992002240 the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of R1or R2is optionally substituted with one or more R1b, and optionally, two substituents of the C1-6alkyl, C2-6alkenyl, -C(=O)R14, -C(=O)OR14, - C(=O)N(R13)(R14), -S(=O)2R14, -S(=O)2N(R13)(R14), or C3-8cycloalkyl group of R1or R2are taken together with the atoms to which they are attached to form a C3- 8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10- membered heteroaryl, wherein the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R1b; or R1and R2are taken together with the N to which they are attached to form a 3- to 12- membered heterocyclyl or 5- to 10-membered heteroaryl, wherein the 3- to 12-membered heterocyclyl or 5- to 10-membered heteroaryl of R1and R2is optionally substituted with one or more R3; each R3is independently halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, oxo, -OR12, -SR12, -SF5, - N(Rx)(Ry), -NO2, -CN, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, - OC(=O)R14, -OC(=O)N(R13)R14, -OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), - C(=O)OR14, -C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, - N(R13)S(=O)2R14, -S(=O)R14, -S(=O)N(R13)R14, -S(=O)OR14, -S(=NR15)R14, - S(=NR15)N(R13)R14, -S(=NR15)OR14, -S(=O)2R14, -S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C1-6alkyl of R3is optionally substituted with one or more R3a, and optionally, two substituents of R3are taken together with the atoms to which they are attached form a C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10- membered aryl, or 5- to 10-membered heteroaryl is optionally substituted one or more R3b; Ring A is 4- to 12-membered cycloalkenyl, 4- to 12-membered unsaturated heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the 4- to 12-membered cycloalkenyl, 4- to 12-membered unsaturated heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of Ring A is optionally substituted by one or more R4, and Attorney Docket No.: 185992002240 the 4- to 12-membered unsaturated heterocyclyl or 5- to 10-membered heteroaryl of Ring A comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S; each R4is independently halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, -OR12, -SR12, -SF5, - N(Rx)(Ry), -NO2, -CN, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, - OC(=O)R14, -OC(=O)N(R13)R14, -OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), - C(=O)OR14, -C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, - N(R13)S(=O)2R14, -S(=O)R14, -S(=O)N(R13)R14, -S(=O)OR14, -S(=NR15)R14, - S(=NR15)N(R13)R14, -S(=NR15)OR14, -S(=O)2R14, -S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C1-6alkyl of R4is optionally substituted by one or more R4a, the C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of R4is optionally substituted with one or more R4b, and the 3- to 8-membered heterocyclyl of R4comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S; L is a bond, C1-6alkyl, -O-(C1-6alkyl)-, -S-(C1-6alkyl)-, or -N(R5)(C1-6alkyl)-, wherein the C1-6alkyl, -O-(C1-6alkyl)-, -S-(C1-6alkyl)-, or -N(R5)(C1-6alkyl)- is optionally substituted by one or more RL; each RLis independently halo, -N(Rx)(Ry), -OR12, -SR12, -SF5, -NO2, -CN, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, -OC(=O)R14, -OC(=O)N(R13)R14, - OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), -C(=O)OR14, C3-8cycloalkyl, 3- to 8- membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, or two RLare taken together along with the atoms to which they are attached to form a C3-8cycloalkyl or 3- to 8-membered heterocyclyl; R5is H, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, -C(=O)R14, -S(=O)2R14, -S(=O)2N(R13)(R14), or C3-8cycloalkyl, wherein the C1-6alkyl of R5is optionally substituted with one or more halo, -N(Rx)(Ry), -OR12, -SR12, -SF5, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, - OC(=O)R14, -OC(=O)N(R13)R14, -OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), - C(=O)OR14, -C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, - N(R13)S(=O)2R14, -S(=O)R14, -S(=O)N(R13)R14, -S(=O)OR14, -S(=NR15)R14, - S(=NR15)N(R13)R14, -S(=NR15)OR14, -S(=O)2R14, or -S(=O)2N(R13)(R14), and the C3-8cycloalkyl is optionally substituted with one or more R5b; R6is H, halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, -OR12, -O-(3- to 12-membered N- containing heterocyclyl), -O-(5- to 6-membered N-containing heteroaryl), -SR12, -SF5, - Attorney Docket No.: 185992002240 N(Rx)(Ry), -NO2, -CN, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, - OC(=O)R14, -OC(=O)N(R13)R14, -OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), - C(=O)OR14, -C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, - N(R13)S(=O)2R14, -S(=O)R14, -S(=O)N(R13)R14, -S(=O)OR14, -S(=NR15)R14, - S(=NR15)N(R13)R14, -S(=NR15)OR14, -S(=O)2R14, -S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C1-6alkyl of R6is optionally substituted by one or more R6a, the C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, 5- to 10- membered heteroaryl, -O-(3- to 12-membered N-containing heterocyclyl), or -O-(5- to 6-membered N-containing heteroaryl) of R6is optionally substituted with one or more R6b, -C(=O)R14, -C(=O)N(R13)(R14), or -C(=O)OR14, and the 3- to 8-membered heterocyclyl of R6comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S, and optionally, two substituents of R6are taken together with the atoms to which they are attached form a C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R6b; R7, R8, R9, and R10are each independently H, halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, - OR11, -OR12, -SR12, -SF5, -N(Rx)(Ry), -NO2, -CN, -N(R13)C(=O)R14, - N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, -OC(=O)R14, -OC(=O)N(R13)R14, - OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), -C(=O)OR14, -C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, -N(R13)S(=O)2R14, -S(=O)R14, -S(=O)N(R13)R14, - S(=O)OR14, -S(=NR15)R14, -S(=NR15)N(R13)R14, -S(=NR15)OR14, -S(=O)2R14, - S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C1-6alkyl of R7, R8, R9, or R10is optionally substituted by one or more R7a, the 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of R7, R8, R9, or R10is optionally substituted with one or more R7b, and the 3- to 8-membered heterocyclyl of R7, R8, R9, or R10comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S, and Attorney Docket No.: 185992002240 optionally, two substituents of R7, R8, R9, or R10are taken together with the atoms to which they are attached form a C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R7b; each R1a, R3a, R4a, R6a, or R7ais independently halo, -N(Rx)(Ry), -OR12, -SR12, -SF5, -NO2, - CN, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, -OC(=O)R14, - OC(=O)N(R13)R14, -OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), -C(=O)OR14, - C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, -N(R13)S(=O)2R14, - S(=O)R14, -S(=O)2R14, -S(=O)N(R13)R14, -S(=O)OR14, -S(=NR15)R14, -S(=NR15)N(R13)R14, - S(=NR15)OR14, -S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10- membered aryl, or 5- to 10-membered heteroaryl, wherein the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of R1a, R3a, R4a, R6a, or R7ais optionally substituted with one or more R1b, and the 3- to 12-membered heterocyclyl of R1a, R3a, R4a, R6a, or R7acomprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S; each R1b, R3b, R4b, R5b, R6b, or R7bis independently halo, C1-6alkyl, -OR11, -N(Rx)(Ry), oxo, - CN, C3-8cycloalkyl, or 3- to 8-membered heterocyclyl, wherein the C1-6alkyl of R1b, R3b, R4b, R5b, R6b, or R7bis optionally substituted by -OR12, - N(Rx)(Ry), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl; each R11is independently H, C1-6alkyl, C2-6alkenyl, C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C1-6alkyl of R11is optionally substituted with 6- to 10-membered aryl, or 5- to 10- membered heteroaryl, wherein the 6- to 10-membered aryl, or 5- to 10-membered heteroaryl is optionally substituted with halo, C1-3alkyl, C1-3alkoxy, or -N(Rx)(Ry), and the 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of R11is optionally substituted with halo, C1-3alkyl, C1-3alkoxy, -N(Rx)(Ry), or 3- to 12-membered heterocyclyl; each R12is independently H, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, 3- to 8- membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, Attorney Docket No.: 185992002240 wherein the C1-6alkyl of R12is optionally substituted with one or more halo, deuterium, C1-6alkoxy, -N(Rx)(Ry), or 3- to 8-membered heterocyclyl; each R13is independently H, C1-6alkyl, or C3-8cycloalkyl; each R14is independently H, C1-6alkyl, C2-6alkenyl, C3-8cycloalkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, or 3- to 12-membered heterocyclyl, wherein the C1-6alkyl of R14is optionally substituted by one or more halo, -OH, -O(C1-6alkyl), -SH, -S(C1-6alkyl), -(C=O)NH2, -(C=O)OH, -O(C=O)C1-8alkyl), -NH(C=NH)NH2, - N(Rx)(Ry), C3-8cycloalkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, or 3- to 12-membered heterocyclyl, wherein the 6- to 10-membered aryl is optionally substituted by -OH, and the C3-8cycloalkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, or 3- to 12-membered heterocyclyl of R14is optionally substituted with halo, C1-6alkyl, -OH, or -N(Rx)(Ry); each R15is independently H or C1-6alkyl; and each Rxand Ryis independently H, C1-6alkyl, C3-8cycloalkyl, -C(=O)(C1-6alkyl), or - C(=O)O(C1-6alkyl), wherein the C1-6alkyl of Rxor Ryis optionally substituted with halo, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -NH2, NH(C1-6alkyl), or -N(C1-6alkyl)(C1-6alkyl), and the C1-6alkyl of -C(=O)(C1-6alkyl) or -C(=O)O(C1-6alkyl) is optionally substituted with -O(C=O)C1-8alkyl) , wherein (i) when Ring A is phenyl and R6is selected from the group consisting of -NH2, -NHCH3, and -N(CH3)3, R1and R2are not both C1-2alkyl; (ii) when R1and R2are taken together with the N to which they are attached to form a 4-methylpiperazinyl, -(Ring A)-X-L-R6 is not (iii) when R1and R2are taken together with the N to which they are attached to form a morpholinyl, R6is not selected from the group consisting of -NH2, -NHC(O)CH3, and - NHC(O)O-C(CH3)3; and (iv) when Ring A is pyridin-4yl substituted with -NHC(CH3)phenyl, R1and R2are not taken together with the N to which they are attached to form an optionally substituted 2,5- diazabicyclo[2.2.2]octanyl. Attorney Docket No.: 185992002240 In some embodiments of formula (I),R1and R2are each independently C1-6alkyl, C2-6alkenyl, -C(=O)R14, -C(=O)OR14, - C(=O)N(R13)(R14), -S(=O)2R14, -S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 12-memberedheterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl whereinthe C1-6alkyl of R1 or R2 is optionally substituted with one or more R1a,the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to10-membered heteroaryl of R1 or R2 is optionally substituted with one or more R1b,and optionally, two substituents of the C1-6alkyl, C2-6alkenyl, -C(=O)R14, -C(=O)OR14, - C(=O)N(R13)(R14), -S(=O)2R14, -S(=O)2N(R13)(R14), or C3-8cycloalkyl group of R1or R2are taken together with the atoms to which they are attached to form a C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl,or 5- to 10-membered heteroaryl is optionally substituted with one or moreR1b;or R1 and R2 are taken together with the N to which they are attached to form a 3- to 12-membered heterocyclyl or 5- to 10-membered heteroaryl, whereinthe 3- to 12-membered heterocyclyl or 5- to 10-membered heteroaryl of R1 and R2 isoptionally substituted with one or more R3; each R3is independently halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, oxo, -OR12, -SR12, -SF5, -N(Rx)(Ry), -NO2, -CN, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, - OC(=O)R14, -OC(=O)N(R13)R14, -OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), -C(=O)OR14, -C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, -N(R13)S(=O)2R14, -S(=O)R14, -S(=O)N(R13)R14, -S(=O)OR14, -S(=NR15)R14, -S(=NR15)N(R13)R14, -S(=NR15)OR14, -S(=O)2R14, -S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, whereinthe C1-6alkyl of R3 is optionally substituted with one or more R3a, andoptionally, two substituents of R3are taken together with the atoms to which they are attached form a C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-memberedaryl, or 5- to 10-membered heteroaryl,wherein the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl is optionally substituted oneor more R3b; Attorney Docket No.: 185992002240 Ring A is 4- to 12-membered cycloalkenyl, 4- to 12-membered unsaturated heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the 4- to 12-membered cycloalkenyl, 4- to 12-membered unsaturated heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of Ring A is optionally substituted by one or more R4, and the 4- to 12-membered unsaturated heterocyclyl or 5- to 10-membered heteroaryl of Ring A comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S; each R4is independently halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, -OR12, -SR12, -SF5, - N(Rx)(Ry), -NO2, -CN, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, - OC(=O)R14, -OC(=O)N(R13)R14, -OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), - C(=O)OR14, -C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, - N(R13)S(=O)2R14, -S(=O)R14, -S(=O)N(R13)R14, -S(=O)OR14, -S(=NR15)R14, - S(=NR15)N(R13)R14, -S(=NR15)OR14, -S(=O)2R14, -S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C1-6alkyl of R4is optionally substituted by one or more R4a, the C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of R4is optionally substituted with one or more R4b, and the 3- to 8-membered heterocyclyl of R4comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S; L is a bond, C1-6alkyl, -O-(C1-6alkyl)-, -S-(C1-6alkyl)-, or -N(R5)(C1-6alkyl)-, wherein the C1-6alkyl, -O-(C1-6alkyl)-, -S-(C1-6alkyl)-, or -N(R5)(C1-6alkyl)- is optionally substituted by one or more RL; each RLis independently halo, -N(Rx)(Ry), -OR12, -SR12, -SF5, -NO2, -CN, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, -OC(=O)R14, -OC(=O)N(R13)R14, - OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), -C(=O)OR14, C3-8cycloalkyl, 3- to 8- membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, or two RLare taken together along with the atoms to which they are attached to form a C3-8cycloalkyl or 3- to 8-membered heterocyclyl; R5is H, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, -C(=O)R14, -S(=O)2R14, -S(=O)2N(R13)(R14), or C3-8cycloalkyl, wherein the C1-6alkyl of R5is optionally substituted with one or more halo, -N(Rx)(Ry), -OR12, -SR12, -SF5, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, - OC(=O)R14, -OC(=O)N(R13)R14, -OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), - C(=O)OR14, -C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, - Attorney Docket No.: 185992002240 N(R13)S(=O)2R14, -S(=O)R14, -S(=O)N(R13)R14, -S(=O)OR14, -S(=NR15)R14, - S(=NR15)N(R13)R14, -S(=NR15)OR14, -S(=O)2R14, or -S(=O)2N(R13)(R14), and the C3-8cycloalkyl is optionally substituted with one or more R5b; R6is H, halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, -OR12, -SR12, -SF5, -N(Rx)(Ry), -NO2, -CN, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, -OC(=O)R14, - OC(=O)N(R13)R14, -OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), -C(=O)OR14, - C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, -N(R13)S(=O)2R14, - S(=O)R14, -S(=O)N(R13)R14, -S(=O)OR14, -S(=NR15)R14, -S(=NR15)N(R13)R14, - S(=NR15)OR14, -S(=O)2R14, -S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C1-6alkyl of R6is optionally substituted by one or more R6a, the C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of R6is optionally substituted with one or more R6b, - C(=O)R14, -C(=O)N(R13)(R14), or -C(=O)OR14, and the 3- to 8-membered heterocyclyl of R6comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S, and optionally, two substituents of R6are taken together with the atoms to which they are attached form a C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R6b; R7, R8, R9, and R10are each independently H, halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, - OR11, -OR12, -SR12, -SF5, -N(Rx)(Ry), -NO2, -CN, -N(R13)C(=O)R14, - N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, -OC(=O)R14, -OC(=O)N(R13)R14, - OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), -C(=O)OR14, -C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, -N(R13)S(=O)2R14, -S(=O)R14, -S(=O)N(R13)R14, - S(=O)OR14, -S(=NR15)R14, -S(=NR15)N(R13)R14, -S(=NR15)OR14, -S(=O)2R14, - S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C1-6alkyl of R7, R8, R9, or R10is optionally substituted by one or more R7a, the 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of R7, R8, R9, or R10is optionally substituted with one or more R7b, and Attorney Docket No.: 185992002240 the 3- to 8-membered heterocyclyl of R7, R8, R9, or R10comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S, and optionally, two substituents of R7, R8, R9, or R10are taken together with the atoms to which they are attached form a C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R7b; each R1a, R3a, R4a, R6a, or R7ais independently halo, -N(Rx)(Ry), -OR12, -SR12, -SF5, -NO2, - CN, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, -OC(=O)R14, - OC(=O)N(R13)R14, -OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), -C(=O)OR14, - C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, -N(R13)S(=O)2R14, - S(=O)R14, -S(=O)2R14, -S(=O)N(R13)R14, -S(=O)OR14, -S(=NR15)R14, -S(=NR15)N(R13)R14, - S(=NR15)OR14, -S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10- membered aryl, or 5- to 10-membered heteroaryl, wherein the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of R1a, R3a, R4a, R6a, or R7ais optionally substituted with one or more R1b, and the 3- to 12-membered heterocyclyl of R1a, R3a, R4a, R6a, or R7acomprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S; each R1b, R3b, R4b, R5b, R6b, or R7bis independently halo, C1-6alkyl, -OR11, -N(Rx)(Ry), oxo, - CN, C3-8cycloalkyl, or 3- to 8-membered heterocyclyl, wherein the C1-6alkyl of R1b, R3b, R4b, R5b, R6b, or R7bis optionally substituted by -OR12, - N(Rx)(Ry), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl; each R11is independently H, C1-6alkyl, C2-6alkenyl, C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C1-6alkyl of R11is optionally substituted with 6- to 10-membered aryl, or 5- to 10- membered heteroaryl, wherein the 6- to 10-membered aryl, or 5- to 10-membered heteroaryl is optionally substituted with halo, C1-3alkyl, C1-3alkoxy, or -N(Rx)(Ry), and the 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of R11is optionally substituted with halo, C1-3alkyl, C1-3alkoxy, -N(Rx)(Ry), or 3- to 12-membered heterocyclyl; Attorney Docket No.: 185992002240 each R12is independently H, C1-6alkyl, C2-6alkenyl, C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C1-6alkyl is optionally substituted with one or more halo, deuterium, C1- 6alkoxy, -N(Rx)(Ry), or 3- to 8-membered heterocyclyl; each R13is independently H, C1-6alkyl, or C3-8cycloalkyl; each R14is independently H, C1-6alkyl, C2-6alkenyl, C3-8cycloalkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, or 3- to 12-membered heterocyclyl, wherein the C1-6alkyl of R14is optionally substituted by one or more halo, -OH, -O(C1-6alkyl), -SH, -S(C1-6alkyl), -(C=O)NH2, -(C=O)OH, -O(C=O)C1-8alkyl), -NH(C=NH)NH2, - N(Rx)(Ry), C3-8cycloalkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, or 3- to 12-membered heterocyclyl, wherein the 6- to 10-membered aryl is optionally substituted by -OH, and the C3-8cycloalkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, or 3- to 12-membered heterocyclyl of R14is optionally substituted with halo, C1-6alkyl, -OH, or -N(Rx)(Ry); each R15is independently H or C1-6alkyl; and each Rxand Ryis independently H, C1-6alkyl, C3-8cycloalkyl, -C(=O)(C1-6alkyl), or - C(=O)O(C1-6alkyl), wherein the C1-6alkyl of Rxor Ryis optionally substituted with halo, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -NH2, NH(C1-6alkyl), or -N(C1-6alkyl)(C1-6alkyl), and the C1-6alkyl of -C(=O)(C1-6alkyl) or -C(=O)O(C1-6alkyl) is optionally substituted with - O(C=O)C1-8alkyl), wherein (i) when Ring A is phenyl and R6is selected from the group consisting of -NH2, -NHCH3, and -N(CH3)3, R1and R2are not both C1-2alkyl; (ii) when R1and R2are taken together with the N to which they are attached to form a 4-methylpiperazinyl, -(Ring A)-X-L-R6 is not (iii) when R1and R2are taken together with the N to which they are attached to form a morpholinyl, R6is not selected from the group consisting of -NH2, -NHC(O)CH3, and - NHC(O)O-C(CH3)3; and Attorney Docket No.: 185992002240 (iv) when Ring A is pyridin-4yl substituted with -NHC(CH3)phenyl, R1and R2are not taken together with the N to which they are attached to form an optionally substituted 2,5- diazabicyclo[2.2.2]octanyl. In some embodiments of a compound of formula (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or salt of any of the foregoing, R1and R2are each independently C1-6alkyl, C2-6alkenyl, -C(=O)R14, -C(=O)OR14, - C(=O)N(R13)(R14), or C3-8cycloalkyl, wherein the C1-6alkyl of R1 or R2 is optionally substituted with one or more R1a,the C3-8cycloalkyl of R1 or R2 is optionally substituted with one or more R1b, andoptionally, two substituents of the C1-6alkyl, C2-6alkenyl, -C(=O)R14, -C(=O)OR14, - C(=O)N(R13)(R14), or C3-8cycloalkyl group of R1or R2are taken together with the atoms to which they are attached to form a C3-8cycloalkyl, 3- to 12-memberedheterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, whereinthe C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl,or 5- to 10-membered heteroaryl is optionally substituted with one or moreR1b;or R1 and R2 are taken together with the N to which they are attached to form a 3- to 12-membered heterocyclyl optionally substituted with one or more R3;each R3is independently halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, oxo, -OR12, -SR12, -SF5, -N(Rx)(Ry), -NO2, -CN, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, - OC(=O)R14, -OC(=O)N(R13)R14, -OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), -C(=O)OR14, -C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, -N(R13)S(=O)2R14, -S(=O)R14, -S(=O)N(R13)R14, -S(=O)OR14, -S(=O)2R14, - S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl,or 5- to 10-membered heteroaryl, whereinthe C1-6alkyl of R3 is optionally substituted with one or more R3a, andoptionally, two substituents of R3are taken together with the atoms to which they are attached form a C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-memberedaryl, or 5- to 10-membered heteroaryl,wherein the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl is optionally substituted oneor more R3b; Attorney Docket No.: 185992002240 Ring A is 4- to 8-membered monocyclic cycloalkenyl, 4- to 8-membered unsaturated monocyclic heterocyclyl, phenyl, or 5- to 6-membered heteroaryl, wherein the 4- to 8-membered monocyclic cycloalkenyl, 4- to 8-membered unsaturated monocyclic heterocyclyl, phenyl, or 5- to 6-membered heteroaryl of Ring A is optionally substituted by one or more R4, and the 4- to 8-membered unsaturated monocyclic heterocyclyl or 5- to 6-membered heteroaryl of Ring A comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S; each R4is independently halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, -OR12, -SR12, -SF5, - N(Rx)(Ry), -NO2, -CN, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, - OC(=O)R14, -OC(=O)N(R13)R14, -OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), - C(=O)OR14, -C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, - N(R13)S(=O)2R14, -S(=O)R14, -S(=O)N(R13)R14, -S(=O)OR14, -S(=O)2R14, - S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C1-6alkyl of R4is optionally substituted by one or more R4a, the C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of R4is optionally substituted with one or more R4b, and the 3- to 8-membered heterocyclyl of R4comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S; L is a bond, C1-6alkyl, -O-(C1-6alkyl)-, -S-(C1-6alkyl)-, or -N(R5)(C1-6alkyl)-, wherein the C1-6alkyl, -O-(C1-6alkyl)-, -S-(C1-6alkyl)-, or -N(R5)(C1-6alkyl)- is optionally substituted by one or more RL; each RLis independently halo, -N(Rx)(Ry), -OR12, -SR12, -SF5, -NO2, -CN, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, -OC(=O)R14, -OC(=O)N(R13)R14, - OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), -C(=O)OR14, C3-8cycloalkyl, 3- to 8- membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, or two RLare taken together along with the atoms to which they are attached to form a C3-8cycloalkyl or 3- to 8-membered heterocyclyl; R5is H, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, -C(=O)R14, -S(=O)2R14, -S(=O)2N(R13)(R14), or C3-8cycloalkyl, wherein the C1-6alkyl of R5is optionally substituted with one or more halo, -N(Rx)(Ry), -OR12, -SR12, -SF5, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, - OC(=O)R14, -OC(=O)N(R13)R14, -OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), - Attorney Docket No.: 185992002240 C(=O)OR14, -C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, - N(R13)S(=O)2R14, -S(=O)R14, -S(=O)N(R13)R14, -S(=O)OR14, -S(=O)2R14, or - S(=O)2N(R13)(R14), and the C3-8cycloalkyl is optionally substituted with one or more R5b; R6is -N(Rx)(Ry), -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, - OC(=O)N(R13)R14, -C(=O)(C1-6alkyl)N(Rx)(Ry), -C(=O)N(R13)(R14), -C(=NR15)N(R13)R14, - N(R13)S(=O)2R14, -S(=O)N(R13)R14, -S(=O)2N(R13)(R14), or 3- to 12-membered N-containing heterocyclyl, wherein the 3- to 12-membered N-containing heterocyclyl of R6is optionally substituted with one or more R6b, -C(=O)R14, -C(=O)N(R13)(R14), or -C(=O)OR14,and the 3- to 12-membered N-containing heterocyclyl of R6further comprises 1 or 2 atoms selected from the group consisting of N, O, and S; R7, R8, R9, and R10are each independently H, halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, - OR11, -OR12, -SR12, -SF5, -N(Rx)(Ry), -NO2, -CN, -N(R13)C(=O)R14, - N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, -OC(=O)R14, -OC(=O)N(R13)R14, - OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), -C(=O)OR14, -C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, -N(R13)S(=O)2R14, -S(=O)R14, -S(=O)N(R13)R14, - S(=O)OR14, -S(=O)2R14, -S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C1-6alkyl of R7, R8, R9, or R10is optionally substituted by one or more R7a, the 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of R7, R8, R9, or R10is optionally substituted with one or more R7b, and the 3- to 8-membered heterocyclyl of R7, R8, R9, or R10comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S, and optionally, two substituents of R7, R8, R9, or R10are taken together with the atoms to which they are attached form a C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R7b; each R1a, R3a, R4a, R6a, or R7ais independently halo, -N(Rx)(Ry), -OR12, -SR12, -SF5, -NO2, - CN, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, -OC(=O)R14, - OC(=O)N(R13)R14, -OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), -C(=O)OR14, - C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, -N(R13)S(=O)2R14, - Attorney Docket No.: 185992002240 S(=O)R14, -S(=O)2R14, -S(=O)N(R13)R14, -S(=O)OR14, -S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of R1a, R3a, R4a, R6a, or R7ais optionally substituted with one or more R1b, and the 3- to 12-membered heterocyclyl of R1a, R3a, R4a, R6a, or R7acomprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S; each R1b, R3b, R4b, R5b, R6b, or R7bis independently halo, C1-6alkyl, -OR11, -N(Rx)(Ry), oxo, - CN, C3-8cycloalkyl, or 3- to 8-membered heterocyclyl, wherein the C1-6alkyl of R1b, R3b, R4b, R5b, R6b, or R7bis optionally substituted by -OR12, - N(Rx)(Ry), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl; each R11is independently H, C1-6alkyl, C2-6alkenyl, C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C1-6alkyl of R11is optionally substituted with 6- to 10-membered aryl, or 5- to 10- membered heteroaryl, wherein the 6- to 10-membered aryl, or 5- to 10-membered heteroaryl is optionally substituted with halo, C1-3alkyl, C1-3alkoxy, or -N(Rx)(Ry), and the 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of R11is optionally substituted with halo, C1-3alkyl, C1-3alkoxy, -N(Rx)(Ry), or 3- to 12-membered heterocyclyl; each R12is independently H, C1-6alkyl, C2-6alkenyl, C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C1-6alkyl is optionally substituted with one or more halo, deuterium, C1- 6alkoxy, -N(Rx)(Ry), or 3- to 8-membered heterocyclyl; each R13is independently H, C1-6alkyl, or C3-8cycloalkyl; each R14is independently H, C1-6alkyl, C2-6alkenyl, C3-8cycloalkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, or 3- to 12-membered heterocyclyl, wherein the C1-6alkyl of R14is optionally substituted by halo, -OH, -O(C1-6alkyl), -O(C=O)C1-8alkyl), -N(Rx)(Ry), C3-8cycloalkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, or 3- to 12-membered heterocyclyl, and Attorney Docket No.: 185992002240 the C3-8cycloalkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, or 3- to12-membered heterocyclyl of R14 is optionally substituted with halo, C1-6alkyl, or -N(Rx)(Ry); each R15is independently H or C1-6alkyl; andeach Rx and Ry is independently H, C1-6alkyl, C3-8cycloalkyl, -C(=O)(C1-6alkyl), or -C(=O)O(C1-6alkyl), wherein the C1-6alkyl of Rx or Ry is optionally substituted with 6- to 10-membered aryl, 5- to10-membered heteroaryl, -NH2, NH(C1-6alkyl), or -N(C1-6alkyl)(C1-6alkyl), and the C1-6alkyl of -C(=O)(C1-6alkyl) or -C(=O)O(C1-6alkyl) is optionally substituted with-O(C=O)C1-8alkyl); wherein (i) when Ring A is phenyl and R6is selected from the group consisting of -NH2, -NHCH3, and -N(CH3)3, R1and R2are not both C1-2alkyl; (ii) when R1and R2are taken together with the N to which they are attached to form a 4-methylpiperazinyl, -(Ring A)-X-L-R6 is not (iii) when R1and R2are taken together with the N to which they are attached to form a morpholinyl, R6is not selected from the group consisting of -NH2, -NHC(O)CH3, and - NHC(O)O-C(CH3)3; and (iv) when Ring A is pyridin-4yl substituted with -NHC(CH3)phenyl, R1and R2are not taken together with the N to which they are attached to form an optionally substituted 2,5-diazabicyclo[2.2.2]octanyl. In some embodiments of the above, the compound is a compoundof formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments of a compound of formula (I), or any variation or embodimentthereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or salt of any of the foregoing, R1and R2are each independently C1-6alkyl, C2-6alkenyl, or C3-8cycloalkyl, wherein the C1-6alkyl of R1 or R2 is optionally substituted with one or more R1a,the C3-8cycloalkyl of R1 or R2 is optionally substituted with one or more R1b, andoptionally, two substituents of the C1-6alkyl, C2-6alkenyl, or C3-8cycloalkyl group of R1 or R2are taken together with the atoms to which they are attached to form a C3- Attorney Docket No.: 185992002240 8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10- membered heteroaryl, wherein the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R1b; or R1and R2are taken together with the N to which they are attached to form a 3- to 12- membered heterocyclyl optionally substituted with one or more R3; each R3is independently halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, oxo, -OR12, -SR12, -SF5, - N(Rx)(Ry), -NO2, -CN, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, - OC(=O)R14, -OC(=O)N(R13)R14, -OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), - C(=O)OR14, -C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, - N(R13)S(=O)2R14, -S(=O)R14, -S(=O)N(R13)R14, -S(=O)OR14, -S(=O)2R14, - S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C1-6alkyl of R3is optionally substituted with one or more R3a, and optionally, two substituents of R3are taken together with the atoms to which they are attached form a C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10- membered aryl, or 5- to 10-membered heteroaryl is optionally substituted one or more R3b; Ring A is 4- to 12-membered cycloalkenyl, 4- to 12-membered unsaturated heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the 4- to 12-membered cycloalkenyl, 4- to 12-membered unsaturated heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of Ring A is optionally substituted by one or more R4, and the 4- to 12-membered unsaturated heterocyclyl or 5- to 10-membered heteroaryl of Ring A comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S; each R4is independently halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, -OR12, -SR12, -SF5, - N(Rx)(Ry), -NO2, -CN, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, - OC(=O)R14, -OC(=O)N(R13)R14, -OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), - C(=O)OR14, -C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, - N(R13)S(=O)2R14, -S(=O)R14, -S(=O)N(R13)R14, -S(=O)OR14, -S(=O)2R14, - Attorney Docket No.: 185992002240 S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C1-6alkyl of R4is optionally substituted by one or more R4a, the C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of R4is optionally substituted with one or more R4b, and the 3- to 8-membered heterocyclyl of R4comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S; L is a bond, C1-6alkyl, -O-(C1-6alkyl)-, -S-(C1-6alkyl)-, or -N(R5)(C1-6alkyl)-, wherein the C1-6alkyl, -O-(C1-6alkyl)-, -S-(C1-6alkyl)-, or -N(R5)(C1-6alkyl)- is optionally substituted by one or more RL; each RLis independently halo, -N(Rx)(Ry), -OR12, -SR12, -SF5, -NO2, -CN, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, -OC(=O)R14, -OC(=O)N(R13)R14, - OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), -C(=O)OR14, C3-8cycloalkyl, 3- to 8- membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, or two RLare taken together along with the atoms to which they are attached to form a C3-8cycloalkyl or 3- to 8-membered heterocyclyl; R5is H, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, or C3-8cycloalkyl, wherein the C1-6alkyl of R5is optionally substituted with one or more halo, -N(Rx)(Ry), -OR12, -SR12, -SF5, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, - OC(=O)R14, -OC(=O)N(R13)R14, -OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), - C(=O)OR14, -C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, - N(R13)S(=O)2R14, -S(=O)R14, -S(=O)N(R13)R14, -S(=O)OR14, -S(=O)2R14, or - S(=O)2N(R13)(R14), and the C3-8cycloalkyl is optionally substituted with one or more R5b; R6is -N(Rx)(Ry), -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, - OC(=O)N(R13)R14, -C(=O)(C1-6alkyl)N(Rx)(Ry), -C(=O)N(R13)(R14), -C(=NR15)N(R13)R14, - N(R13)S(=O)2R14, -S(=O)N(R13)R14, -S(=O)2N(R13)(R14), or 3- to 12-membered N-containing heterocyclyl, wherein the 3- to 12-membered N-containing heterocyclyl of R6is optionally substituted with one or more R6b, -C(=O)R14, -C(=O)N(R13)(R14), or -C(=O)OR14, and the 3- to 12-membered N-containing heterocyclyl of R6further comprises 1 or 2 atoms selected from the group consisting of N, O, and S; R7, R8, R9, and R10are each independently H, halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, - OR11, -OR12, -SR12, -SF5, -N(Rx)(Ry), -NO2, -CN, -N(R13)C(=O)R14, - Attorney Docket No.: 185992002240 N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, -OC(=O)R14, -OC(=O)N(R13)R14, - OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), -C(=O)OR14, -C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, -N(R13)S(=O)2R14, -S(=O)R14, -S(=O)2R14, - S(=O)N(R13)R14, -S(=O)OR14, -S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C1-6alkyl of R7, R8, R9, or R10is optionally substituted by one or more R7a, the 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of R7, R8, R9, or R10is optionally substituted with one or more R7b, and the 3- to 8-membered heterocyclyl of R7, R8, R9, or R10comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S, and optionally, two substituents of R7, R8, R9, or R10are taken together with the atoms to which they are attached form a C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R7b; each R1a, R3a, R6a, or R7ais independently halo, -N(Rx)(Ry), -OR12, -SR12, -SF5, -NO2, -CN, - N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, -OC(=O)R14, - OC(=O)N(R13)R14, -OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), -C(=O)OR14, - C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, -N(R13)S(=O)2R14, - S(=O)R14, -S(=O)N(R13)R14, -S(=O)OR14, -S(=O)2R14, -S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of R1a, R3a, R6a, or R7ais optionally substituted with one or more R1b, and the 3- to 12-membered heterocyclyl of R1a, R3a, R6a, or R7acomprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S; each R1b, R3b, R4b, R5b, R6b, or R7bis independently halo, C1-6alkyl, -OR11, -N(Rx)(Ry), oxo, - CN, C3-8cycloalkyl, or 3- to 8-membered heterocyclyl, wherein the C1-6alkyl of R1b, R3b, R4b, R5b, R6b, or R7bis optionally substituted by -OR12, - N(Rx)(Ry), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 6- membered heteroaryl; Attorney Docket No.: 185992002240 each R11is independently H, C1-6alkyl, C3-8cycloalkyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 6-membered heteroaryl, wherein the C1-6alkyl of R11is optionally substituted with 6- to 10-membered aryl, or 5- to 10- membered heteroaryl wherein the 6- to 10-membered aryl, or 5- to 10-membered heteroaryl is optionally substituted with halo, C1-3alkyl, C1-3alkoxy, or -N(Rx)(Ry) , and the phenyl or 5- to 6-membered heteroaryl of R11is optionally substituted with halo, C1-3alkyl, C1-3alkoxy, -N(Rx)(Ry), or 3- to 8-membered heterocyclyl; each R12is independently H, C1-6alkyl, or C3-8cycloalkyl, wherein the C1-6alkyl is optionally substituted with one or more halo, deuterium, C1- 6alkoxy, -N(Rx)(Ry), or 3- to 8-membered heterocyclyl; each R13is independently H, C1-6alkyl, or C3-8cycloalkyl; each R14is independently H, C1-6alkyl, C3-8cycloalkyl, phenyl, 5- to 6-membered heteroaryl, or 3- to 12-membered heterocyclyl, wherein the C1-6alkyl of R14is optionally substituted by halo, -OH, -O(C1-6alkyl), -N(Rx)(Ry), C3-8cycloalkyl, phenyl, 5- to 6-membered heteroaryl, or 3- to 12-membered heterocyclyl, and the C3-8cycloalkyl, phenyl, 5- to 6-membered heteroaryl, or 3- to 12-membered heterocyclyl of R14is optionally substituted with halo, C1-6alkyl, or -N(Rx)(Ry); each R15is independently H or C1-6alkyl; and each Rxand Ryis independently H, C1-6alkyl, C3-8cycloalkyl, -C(=O)(C1-6alkyl), or - C(=O)O(C1-6alkyl), wherein the C1-6alkyl of Rxor Ryis optionally substituted with 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -NH2, NH(C1-6alkyl), or -N(C1-6alkyl)(C1-6alkyl), and the C1-6alkyl of -C(=O)(C1-6alkyl) or -C(=O)O(C1-6alkyl) is optionally substituted with - O(C=O)C1-8alkyl); wherein (i) when Ring A is phenyl and R6is selected from the group consisting of -NH2, -NHCH3, and -N(CH3)3, R1and R2are not both C1-2alkyl; (ii) when R1and R2are taken together with the N to which they are attached to form a 4-methylpiperazinyl, -(Ring A)-X-L-R6 is not Attorney Docket No.: 185992002240 (iii) when R1and R2are taken together with the N to which they are attached to form a morpholinyl, R6is not selected from the group consisting of -NH2, -NHC(O)CH3, and - NHC(O)O-C(CH3)3; and (iv) when Ring A is pyridin-4yl substituted with -NHC(CH3)phenyl, R1and R2are not taken together with the N to which they are attached to form an optionally substituted 2,5-diazabicyclo[2.2.2]octanyl. In some embodiments of the above, the compound is a compoundof formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments of a compound of formula (I), or any variation or embodimentthereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or salt of any of the foregoing, R1and R2are each independently C1-6alkyl, C2-6alkenyl, or C3-8cycloalkyl, wherein the C1-6alkyl of R1 or R2 is optionally substituted with one or more R1a,the C3-8cycloalkyl of R1 or R2 is optionally substituted with one or more R1b, andoptionally, two substituents of the C1-6alkyl, C2-6alkenyl, or C3-8cycloalkyl group of R1 or R2are taken together with the atoms to which they are attached to form a C3- 8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl,or 5- to 10-membered heteroaryl is optionally substituted with one or moreR1b;or R1 and R2 are taken together with the N to which they are attached to form a 3- to 12-membered heterocyclyl optionally substituted with one or more R3;each R3is independently halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, oxo, -OR12, -SR12, -SF5, -N(Rx)(Ry), -NO2, -CN, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, - OC(=O)R14, -OC(=O)N(R13)R14, -OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), -C(=O)OR14, -C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, -N(R13)S(=O)2R14, -S(=O)R14, -S(=O)N(R13)R14, -S(=O)OR14, -S(=O)2R14, - S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl,or 5- to 10-membered heteroaryl, whereinthe C1-6alkyl of R3 is optionally substituted with one or more R3a, andoptionally, two substituents of R3are taken together with the atoms to which they are attached form a C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-memberedaryl, or 5- to 10-membered heteroaryl, Attorney Docket No.: 185992002240 wherein the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10- membered aryl, or 5- to 10-membered heteroaryl is optionally substituted one or more R3b; Ring A is 4- to 8-membered monocyclic cycloalkenyl, 4- to 8-membered unsaturated monocyclic heterocyclyl, phenyl, or 5- to 6-membered heteroaryl, wherein the 4- to 8-membered monocyclic cycloalkenyl, 4- to 8-membered unsaturated monocyclic heterocyclyl, phenyl, or 5- to 6-membered heteroaryl of Ring A is optionally substituted by one or more R4, and the 4- to 8-membered unsaturated monocyclic heterocyclyl or 5- to 6-membered heteroaryl of Ring A comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S; each R4is independently halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, -OR12, -SR12, -SF5, - N(Rx)(Ry), -NO2, -CN, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, - OC(=O)R14, -OC(=O)N(R13)R14, -OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), - C(=O)OR14, -C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, - N(R13)S(=O)2R14, -S(=O)R14, -S(=O)N(R13)R14, -S(=O)OR14, -S(=O)2R14, - S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C1-6alkyl of R4is optionally substituted by one or more R4a, the C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of R4is optionally substituted with one or more R4b, and the 3- to 8-membered heterocyclyl of R4comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S; L is a bond, C1-6alkyl, -O-(C1-6alkyl)-, -S-(C1-6alkyl)-, or -N(R5)(C1-6alkyl)-, wherein the C1-6alkyl, -O-(C1-6alkyl)-, -S-(C1-6alkyl)-, or -N(R5)(C1-6alkyl)- is optionally substituted by one or more RL; each RLis independently halo, -N(Rx)(Ry), -OR12, -SR12, -SF5, -NO2, -CN, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, -OC(=O)R14, -OC(=O)N(R13)R14, - OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), -C(=O)OR14, C3-8cycloalkyl, 3- to 8- membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, or two RLare taken together along with the atoms to which they are attached to form a C3-8cycloalkyl or 3- to 8-membered heterocyclyl; R5is H, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, or C3-8cycloalkyl, wherein Attorney Docket No.: 185992002240 the C1-6alkyl of R5is optionally substituted with one or more halo, -N(Rx)(Ry), -OR12, -SR12, -SF5, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, - OC(=O)R14, -OC(=O)N(R13)R14, -OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), - C(=O)OR14, -C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, - N(R13)S(=O)2R14, -S(=O)R14, -S(=O)2R14, -S(=O)N(R13)R14, -S(=O)OR14, or - S(=O)2N(R13)(R14), and the C3-8cycloalkyl is optionally substituted with one or more R5b; R6is -N(Rx)(Ry), -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, - OC(=O)N(R13)R14, -C(=O)(C1-6alkyl)N(Rx)(Ry), -C(=O)N(R13)(R14), -C(=NR15)N(R13)R14, - N(R13)S(=O)2R14, -S(=O)N(R13)R14, -S(=O)2N(R13)(R14), or 3- to 12-membered N-containing heterocyclyl, wherein the 3- to 12-membered N-containing heterocyclyl of R6is optionally substituted with one or more R6b, -C(=O)R14, -C(=O)N(R13)(R14), or -C(=O)OR14, and the 3- to 12-membered N-containing heterocyclyl of R6further comprises 1 or 2 atoms selected from the group consisting of N, O, and S; R7, R8, R9, and R10are each independently H, halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, - OR11, -OR12, -SR12, -SF5, -N(Rx)(Ry), -NO2, -CN, -N(R13)C(=O)R14, - N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, -OC(=O)R14, -OC(=O)N(R13)R14, - OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), -C(=O)OR14, -C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, -N(R13)S(=O)2R14, -S(=O)R14, -S(=O)N(R13)R14, - S(=O)OR14, -S(=O)2R14, -S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C1-6alkyl of R7, R8, R9, or R10is optionally substituted by one or more R7a, the 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of R7, R8, R9, or R10is optionally substituted with one or more R7b, and the 3- to 8-membered heterocyclyl of R7, R8, R9, or R10comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S, and optionally, two substituents of R7, R8, R9, or R10are taken together with the atoms to which they are attached form a C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R7b; Attorney Docket No.: 185992002240 each R1a, R3a, R6a, or R7ais independently halo, -N(Rx)(Ry), -OR12, -SR12, -SF5, -NO2, -CN, - N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, -OC(=O)R14, - OC(=O)N(R13)R14, -OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), -C(=O)OR14, - C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, -N(R13)S(=O)2R14, - S(=O)R14, -S(=O)N(R13)R14, -S(=O)OR14, -S(=O)2R14, -S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of R1a, R3a, R6a, or R7ais optionally substituted with one or more R1b, and the 3- to 12-membered heterocyclyl of R1a, R3a, R6a, or R7acomprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S; each R1b, R3b, R4b, R5b, R6b, or R7bis independently halo, C1-6alkyl, -OR11, -N(Rx)(Ry), oxo, - CN, C3-8cycloalkyl, or 3- to 8-membered heterocyclyl, wherein the C1-6alkyl of R1b, R3b, R4b, R5b, R6b, or R7bis optionally substituted by -OR12, - N(Rx)(Ry), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 6- membered heteroaryl; each R11is independently H, C1-6alkyl, C3-8cycloalkyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 6-membered heteroaryl, wherein the C1-6alkyl of R11is optionally substituted with 6- to 10-membered aryl, or 5- to 10- membered heteroaryl wherein the 6- to 10-membered aryl, or 5- to 10-membered heteroaryl is optionally substituted with halo, C1-3alkyl, C1-3alkoxy, or -N(Rx)(Ry) , and the phenyl or 5- to 6-membered heteroaryl of R11is optionally substituted with halo, C1-3alkyl, C1-3alkoxy, -N(Rx)(Ry), or 3- to 8-membered heterocyclyl; each R12is independently H, C1-6alkyl, or C3-8cycloalkyl, wherein the C1-6alkyl is optionally substituted with one or more halo, deuterium, C1-6alkoxy, -N(Rx)(Ry), or 3- to 8-membered heterocyclyl; each R13is independently H, C1-6alkyl, or C3-8cycloalkyl; each R14is independently H, C1-6alkyl, C3-8cycloalkyl, phenyl, 5- to 6-membered heteroaryl, or 3- to 12-membered heterocyclyl, wherein the C1-6alkyl of R14is optionally substituted by halo, -OH, -O(C1-6alkyl), -N(Rx)(Ry), C3-8cycloalkyl, phenyl, 5- to 6-membered heteroaryl, or 3- to 12-membered heterocyclyl, and Attorney Docket No.: 185992002240 the C3-8cycloalkyl, phenyl, 5- to 6-membered heteroaryl, or 3- to 12-memberedheterocyclyl of R14 is optionally substituted with halo, C1-6alkyl, or -N(Rx)(Ry); each R15is independently H or C1-6alkyl; andeach Rx and Ry is independently H, C1-6alkyl, C3-8cycloalkyl, -C(=O)(C1-6alkyl), or -C(=O)O(C1-6alkyl), wherein the C1-6alkyl of Rx or Ry is optionally substituted with 6- to 10-membered aryl, 5- to10-membered heteroaryl, -NH2, NH(C1-6alkyl), or -N(C1-6alkyl)(C1-6alkyl), andthe C1-6alkyl of -C(=O)(C1-6alkyl) or -C(=O)O(C1-6alkyl) is optionally substituted with -O(C=O)C1-8alkyl); wherein (i) when Ring A is phenyl and R6is selected from the group consisting of -NH2, -NHCH3, and -N(CH3)3, R1and R2are not both C1-2alkyl; (ii) when R1and R2are taken together with the N to which they are attached to form a 4-methylpiperazinyl, -(Ring A)-X-L-R6 is not (iii) when R1and R2are taken together with the N to which they are attached to form a morpholinyl, R6is not selected from the group consisting of -NH2, -NHC(O)CH3, and - NHC(O)O-C(CH3)3; and (iv) when Ring A is pyridin-4yl substituted with -NHC(CH3)phenyl, R1and R2are not taken together with the N to which they are attached to form an optionally substituted 2,5-diazabicyclo[2.2.2]octanyl. In some embodiments of the above, the compound is a compoundof formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments of formula (I), R1and R2are each independently C1-6alkyl, C2-6alkenyl, -C(=O)R14, -C(=O)OR14, - C(=O)N(R13)(R14), or C3-8cycloalkyl, wherein the C1-6alkyl of R1 or R2 is optionally substituted with one or more R1a,the C3-8cycloalkyl of R1 or R2 is optionally substituted with one or more R1b, andoptionally, two substituents of the C1-6alkyl, C2-6alkenyl, -C(=O)R14, -C(=O)OR14, - C(=O)N(R13)(R14), or C3-8cycloalkyl group of R1or R2are taken together with the atoms to which they are attached to form a C3-8cycloalkyl, 3- to 12-memberedheterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein Attorney Docket No.: 185992002240 the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R1b; or R1and R2are taken together with the N to which they are attached to form a 3- to 12- membered heterocyclyl optionally substituted with one or more R3; each R3is independently halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, oxo, -OR12, -SR12, -SF5, - N(Rx)(Ry), -NO2, -CN, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, - OC(=O)R14, -OC(=O)N(R13)R14, -OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), - C(=O)OR14, -C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, - N(R13)S(=O)2R14, -S(=O)R14, -S(=O)N(R13)R14, -S(=O)OR14, -S(=NR15)R14, - S(=NR15)N(R13)R14, -S(=NR15)OR14, -S(=O)2R14, -S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C1-6alkyl of R3is optionally substituted with one or more R3a, and optionally, two substituents of R3are taken together with the atoms to which they are attached form a C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10- membered aryl, or 5- to 10-membered heteroaryl is optionally substituted one or more R3b; Ring A is 4- to 8-membered monocyclic cycloalkenyl, 4- to 8-membered unsaturated monocyclic heterocyclyl, phenyl, or 5- to 6-membered heteroaryl, wherein the 4- to 8-membered monocyclic cycloalkenyl, 4- to 8-membered unsaturated monocyclic heterocyclyl, phenyl, or 5- to 6-membered heteroaryl of Ring A is optionally substituted by one or more R4, and the 4- to 8-membered unsaturated monocyclic heterocyclyl or 5- to 6-membered heteroaryl of Ring A comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S; each R4is independently halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, -OR12, -SR12, -SF5, - N(Rx)(Ry), -NO2, -CN, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, - OC(=O)R14, -OC(=O)N(R13)R14, -OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), - C(=O)OR14, -C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, - N(R13)S(=O)2R14, -S(=O)R14, -S(=O)N(R13)R14, -S(=O)OR14, -S(=NR15)R14, - S(=NR15)N(R13)R14, -S(=NR15)OR14, -S(=O)2R14, -S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein Attorney Docket No.: 185992002240 the C1-6alkyl of R4is optionally substituted by one or more R4a, the C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of R4is optionally substituted with one or more R4b, and the 3- to 8-membered heterocyclyl of R4comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S; L is a bond, C1-6alkyl, -O-(C1-6alkyl)-, -S-(C1-6alkyl)-, or -N(R5)(C1-6alkyl)-, wherein the C1-6alkyl, -O-(C1-6alkyl)-, -S-(C1-6alkyl)-, or -N(R5)(C1-6alkyl)- is optionally substituted by one or more RL; each RLis independently halo, -N(Rx)(Ry), -OR12, -SR12, -SF5, -NO2, -CN, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, -OC(=O)R14, -OC(=O)N(R13)R14, - OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), -C(=O)OR14, C3-8cycloalkyl, 3- to 8- membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, or two RLare taken together along with the atoms to which they are attached to form a C3-8cycloalkyl or 3- to 8-membered heterocyclyl; R5is H, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, -C(=O)R14, -S(=O)2R14, -S(=O)2N(R13)(R14), or C3-8cycloalkyl, wherein the C1-6alkyl of R5is optionally substituted with one or more halo, -N(Rx)(Ry), -OR12, -SR12, -SF5, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, - OC(=O)R14, -OC(=O)N(R13)R14, -OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), - C(=O)OR14, -C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, - N(R13)S(=O)2R14, -S(=O)R14, -S(=O)N(R13)R14, -S(=O)OR14, -S(=NR15)R14, - S(=NR15)N(R13)R14, -S(=NR15)OR14, -S(=O)2R14, or -S(=O)2N(R13)(R14), and the C3-8cycloalkyl is optionally substituted with one or more R5b; R6is -OR12, -O-(3- to 12-membered N-containing heterocyclyl), -O-(5- to 6-membered N- containing heteroaryl), -N(Rx)(Ry), -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, - N(R13)C(=O)OR14, -OC(=O)N(R13)R14, -C(=O)(C1-6alkyl)N(Rx)(Ry), -C(=O)N(R13)(R14), - C(=NR15)N(R13)R14, -N(R13)S(=O)2R14, -S(=O)N(R13)R14, -S(=O)2N(R13)(R14), or 3- to 12- membered N-containing heterocyclyl, wherein the 3- to 12-membered N-containing heterocyclyl, -O-(3- to 12-membered N- containing heterocyclyl), or -O-(5- to 6-membered N-containing heteroaryl) of R6is optionally substituted with one or more R6b, -C(=O)R14, -C(=O)N(R13)(R14), or - C(=O)OR14, and the 3- to 12-membered N-containing heterocyclyl of R6optionally further comprises 1 or 2 atoms selected from the group consisting of N, O, and S; Attorney Docket No.: 185992002240 R7, R8, R9, and R10are each independently H, halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, - OR11, -OR12, -SR12, -SF5, -N(Rx)(Ry), -NO2, -CN, -N(R13)C(=O)R14, - N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, -OC(=O)R14, -OC(=O)N(R13)R14, - OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), -C(=O)OR14, -C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, -N(R13)S(=O)2R14, -S(=O)R14, -S(=O)N(R13)R14, - S(=O)OR14, -S(=NR15)R14, -S(=NR15)N(R13)R14, -S(=NR15)OR14, -S(=O)2R14, - S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C1-6alkyl of R7, R8, R9, or R10is optionally substituted by one or more R7a, the 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of R7, R8, R9, or R10is optionally substituted with one or more R7b, and the 3- to 8-membered heterocyclyl of R7, R8, R9, or R10comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S, and optionally, two substituents of R7, R8, R9, or R10are taken together with the atoms to which they are attached form a C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R7b; each R1a, R3a, R4a, R6a, or R7ais independently halo, -N(Rx)(Ry), -OR12, -SR12, -SF5, -NO2, - CN, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, -OC(=O)R14, - OC(=O)N(R13)R14, -OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), -C(=O)OR14, - C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, -N(R13)S(=O)2R14, - S(=O)R14, -S(=O)2R14, -S(=O)N(R13)R14, -S(=O)OR14, -S(=NR15)R14, -S(=NR15)N(R13)R14, - S(=NR15)OR14, -S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10- membered aryl, or 5- to 10-membered heteroaryl, wherein the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of R1a, R3a, R4a, R6a, or R7ais optionally substituted with one or more R1b, and the 3- to 12-membered heterocyclyl of R1a, R3a, R4a, R6a, or R7acomprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S; each R1b, R3b, R4b, R5b, R6b, or R7bis independently halo, C1-6alkyl, -OR11, -N(Rx)(Ry), oxo, - CN, C3-8cycloalkyl, or 3- to 8-membered heterocyclyl, wherein Attorney Docket No.: 185992002240 the C1-6alkyl of R1b, R3b, R4b, R5b, R6b, or R7bis optionally substituted by -OR12, - N(Rx)(Ry), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl; each R11is independently H, C1-6alkyl, C2-6alkenyl, C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C1-6alkyl of R11is optionally substituted with 6- to 10-membered aryl, or 5- to 10- membered heteroaryl, wherein the 6- to 10-membered aryl, or 5- to 10-membered heteroaryl is optionally substituted with halo, C1-3alkyl, C1-3alkoxy, or -N(Rx)(Ry), and the 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of R11is optionally substituted with halo, C1-3alkyl, C1-3alkoxy, -N(Rx)(Ry), or 3- to 12-membered heterocyclyl; each R12is independently H, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, 3- to 8- membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C1-6alkyl of R12is optionally substituted with one or more halo, deuterium, C1-6alkoxy, -N(Rx)(Ry), or 3- to 8-membered heterocyclyl; each R13is independently H, C1-6alkyl, or C3-8cycloalkyl; each R14is independently H, C1-6alkyl, C2-6alkenyl, C3-8cycloalkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, or 3- to 12-membered heterocyclyl, wherein the C1-6alkyl of R14is optionally substituted by one or more halo, -OH, -O(C1-6alkyl), -SH, -S(C1-6alkyl), -(C=O)NH2, -(C=O)OH, -O(C=O)C1-8alkyl), -NH(C=NH)NH2, - N(Rx)(Ry), C3-8cycloalkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, or 3- to 12-membered heterocyclyl, wherein the 6- to 10-membered aryl is optionally substituted by -OH, and the C3-8cycloalkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, or 3- to 12-membered heterocyclyl of R14is optionally substituted with halo, C1-6alkyl, -OH, or -N(Rx)(Ry); each R15is independently H or C1-6alkyl; and each Rxand Ryis independently H, C1-6alkyl, C3-8cycloalkyl, -C(=O)(C1-6alkyl), or - C(=O)O(C1-6alkyl), wherein the C1-6alkyl of Rxor Ryis optionally substituted with halo, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -NH2, NH(C1-6alkyl), or -N(C1-6alkyl)(C1-6alkyl), and the C1-6alkyl of -C(=O)(C1-6alkyl) or -C(=O)O(C1-6alkyl) is optionally substituted with -O(C=O)C1-8alkyl) , wherein Attorney Docket No.: 185992002240 (i) when Ring A is phenyl and R6is selected from the group consisting of -NH2, -NHCH3, and -N(CH3)3, R1and R2are not both C1-2alkyl; (ii) when R1and R2are taken together with the N to which they are attached to form a 4-methylpiperazinyl, -(Ring A)-X-L-R6 is not (iii) when R1and R2are taken together with the N to which they are attached to form a morpholinyl, R6is not selected from the group consisting of -NH2, -NHC(O)CH3, and - NHC(O)O-C(CH3)3; and (iv) when Ring A is pyridin-4yl substituted with -NHC(CH3)phenyl, R1and R2are not taken together with the N to which they are attached to form an optionally substituted 2,5- diazabicyclo[2.2.2]octanyl. In some embodiments of formula (I),R1and R2are each independently C1-6alkyl optionally substituted with one or more R1a;or R1 and R2 are taken together with the N to which they are attached to form a 3- to 12-membered heterocyclyl optionally substituted with one or more R3;each R3 is independently halo, C1-6alkyl, oxo, -OR12, -N(Rx)(Ry), -CN, or -C(=O)N(R13)(R14), wherein the C1-6alkyl of R3is optionally substituted with R3a;Ring A is 4- to 12-membered cycloalkenyl, 4- to 12-membered unsaturated heterocyclyl, 6-to 10-membered aryl, or 5- to 10-membered heteroaryl, whereinthe 4- to 12-membered cycloalkenyl, 4- to 12-membered unsaturated heterocyclyl, 6-to 10-membered aryl, or 5- to 10-membered heteroaryl of Ring A is optionallysubstituted by one or more R4, and the 4- to 12-membered unsaturated heterocyclyl or 5- to 10-membered heteroaryl ofRing A comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S;each R4 is independently halo, C1-6alkyl, or -OR12; L is a bond, C1-6alkyl, -O-(C1-6alkyl)-, -S-(C1-6alkyl)-, or -N(R5)(C1-6alkyl)-, wherein the C1-6alkyl, -O-(C1-6alkyl)-, -S-(C1-6alkyl)-, or -N(R5)(C1-6alkyl)- is optionallysubstituted by one or more RL;each RL is independently halo, -N(Rx)(Ry), -OR12, -SR12, -SF5, -NO2, -CN, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, -OC(=O)R14, -OC(=O)N(R13)R14, - Attorney Docket No.: 185992002240 OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), -C(=O)OR14, C3-8cycloalkyl, 3- to 8- membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, or two RLare taken together along with the atoms to which they are attached to form a C3-8cycloalkyl or 3- to 8-membered heterocyclyl; R5is H, C1-6alkyl, or C3-8cycloalkyl, wherein the C1-6alkyl of R5is optionally substituted with one or more halo, -N(Rx)(Ry), or - OR12, and the C3-8cycloalkyl is optionally substituted with one or more R5b; R6is -OR12, -O-(3- to 12-membered N-containing heterocyclyl), -O-(5- to 6-membered N- containing heteroaryl), -N(Rx)(Ry), -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, - N(R13)C(=O)OR14, -OC(=O)N(R13)R14, -C(=O)(C1-6alkyl)N(Rx)(Ry), C(=O)N(R13)(R14), - N(R13)S(=O)2R14, -S(=O)N(R13)R14, -S(=O)2N(R13)(R14), -(C3-8cycloalkyl)N(Rx)(Ry), or 3- to 12-membered N-containing heterocyclyl, wherein the 3- to 12-membered N-containing heterocyclyl of R6is optionally substituted with one or more R6b, -C(=O)R14, -C(=O)N(R13)(R14), or -C(=O)OR14, and the 3- to 12-membered N-containing heterocyclyl of R6further comprises 1 or 2 atoms selected from the group consisting of N, O, and S; R7is H; R8and R9are each independently H, halo, C1-6alkyl, -OR12, -N(Rx)(Ry), -N(R13)C(O)R14, - N(R13)C(O)OR14, -N(R13)C(O)N(R13)R14, -OC(O)R14, -OC(O)OR14, -OC(O)N(R13)R14, - C(O)R14, -C(O)OR14, -C(O)N(R13)(R14), or 3- to 8-membered heterocyclyl, wherein the C1-6alkyl of R8or R9is optionally substituted by one or more R7a, the 3- to 8-membered heterocyclyl of R8is optionally substituted with one or more R7b, and the 3- to 8-membered heterocyclyl of R8comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S; R10is H; each R1a, R3a, R6a, or R7ais independently -OR12or -N(Rx)(Ry); each R1b, R3b, R4b, R5b, R6b, or R7bis independently halo, C1-6alkyl, -OR11, or -N(Rx)(Ry), wherein the C1-6alkyl of R1b, R3b, R4b, R5b, R6b, or R7bis optionally substituted by -OR12, - N(Rx)(Ry), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 6- membered heteroaryl; each R11is independently H or C1-6alkyl; Attorney Docket No.: 185992002240 each R12is independently H, C1-6alkyl, C2-6alkynyl, or C3-8cycloalkyl, wherein the C1-6alkyl of R12is optionally substituted with one or more halo, deuterium, or - N(Rx)(Ry); each R13is independently H or C1-6alkyl; each R14is independently H, C1-6alkyl, C2-6alkenyl, C3-8cycloalkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, or 3- to 12-membered heterocyclyl, wherein the C1-6alkyl of R14is optionally substituted by halo, -OH, -O(C1-6alkyl), -O(C=O)C1- 8alkyl), -N(Rx)(Ry), C3-8cycloalkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, or 3- to 12-membered heterocyclyl, and the C3-8cycloalkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, or 3- to 12-membered heterocyclyl of R14is optionally substituted with halo, C1-6alkyl, or - N(Rx)(Ry); each R15is independently H or C1-6alkyl; and each Rxand Ryis independently H, C1-6alkyl, C3-8cycloalkyl, -C(=O)(C1-6alkyl), or - C(=O)O(C1-6alkyl), wherein the C1-6alkyl of Rxor Ryis optionally substituted with halo, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -NH2, NH(C1-6alkyl), or -N(C1-6alkyl)(C1-6alkyl), and the C1-6alkyl of -C(=O)(C1-6alkyl) or -C(=O)O(C1-6alkyl) is optionally substituted with -O(C=O)C1-8alkyl); wherein (i) when Ring A is phenyl and R6is selected from the group consisting of -NH2, -NHCH3, and -N(CH3)3, R1and R2are not both C1-2alkyl; (ii) when R1and R2are taken together with the N to which they are attached to form a 4-methylpiperazinyl, -(Ring A)-X-L-R6 is not (iii) when R1and R2are taken together with the N to which they are attached to form a morpholinyl, R6is not selected from the group consisting of -NH2, -NHC(O)CH3, and - NHC(O)O-C(CH3)3; and (iv) when Ring A is pyridin-4yl substituted with -NHC(CH3)phenyl, R1and R2are not taken together with the N to which they are attached to form an optionally substituted 2,5- diazabicyclo[2.2.2]octanyl. Attorney Docket No.: 185992002240 In some embodiments of a compound of formula (I), or any variation or embodimentthereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, R1and R2are each independently C1-6alkyl optionally substituted with one or more R1a;or R1 and R2 are taken together with the N to which they are attached to form a 3- to 12-membered heterocyclyl optionally substituted with one or more R3;each R3 is independently halo, C1-6alkyl, oxo, -OR12, or -N(Rx)(Ry) wherein the C1-6alkyl of R3is optionally substituted with R3a;Ring A is 4- to 12-membered cycloalkenyl, 4- to 12-membered unsaturated heterocyclyl, 6-to 10-membered aryl, or 5- to 10-membered heteroaryl, whereinthe 4- to 12-membered cycloalkenyl, 4- to 12-membered unsaturated heterocyclyl, 6-to 10-membered aryl, or 5- to 10-membered heteroaryl of Ring A is optionallysubstituted by one or more R4, and the 4- to 12-membered unsaturated heterocyclyl or 5- to 10-membered heteroaryl ofRing A comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S;each R4 is independently halo, C1-6alkyl, or -OR12; L is a bond, C1-6alkyl, -O-(C1-6alkyl)-, -S-(C1-6alkyl)-, or -N(R5)(C1-6alkyl)-, wherein the C1-6alkyl, -O-(C1-6alkyl)-, -S-(C1-6alkyl)-, or -N(R5)(C1-6alkyl)- is optionallysubstituted by one or more RL;each RL is independently halo, -N(Rx)(Ry), -OR12, -SR12, -SF5, -NO2, -CN, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, -OC(=O)R14, -OC(=O)N(R13)R14, -OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), -C(=O)OR14, C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, ortwo RLare taken together along with the atoms to which they are attached to form a C3-8cycloalkyl or 3- to 8-membered heterocyclyl;R5 is H, C1-6alkyl, or C3-8cycloalkyl, whereinthe C1-6alkyl of R5 is optionally substituted with one or more halo, -N(Rx)(Ry), or -OR12, and the C3-8cycloalkyl is optionally substituted with one or more R5b;R6 is -N(Rx)(Ry), -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, -OC(=O)N(R13)R14, -C(=O)(C1-6alkyl)N(Rx)(Ry), C(=O)N(R13)(R14), -N(R13)S(=O)2R14, -S(=O)N(R13)R14, -S(=O)2N(R13)(R14), or 3- to 12-membered N-containing heterocyclyl,wherein Attorney Docket No.: 185992002240 the 3- to 12-membered N-containing heterocyclyl of R6is optionally substituted with one or more R6b, -C(=O)R14, -C(=O)N(R13)(R14), or -C(=O)OR14, and the 3- to 12-membered N-containing heterocyclyl of R6further comprises 1 or 2 atoms selected from the group consisting of N, O, and S; R7is H; R8and R9are each independently H, halo, C1-6alkyl, -OR12, -N(Rx)(Ry), -N(R13)C(O)R14, - N(R13)C(O)OR14, -N(R13)C(O)N(R13)R14, -OC(O)R14, -OC(O)OR14, -OC(O)N(R13)R14, - C(O)R14, -C(O)OR14, or -C(O)N(R13)(R14) , wherein the C1-6alkyl of R8or R9is optionally substituted by one or more R7a; R10is H; each R1a, R3a, R6a, or R7ais independently -OR12or -N(Rx)(Ry); each R1b, R3b, R4b, R5b, R6b, or R7bis independently halo, C1-6alkyl, -OR11, or -N(Rx)(Ry), wherein the C1-6alkyl of R1b, R3b, R4b, R5b, R6b, or R7bis optionally substituted by -OR12, - N(Rx)(Ry), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 6- membered heteroaryl; each R11is independently H or C1-6alkyl; each R12is independently H, C1-6alkyl, or C3-8cycloalkyl, wherein the C1-6alkyl is optionally substituted with one or more halo, deuterium, or - N(Rx)(Ry); each R13is independently H or C1-6alkyl; each R14is independently H, C1-6alkyl, C2-6alkenyl, C3-8cycloalkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, or 3- to 12-membered heterocyclyl, wherein the C1-6alkyl of R14is optionally substituted by halo, -OH, -O(C1-6alkyl), -O(C=O)C1-8alkyl), -N(Rx)(Ry), C3-8cycloalkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, or 3- to 12-membered heterocyclyl, and the C3-8cycloalkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, or 3- to 12-membered heterocyclyl of R14is optionally substituted with halo, C1-6alkyl, or - N(Rx)(Ry); each R15is independently H or C1-6alkyl; and each Rxand Ryis independently H, C1-6alkyl, C3-8cycloalkyl, -C(=O)(C1-6alkyl), or - C(=O)O(C1-6alkyl), wherein the C1-6alkyl of Rxor Ryis optionally substituted with 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -NH2, NH(C1-6alkyl), or -N(C1-6alkyl)(C1-6alkyl), and Attorney Docket No.: 185992002240 the C1-6alkyl of -C(=O)(C1-6alkyl) or -C(=O)O(C1-6alkyl) is optionally substituted with-O(C=O)C1-8alkyl); wherein (i) when Ring A is phenyl and R6is selected from the group consisting of -NH2, -NHCH3, and -N(CH3)3, R1and R2are not both C1-2alkyl; (ii) when R1and R2are taken together with the N to which they are attached to form a 4-methylpiperazinyl, -(Ring A)-X-L-R6 is not (iii) when R1and R2are taken together with the N to which they are attached to form a morpholinyl, R6is not selected from the group consisting of -NH2, -NHC(O)CH3, and - NHC(O)O-C(CH3)3; and (iv) when Ring A is pyridin-4yl substituted with -NHC(CH3)phenyl, R1and R2are not taken together with the N to which they are attached to form an optionally substituted 2,5-diazabicyclo[2.2.2]octanyl. In some embodiments of the above, the compound is a compoundof formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments of formula (I),R1 and R2 are taken together with the N to which they are attached to form a saturated 4- to 5-membered monocyclic heterocyclyl, saturated 7- to 10-membered fused heterocyclyl, orsaturated 7- to 10-membered spirocyclic heterocyclyl, whereinthe saturated 4- to 5-membered monocyclic heterocyclyl, saturated 7- to 9-memberedfused heterocyclyl, or saturated 7- to 10-membered spirocyclic heterocyclyl isoptionally substituted with one or more R3;each R3 is independently halo, C1-6alkyl, oxo, -OR12, -N(Rx)(Ry), -CN, or -C(=O)N(R13)(R14),wherein the C1-6alkyl of R3is optionally substituted with R3a;Ring A is 4- to 8-membered cycloalkenyl, 4- to 8-membered unsaturated heterocyclyl,phenyl, or 5- to 6-membered heteroaryl, whereinthe 4- to 8-membered cycloalkenyl, 4- to 8-membered unsaturated heterocyclyl,phenyl, or 5- to 6-membered heteroaryl of Ring A is optionally substituted by one ormore R4, and Attorney Docket No.: 185992002240 the 4- to 8-membered unsaturated heterocyclyl or 5- to 6-membered heteroaryl of Ring A comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S; each R4is independently halo, C1-6alkyl, or -OR12; L is a bond, C1-6alkyl, -O-(C1-6alkyl)-, -S-(C1-6alkyl)-, or -N(R5)(C1-6alkyl)-; R5is H, C1-6alkyl, or C3-8cycloalkyl, wherein the C1-6alkyl of R5is optionally substituted with one or more halo, -N(Rx)(Ry), or - OR12, and the C3-8cycloalkyl is optionally substituted with one or more R5b; R6is -OR12, -O-(3- to 12-membered N-containing heterocyclyl), -O-(5- to 6-membered N- containing heteroaryl), -N(Rx)(Ry), -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, - N(R13)C(=O)OR14, -OC(=O)N(R13)R14, -C(=O)(C1-6alkyl)N(Rx)(Ry), -C(=O)N(R13)(R14), - N(R13)S(=O)2R14, -S(=O)N(R13)R14, -S(=O)2N(R13)(R14), -(C3-8cycloalkyl)N(Rx)(Ry), or 3- to 8-membered N-containing heterocyclyl, wherein the -O-(3- to 8-membered N-containing heterocyclyl), -O-(5- to 6-membered N- containing heteroaryl), or 3- to 8-membered N-containing heterocyclyl of R6is optionally substituted with one or more R6b, -C(=O)R14, -C(=O)N(R13)(R14), or - C(=O)OR14, and the 3- to 8-membered N-containing heterocyclyl of R6optionally further comprises 1 or 2 atoms selected from the group consisting of N, O, and S; R7is H or halo; R8and R9are each independently H, halo, C1-6alkyl, -OR12, -N(Rx)(Ry), -N(R13)C(O)R14, - N(R13)C(O)OR14, -N(R13)C(O)N(R13)R14, -OC(O)R14, -OC(O)OR14, -OC(O)N(R13)R14, - C(O)R14, -C(O)OR14, -C(O)N(R13)(R14), C3-8cycloalkyl, or 3- to 8-membered heterocyclyl, wherein the C1-6alkyl of R8or R9is optionally substituted by one or more R7a, the 3- to 8-membered heterocyclyl of R8is optionally substituted with one or more R7b, and the 3- to 8-membered heterocyclyl of R8comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S; R10is H; each R1a, R3a, R4a, R6a, or R7ais independently -OR12or -N(Rx)(Ry); each R1b, R3b, R4b, R5b, R6b, or R7bis independently halo, C1-6alkyl, -OR11, or -N(Rx)(Ry), wherein Attorney Docket No.: 185992002240 the C1-6alkyl of R1b, R3b, R4b, R5b, R6b, or R7b is optionally substituted by -OR12, -N(Rx)(Ry), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 6-membered heteroaryl; each R11is independently H or C1-6alkyl;each R12 is independently H, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, or 5- to 10-membered heteroaryl, wherein the C1-6alkyl is optionally substituted with one or more halo, deuterium, -O(C1-6alkyl), or -N(Rx)(Ry);each R13 is independently H, C1-6alkyl, or C3-8cycloalkyl;each R14 is independently H, C1-6alkyl, C2-6alkenyl, C3-8cycloalkyl, 6- to 10-membered aryl,5- to 10-membered heteroaryl, or 3- to 12-membered heterocyclyl, whereinthe C1-6alkyl of R14 is optionally substituted by one or more halo, -OH, -O(C1-6alkyl),-SH, -S(C1-6alkyl), -(C=O)NH2, -(C=O)OH, -O(C=O)C1-8alkyl), -NH(C=NH)NH2, -N(Rx)(Ry), C3-8cycloalkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, or3- to 12-membered heterocyclyl, whereinthe 6- to 10-membered aryl of R14 is optionally substituted by -OH, andthe C3-8cycloalkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, or 3- to12-membered heterocyclyl of R14 is optionally substituted with halo, C1-6alkyl, -OH,or -N(Rx)(Ry); each R15is independently H or C1-6alkyl; andeach Rx and Ry is independently H, C1-6alkyl, C3-8cycloalkyl, -C(=O)(C1-6alkyl), or -C(=O)O(C1-6alkyl), wherein the C1-6alkyl of Rx or Ry is optionally substituted with halo, 6- to 10-membered aryl,5- to 10-membered heteroaryl, -NH2, NH(C1-6alkyl), or -N(C1-6alkyl)(C1-6alkyl), andthe C1-6alkyl of -C(=O)(C1-6alkyl) or -C(=O)O(C1-6alkyl) is optionally substituted with-O(C=O)C1-8alkyl), whereinwhen Ring A is phenyl, then -L-R6 is not -NH2 or -OCH3. In some embodiments of theforegoing, the compound is a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments of formula (I),R1 and R2 are taken together with the N to which they are attached to form a saturated 4- to 5-membered monocyclic heterocyclyl, saturated 7- to 10-membered fused heterocyclyl, orsaturated 7- to 10-membered spirocyclic heterocyclyl, wherein Attorney Docket No.: 185992002240 the saturated 4- to 5-membered monocyclic heterocyclyl, saturated 7- to 9-membered fused heterocyclyl, or saturated 7- to 10-membered spirocyclic heterocyclyl is optionally substituted with one or more R3; each R3is independently halo, C1-6alkyl, oxo, -OR12, -N(Rx)(Ry), -CN, or -C(=O)N(R13)(R14), wherein the C1-6alkyl of R3is optionally substituted with R3a; Ring A is 4- to 8-membered cycloalkenyl, 4- to 8-membered unsaturated heterocyclyl, phenyl, or 5- to 6-membered heteroaryl, wherein the 4- to 8-membered cycloalkenyl, 4- to 8-membered unsaturated heterocyclyl, phenyl, or 5- to 6-membered heteroaryl of Ring A is optionally substituted by one or more R4, and the 4- to 8-membered unsaturated heterocyclyl or 5- to 6-membered heteroaryl of Ring A comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S; each R4is independently halo, C1-6alkyl, or -OR12; L is a bond, C1-6alkyl, -O-(C1-6alkyl)-, -S-(C1-6alkyl)-, or -N(R5)(C1-6alkyl)-; R5is H, C1-6alkyl, or C3-8cycloalkyl, wherein the C1-6alkyl of R5is optionally substituted with one or more halo, -N(Rx)(Ry), or - OR12, and the C3-8cycloalkyl is optionally substituted with one or more R5b; R6is -OR12, -O-(3- to 12-membered N-containing heterocyclyl), -O-(5- to 6-membered N- containing heteroaryl), -N(Rx)(Ry), -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, - N(R13)C(=O)OR14, -OC(=O)N(R13)R14, -C(=O)(C1-6alkyl)N(Rx)(Ry), -C(=O)N(R13)(R14), - N(R13)S(=O)2R14, -S(=O)N(R13)R14, -S(=O)2N(R13)(R14), -(C3-8cycloalkyl)N(Rx)(Ry), or 3- to 8-membered N-containing heterocyclyl, wherein the -O-(3- to 8-membered N-containing heterocyclyl), -O-(5- to 6-membered N- containing heteroaryl), or 3- to 8-membered N-containing heterocyclyl of R6is optionally substituted with one or more R6b, -C(=O)R14, -C(=O)N(R13)(R14), or - C(=O)OR14, and the 3- to 8-membered N-containing heterocyclyl of R6optionally further comprises 1 or 2 atoms selected from the group consisting of N, O, and S; R7is H or halo; R8and R9are each independently H, halo, C1-6alkyl, -OR12, -N(Rx)(Ry), -N(R13)C(O)R14, - N(R13)C(O)OR14, -N(R13)C(O)N(R13)R14, -OC(O)R14, -OC(O)OR14, -OC(O)N(R13)R14, - Attorney Docket No.: 185992002240 C(O)R14, -C(O)OR14, -C(O)N(R13)(R14), C3-8cycloalkyl, or 3- to 8-membered heterocyclyl, wherein the C1-6alkyl of R8or R9is optionally substituted by one or more R7a, the 3- to 8-membered heterocyclyl of R8is optionally substituted with one or more R7b, and the 3- to 8-membered heterocyclyl of R8comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S; R10is H; each R1a, R3a, R4a, R6a, or R7ais independently -OR12or -N(Rx)(Ry); each R1b, R3b, R4b, R5b, R6b, or R7bis independently halo, C1-6alkyl, -OR11, or -N(Rx)(Ry), wherein the C1-6alkyl of R1b, R3b, R4b, R5b, R6b, or R7bis optionally substituted by -OR12, - N(Rx)(Ry), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 6- membered heteroaryl; each R11is independently H or C1-6alkyl; each R12is independently H, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, or 5- to 10- membered heteroaryl, wherein the C1-6alkyl is optionally substituted with one or more halo, deuterium, - O(C1-6alkyl), or -N(Rx)(Ry); each R13is independently H or C1-6alkyl, each R14is independently H, C1-6alkyl, C3-8cycloalkyl, phenyl, 5- to 6-membered heteroaryl, or 3- to 12-membered heterocyclyl, wherein the C1-6alkyl of R14is optionally substituted by one or more halo, -OH, -O(C1-6alkyl), -N(Rx)(Ry), C3-8cycloalkyl, phenyl, 5- to 6-membered heteroaryl, or 3- to 12- membered heterocyclyl, and the C3-8cycloalkyl, phenyl, 5- to 6-membered heteroaryl, or 3- to 12-membered heterocyclyl of R14is optionally substituted with halo, C1-6alkyl, or -N(Rx)(Ry); each R15is independently H or C1-6alkyl; and each Rxand Ryis independently H, C1-6alkyl, C3-8cycloalkyl, -C(=O)(C1-6alkyl), or - C(=O)O(C1-6alkyl), wherein the C1-6alkyl of Rxor Ryis optionally substituted with halo, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -NH2, NH(C1-6alkyl), or -N(C1-6alkyl)(C1-6alkyl), and the C1-6alkyl of -C(=O)(C1-6alkyl) or -C(=O)O(C1-6alkyl) is optionally substituted with -O(C=O)C1-8alkyl), wherein Attorney Docket No.: 185992002240 when Ring A is phenyl, then -L-R6is not -NH2or -OCH3. In some embodiments of a compound of formula (I), or any variation or embodimentthereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing: R1and R2are each independently C1-6alkyl optionally substituted with one or more R1a;or R1 and R2 are taken together with the N to which they are attached to form a 3- to 12-membered heterocyclyl optionally substituted with one or more R3;each R3 is independently halo, C1-6alkyl, oxo, -OR12, or -N(Rx)(Ry) wherein the C1-6alkyl of R3is optionally substituted with R3a;Ring A is 4- to 8-membered monocyclic cycloalkenyl, 4- to 8-membered unsaturatedmonocyclic heterocyclyl, phenyl, or 5- to 6-membered heteroaryl, whereinthe 4- to 8-membered monocyclic cycloalkenyl, 4- to 8-membered unsaturatedmonocyclic heterocyclyl, phenyl, or 5- to 6-membered heteroaryl of Ring A isoptionally substituted by one or more R4, and the 4- to 8-membered unsaturated monocyclic heterocyclyl or 5- to 6-memberedheteroaryl of Ring A comprises 1, 2, or 3 atoms selected from the group consisting ofN, O, and S;each R4 is independently halo, C1-6alkyl, or -OR12; L is a bond, C1-6alkyl, -O-(C1-6alkyl)-, -S-(C1-6alkyl)-, or -N(R5)(C1-6alkyl)-;R5 is H, C1-6alkyl, or C3-8cycloalkyl, whereinthe C1-6alkyl of R5 is optionally substituted with one or more halo, -N(Rx)(Ry), or -OR12, and the C3-8cycloalkyl is optionally substituted with one or more R5b;R6 is (i) -N(Rx)(Ry), -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, -OC(=O)N(R13)R14, -C(=O)N(R13)(R14), -N(R13)S(=O)2R14, -S(=O)N(R13)R14, -S(=O)2N(R13)(R14), or 3- to 12-membered N-containing heterocyclyl, whereinthe 3- to 12-membered N-containing heterocyclyl of R6 is optionallysubstituted with one or more R6b, -C(=O)R14, -C(=O)N(R13)(R14), or -C(=O)OR14, and the 3- to 12-membered N-containing heterocyclyl of R6 further comprises 1 or2 atoms selected from the group consisting of N, O, and S; or(ii) -OC(=O)(C1-6alkyl)N(Rx)(Ry), -OC(=O)O(C1-6alkyl)N(Rx)(Ry), -C(=O)(C1- 6alkyl)N(Rx)(Ry), -C(=O)O(C1-6alkyl)N(Rx)(Ry), -S(=O)(C1-6alkyl)N(Rx)(Ry), - Attorney Docket No.: 185992002240 S(=O)(C1-6alkyl)N(Rx)(Ry), -S(=O)O(C1-6alkyl)N(Rx)(Ry), or -S(=O)2(C1-6alkyl)N(Rx)(Ry), wherein the -OC(=O)(C1-6alkyl)N(Rx)(Ry), -OC(=O)O(C1-6alkyl)N(Rx)(Ry), -C(=O)(C1- 6alkyl)N(Rx)(Ry), -C(=O)O(C1-6alkyl)N(Rx)(Ry), -S(=O)(C1-6alkyl)N(Rx)(Ry), -S(=O)(C1-6alkyl)N(Rx)(Ry), -S(=O)O(C1-6alkyl)N(Rx)(Ry), or -S(=O)2(C1-6alkyl)N(Rx)(Ry) of R6is optionally substituted with one or more halo, -OH, - O(C1-6alkyl), -SH, -S(C1-6alkyl), -(C=O)NH2, -(C=O)OH, -O(C=O)C1-8alkyl), -NH(C=NH)NH2, -N(Rx)(Ry), C3-8cycloalkyl, phenyl, phenol, 5- to 10- membered heteroaryl, or 3- to 12-membered heterocyclyl; R7is H; R8and R9are each independently H, halo, C1-6alkyl, -OR12, -N(Rx)(Ry), -N(R13)C(O)R14, - N(R13)C(O)OR14, -N(R13)C(O)N(R13)R14, -OC(O)R14, -OC(O)OR14, -OC(O)N(R13)R14, - C(O)R14, -C(O)OR14, or -C(O)N(R13)(R14) , wherein the C1-6alkyl of R8or R9is optionally substituted by one or more R7a; R10is H; each R1a, R3a, R6a, or R7ais independently -OR12or -N(Rx)(Ry); each R1b, R3b, R4b, R5b, R6b, or R7bis independently halo, C1-6alkyl, -OR11, or -N(Rx)(Ry), wherein the C1-6alkyl of R1b, R3b, R4b, R5b, R6b, or R7bis optionally substituted by -OR12, - N(Rx)(Ry), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 6- membered heteroaryl; each R11is independently H or C1-6alkyl; each R12is independently H, C1-6alkyl, or C3-8cycloalkyl, wherein the C1-6alkyl is optionally substituted with one or more halo, deuterium, or - N(Rx)(Ry); each R13is independently H or C1-6alkyl; each R14is independently H, C1-6alkyl, C3-8cycloalkyl, phenyl, 5- to 6-membered heteroaryl, or 3- to 12-membered heterocyclyl, wherein the C1-6alkyl of R14is optionally substituted by halo, -OH, -O(C1-6alkyl), -N(Rx)(Ry), C3-8cycloalkyl, phenyl, 5- to 6-membered heteroaryl, or 3- to 12-membered heterocyclyl, and the C3-8cycloalkyl, phenyl, 5- to 6-membered heteroaryl, or 3- to 12-membered heterocyclyl of R14is optionally substituted with halo, C1-6alkyl, or -N(Rx)(Ry) each R15is independently H or C1-6alkyl; and Attorney Docket No.: 185992002240each Rx and Ry is independently H, C1-6alkyl, C3-8cycloalkyl, -C(=O)(C1-6alkyl), or -C(=O)O(C1-6alkyl), wherein the C1-6alkyl of Rx or Ry is optionally substituted with 6- to 10-membered aryl, 5- to10-membered heteroaryl, -NH2, NH(C1-6alkyl), or -N(C1-6alkyl)(C1-6alkyl), and the C1-6alkyl of -C(=O)(C1-6alkyl) or -C(=O)O(C1-6alkyl) is optionally substituted with-O(C=O)C1-8alkyl); wherein (i) when Ring A is phenyl and R6is selected from the group consisting of -NH2, -NHCH3, and -N(CH3)3, R1and R2are not both C1-2alkyl; (ii) when R1and R2are taken together with the N to which they are attached to form a 4-methylpiperazinyl, -(Ring A)-X-L-R6 is not (iii) when R1and R2are taken together with the N to which they are attached to form a morpholinyl, R6is not selected from the group consisting of -NH2, -NHC(O)CH3, and - NHC(O)O-C(CH3)3; and (iv) when Ring A is pyridin-4yl substituted with -NHC(CH3)phenyl, R1and R2are not taken together with the N to which they are attached to form an optionally substituted 2,5-diazabicyclo[2.2.2]octanyl. In some embodiments of the above, the compound is a compoundof formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments of a compound of formula (I), or any variation or embodimentthereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, R1and R2are each independently C1-6alkyl optionally substituted with one or more R1a;or R1 and R2 are taken together with the N to which they are attached to form a 3- to 12-membered heterocyclyl optionally substituted with one or more R3;each R3 is independently halo, C1-6alkyl, oxo, -OR12, or -N(Rx)(Ry) wherein the C1-6alkyl of R3is optionally substituted with R3a;Ring A is 4- to 8-membered monocyclic cycloalkenyl, 4- to 8-membered unsaturatedmonocyclic heterocyclyl, phenyl, or 5- to 6-membered heteroaryl, wherein Attorney Docket No.: 185992002240 the 4- to 8-membered monocyclic cycloalkenyl, 4- to 8-membered unsaturated monocyclic heterocyclyl, phenyl, or 5- to 6-membered heteroaryl of Ring A is optionally substituted by one or more R4, and the 4- to 8-membered unsaturated monocyclic heterocyclyl or 5- to 6-membered heteroaryl of Ring A comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S; each R4is independently halo, C1-6alkyl, or -OR12; L is a bond, C1-6alkyl, -O-(C1-6alkyl)-, -S-(C1-6alkyl)-, or -N(R5)(C1-6alkyl)-; R5is H, C1-6alkyl, or C3-8cycloalkyl, wherein the C1-6alkyl of R5is optionally substituted with one or more halo, -N(Rx)(Ry), or - OR12, and the C3-8cycloalkyl is optionally substituted with one or more R5b; R6is -N(Rx)(Ry), -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, - OC(=O)N(R13)R14, -C(=O)(C1-6alkyl)N(Rx)(Ry), -C(=O)N(R13)(R14), -N(R13)S(=O)2R14, - S(=O)N(R13)R14, -S(=O)2N(R13)(R14), or 3- to 12-membered N-containing heterocyclyl, wherein the 3- to 12-membered N-containing heterocyclyl of R6is optionally substituted with one or more R6b, -C(=O)R14, -C(=O)N(R13)(R14), or -C(=O)OR14, and the 3- to 12-membered N-containing heterocyclyl of R6further comprises 1 or 2 atoms selected from the group consisting of N, O, and S; R7is H; R8and R9are each independently H, halo, C1-6alkyl, -OR12, -N(Rx)(Ry), -N(R13)C(O)R14, - N(R13)C(O)OR14, -N(R13)C(O)N(R13)R14, -OC(O)R14, -OC(O)OR14, -OC(O)N(R13)R14, - C(O)R14, -C(O)OR14, or -C(O)N(R13)(R14) , wherein the C1-6alkyl of R8or R9is optionally substituted by one or more R7a; R10is H; each R1a, R3a, R6a, or R7ais independently -OR12or -N(Rx)(Ry); each R1b, R3b, R4b, R5b, R6b, or R7bis independently halo, C1-6alkyl, -OR11, or -N(Rx)(Ry), wherein the C1-6alkyl of R1b, R3b, R4b, R5b, R6b, or R7bis optionally substituted by -OR12, - N(Rx)(Ry), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 6- membered heteroaryl; each R11is independently H or C1-6alkyl; each R12is independently H, C1-6alkyl, or C3-8cycloalkyl, Attorney Docket No.: 185992002240 wherein the C1-6alkyl is optionally substituted with one or more halo, deuterium, or - N(Rx)(Ry); each R13is independently H or C1-6alkyl; each R14is independently H, C1-6alkyl, C3-8cycloalkyl, phenyl, 5- to 6-membered heteroaryl, or 3- to 12-membered heterocyclyl, wherein the C1-6alkyl of R14is optionally substituted by halo, -OH, -O(C1-6alkyl), -N(Rx)(Ry), C3-8cycloalkyl, phenyl, 5- to 6-membered heteroaryl, or 3- to 12-membered heterocyclyl, and the C3-8cycloalkyl, phenyl, 5- to 6-membered heteroaryl, or 3- to 12-membered heterocyclyl of R14is optionally substituted with halo, C1-6alkyl, or -N(Rx)(Ry) each R15is independently H or C1-6alkyl; and each Rxand Ryis independently H, C1-6alkyl, C3-8cycloalkyl, -C(=O)(C1-6alkyl), or - C(=O)O(C1-6alkyl), wherein the C1-6alkyl of Rxor Ryis optionally substituted with 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -NH2, NH(C1-6alkyl), or -N(C1-6alkyl)(C1-6alkyl), and the C1-6alkyl of -C(=O)(C1-6alkyl) or -C(=O)O(C1-6alkyl) is optionally substituted with -O(C=O)C1-8alkyl); wherein (i) when Ring A is phenyl and R6is selected from the group consisting of -NH2, -NHCH3, and -N(CH3)3, R1and R2are not both C1-2alkyl; (ii) when R1and R2are taken together with the N to which they are attached to form a 4-methylpiperazinyl, -(Ring A)-X-L-R6 is not (iii) when R1and R2are taken together with the N to which they are attached to form a morpholinyl, R6is not selected from the group consisting of -NH2, -NHC(O)CH3, and - NHC(O)O-C(CH3)3; and (iv) when Ring A is pyridin-4yl substituted with -NHC(CH3)phenyl, R1and R2are not taken together with the N to which they are attached to form an optionally substituted 2,5- diazabicyclo[2.2.2]octanyl. In some embodiments of the above, the compound is a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Attorney Docket No.: 185992002240 In some embodiments of a compound of formula (I), or any variation or embodiment thereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, R1 and R2 are taken together with the N to which they are attached to form a 3- to 12-membered heterocyclyl optionally substituted with one or more R3; R8 is H, halo, C1-6alkyl, -OR12, -N(Rx)(Ry), -N(R13)C(O)R14, -N(R13)C(O)OR14, -N(R13)C(O)N(R13)R14, -C(O)N(R13)(R14), or C3-6cycloalkyl, whereinthe C1-6alkyl of R8is optionally substituted by one or more R7a; and R9 is H, halo, C1-6alkyl, -OR12, -CN, or C3-6cycloalkyl, whereinthe C1-6alkyl of R9 is optionally substituted by one or more R7a. In someembodiments of the above, the compound is a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments of a compound of formula (I), or any variation or embodiment thereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, R1 and R2 are taken together with the N to which they are attached to form a 4- to 12-membered heterocyclyl optionally substituted with one or more R3; Ring A is pyridinyl; and Lis a bond or -O-(C1-6alkyl)-. In some embodiments of the above, the compound is acompound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments of a compound of formula (I), or any variation or embodiment thereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, R1 and R2 are taken together with the N to which they are attached to form a 4- to 12-membered heterocyclyl optionally substituted with one or more R3; Ring A is pyridinyl; L is a bond; and R6 is piperazinyl optionally substituted with one or more R6b. In some embodimentsof the above, the compound is a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments of a compound of formula (I), or any variation or embodiment thereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, Attorney Docket No.: 185992002240 R1 and R2 are taken together with the N to which they are attached to form a 4- to 12-membered heterocyclyl optionally substituted with one or more R3; and R8 and R9 are each independently H, F, -N(CH3)(CH3), -OCH3 or -OCD3. In someembodiments of the above, the compound is a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments, (i) when Ring A is phenyl and R6is selected from the group consisting of -NH2, - NHCH3, and -N(CH3)3, R1and R2are not both C1-2alkyl; (ii) when R1and R2are taken together with the N to which they are attached to form a4-methylpiperazinyl, -(Ring A)-X-L-R6 is not (iii) when R1and R2are taken together with the N to which they are attached to form a morpholinyl, R6is not selected from the group consisting of -NH2, -NHC(O)CH3, and -NHC(O)O-C(CH3)3; and (iv) when Ring A is pyridin-4yl substituted with -NHC(CH3)phenyl, R1and R2are not taken together with the N to which they are attached to form an optionally substituted 2,5-diazabicyclo[2.2.2]octanyl. In some embodiments, when Ring A is phenyl, then -L-R6is not -NH2or -OCH3. In some embodiments of a compound of formula (I), or any variation or embodiment thereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, orsolvate of any of the foregoing, Ring A is phenyl or 5- to 6-membered heteroaryl. In someembodiments, Ring A is selected from the group consisting of phenyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, furan, thiophene, oxazolyl, isoxazolyl, isothiazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyrazinyl, and triazinyl. In some embodiments, Ring A is phenyl, thiazolyl, or pyridinyl. In some embodiments, Ring A is 4- to 8-membered cycloalkenyl, 4- to 8-memberedunsaturated heterocyclyl, phenyl, or 5- to 6-membered heteroaryl, wherein the 4- to 8-membered cycloalkenyl, 4- to 8-membered unsaturated heterocyclyl, phenyl, or 5- to 6-membered heteroaryl of Ring A is optionally substituted by one or more R4; and the 4- to 8-membered unsaturated heterocyclyl or 5- to 6-membered heteroaryl of Ring A comprises 1,2, or 3 atoms selected from the group consisting of N, O, and S. In some embodiments, Ring Attorney Docket No.: 185992002240A is phenyl or 5- to 6-membered heteroaryl, wherein the phenyl or 5- to 6-memberedheteroaryl of Ring A is optionally substituted by one or more R4; and the 5- to 6-memberedheteroaryl of Ring A comprises 1, 2, or 3 atoms selected from the group consisting of N, O,and S. In some embodiments, Ring A is phenyl or 5- to 6-membered heteroaryl, wherein thephenyl or 5- to 6-membered heteroaryl of Ring A is optionally substituted by one or more R4.In some embodiments of a compound of formula (I), or any variation or embodiment thereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, R1and R2are each independently C1-6alkyl optionallysubstituted with one or more R1a. In some embodiments, R1 and R2 are each independentlyC1-4alkyl optionally substituted with one or more R1a. In some embodiments of a compound of formula (I), or any variation or embodiment thereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, each R1ais independently -OH, -NH2, -NH(C1-6alkyl), -N(C1-6alkyl)(C1-6alkyl), -NH(C3-6cycloalkyl), or -N(C1-6alkyl)(C3-6cycloalkyl). In someembodiments, each R1ais independently -OH, -NH2, -NH(C1-4alkyl), -N(C1-4alkyl)(C1-4alkyl),-NH(C3-6cycloalkyl), or -N(C1-4alkyl)(C3-6cycloalkyl). In some embodiments, each R1ais independently -OH, -NH2, -NH(C1-4alkyl), -N(C1-4alkyl)(C1-4alkyl), -NH(C3-6cycloalkyl), or -N(C1-4alkyl)(C3-6cycloalkyl). In some embodiments, each R1ais independently -OH, -NH2, - NH(CH3), -N(CH3)(CH3), -NH(CH2CH3), -N(CH3)(CH2CH3), or -N(CH2CH3)(CH2CH3). In some embodiments of a compound of formula (I), or any variation or embodiment thereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, R1and R2are taken together with the N to which they areattached to form a 3- to 12-membered heterocyclyl optionally substituted with one or moreR3, wherein the 3- to 12-membered heterocyclyl comprises a 3- to 8-membered monocyclicheterocyclyl, a 5- to 12-membered fused heterocyclyl, or a 6- to 12-membered spirocyclicheterocyclyl. In some embodiments, R1 and R2 are taken together with the N to which theyare attached to form a 4- to 12-membered heterocyclyl optionally substituted with one ormore R3. In some embodiments, R1 and R2 are taken together with the N to which they areattached to form a 4- to 7-membered monocyclic heterocyclyl optionally substituted with oneor more R3. In some embodiments, R1and R2are taken together with the N to which they are attached to form an azetidinyl, pyrrolidinyl, or diazepanyl optionally substituted with one ormore R3. In some embodiments, R1 and R2 are taken together with the N to which they areattached to form a pyrrolidinyl or diazepanyl optionally substituted with one or more R3. Insome embodiments, R1and R2are taken together with the N to which they are attached to Attorney Docket No.: 185992002240form a 6- to 12-membered fused heterocyclyl optionally substituted with one or more R3. Insome embodiments, R1and R2are taken together with the N to which they are attached toform a 6- to 12-membered spirocyclic heterocyclyl optionally substituted with one or moreR3. In some embodiments, R1and R2are taken together with the N to which they areattached to form a saturated 4- to 5-membered monocyclic heterocyclyl, saturated 7- to 9-membered fused heterocyclyl, or saturated 7- to 10-membered spirocyclic heterocyclyl,wherein the saturated 4- to 5-membered monocyclic heterocyclyl, saturated 7- to 9-memberedfused heterocyclyl, or saturated 7- to 10-membered spirocyclic heterocyclyl is optionallysubstituted with one or more R3. In some embodiments, R1 and R2 are taken together with theN to which they are attached to form a saturated 4- to 5-membered monocyclic heterocyclyloptionally substituted with one or more R3. In some embodiments, R1and R2are takentogether with the N to which they are attached to form a saturated 7- to 10-membered fusedheterocyclyl optionally substituted with one or more R3. In some embodiments, R1 and R2 aretaken together with the N to which they are attached to form a saturated 7- to 9-memberedfused heterocyclyl optionally substituted with one or more R3. In some embodiments, R1 andR2 are taken together with the N to which they are attached to form a saturated 7- to 10-membered spirocyclic heterocyclyl optionally substituted with one or more R3.In some embodiments of a compound of formula (I), or any variation or embodiment thereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, each R3is independently halo, C2-6alkyl, C2-6alkenyl, C2- 6alkynyl, oxo, -OR12, -SR12, -N(Rx)(Ry), -NO2, -CN, -N(R13)C(=O)R14, - N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, -OC(=O)R14, -OC(=O)N(R13)R14, - OC(=O)OR14, -SC(=O)R14, -SC(=O)N(R13)R14, -SC(=O)OR14, -C(=O)R14, - C(=O)N(R13)(R14), -C(=O)OR14, -C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, - C(=NR15)OR14, -N(R13)S(=O)2R14, -S(=O)R14, -S(=O)2R14, -S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-memberedheteroaryl, wherein the C2-6alkyl of R3is optionally substituted with one or more R3a, and optionally, two substituents of R3are taken together with the atoms to which they areattached form a C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or5- to 10-membered heteroaryl, wherein the C3-8cycloalkyl, 3- to 12-membered heterocyclyl,6- to 10-membered aryl, or 5- to 10-membered heteroaryl is optionally substituted one ormore R3b. Attorney Docket No.: 185992002240 In some embodiments of a compound of formula (I), or any variation or embodiment thereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, orsolvate of any of the foregoing, each R3 is independently halo, C2-6alkyl, oxo, -OR12, or -N(Rx)(Ry) wherein the C2-6alkyl of R3 is optionally substituted with R3a. In someembodiments, each R3is independently halo, -OH, C1-6alkyl, C1-6alkoxy, oxo, or -N(Rx)(Ry) wherein the C1-6alkyl of the R3is optionally substituted with R3a. In some embodiments, each R3is independently halo, -OH, C1-4alkyl, C1-4alkoxy, oxo, -NH2, -NH(C1-4alkyl), -N(C1-4alkyl)(C1-4alkyl), -NH(C3-6cycloalkyl), or -N(C1-4alkyl)(C3-6cycloalkyl), wherein the C1-4alkyl of the R3is optionally substituted with R3a. In some embodiments, each R3is independently F, -OH, -CH 3 3, -CH2OH, -OCH3, oxo, or -NH2. In some embodiments, each R is independently -OH, C1-6alkyl, C1-6alkoxy, or -N(Rx)(Ry) wherein the C1-6alkyl of the R3is optionally substituted with R3a. In some embodiments, each R3is independently -OH, C1- 4alkyl, C1-4alkoxy, -NH2, -NH(C1-4alkyl), -N(C1-4alkyl)(C1-4alkyl), -NH(C3-6cycloalkyl), or - N(C1-4alkyl)(C3-6cycloalkyl), wherein the C1-4alkyl of the R3is optionally substituted with R3a. In some embodiments, each R3is independently -OH, -CH3, -CH2OH, -OCH3, or -NH2.In some embodiments, R3 is independently C1-6alkyl or oxo. In some embodiments, each R3is independently -CH3 or oxo. In some embodiments, each R3is halo. In some embodiments, R3is F. In some embodiments, each R3 is independently halo, C1-6alkyl, oxo, -OR12, -N(Rx)(Ry), -CN, or -C(=O)N(R13)(R14), wherein the C1-6alkyl of R3is optionally substitutedwith R3a. In some embodiments, each R3 is independently halo, C2-6alkyl, oxo, -OR12, -N(Rx)(Ry), -CN, or -C(=O)N(R13)(R14), wherein the C1-6alkyl of R3is optionally substituted with R3a. In some embodiments of a compound of formula (I), or any variation or embodiment thereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, R1and R2are taken together with the N to which they areattached to form a heterocyclyl selected from the group consisting of Attorney Docket No.: 185992002240 In some embodiments, R1and R2are taken together with the N to which they areattached to form a heterocyclyl selected from the group consisting Attorney Docket No.: 185992002240 In some embodiments of a compound of formula (I), or any variation or embodiment thereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, R1and R2are taken together with the N to which they areattached to form a heterocyclyl selected from the group consisting of some embodi 1 ments, R andR2are taken together with the N to which they are attached to form a heterocyclyl selected from the group consisting some embodiments, R1 and R2 are taken together with the N to which they are Attorney Docket No.: 185992002240 attached to form a heterocyclyl selected from the group consisting , some embodiments, R1and R2are taken together with the N to which they are attached to form a heterocyclyl selected from the group consisting of In some embodiments, R1and R2are taken together with the N to which they areattached to form a heterocyclyl selected from the group consisting Attorney Docket No.: 185992002240 In some embodiments, R1and R2are taken together with the N to which they are attached to form a heterocyclyl selected from the group consisting some embodiments, R1and R2are taken together with the N to which they are attached to form a heterocyclyl selected from the group consisting some embodiments, R1and R2are taken together with the N to which they are attached to form a heterocyclyl selected from the group consisting Attorney Docket No.: 185992002240 In some embodiments of a compound of formula (I), or any variation or embodiment thereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, orsolvate of any of the foregoing, each R4 is independently halo or -O-(C1-6alkyl). In someembodiments, each R4 is independently halo or -OCH3. In some embodiments, each R4isindependently F, Cl, or -OCH3.In some embodiments of a compound of formula (I), or any variation or embodiment thereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, orsolvate of any of the foregoing, R5 is H, C1-6alkyl, or C3-8cycloalkyl, wherein the C1-6alkyl ofR5 is optionally substituted with one or more halo, -N(Rx)(Ry), -OR12; and the C3-8cycloalkylof R5 is optionally substituted with one or more R5b. In some embodiments, R5 is H, C1-6alkyl,or C3-8cycloalkyl. In some embodiments, R5 is H or C1-6alkyl. In some embodiments, R5is H. In some embodiments of a compound of formula (I), or any variation or embodiment thereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, orsolvate of any of the foregoing, L is a bond or -O-(C1-6alkyl)-. In some embodiments, L is abond or -O-(CH2CH2)-. In some embodiments of a compound of formula (I), or any variation or embodiment thereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, orsolvate of any of the foregoing, R6 is -N(Rx)(Ry), -N(R13)C(=O)R14, -N(R13)C(=O)OR14, -N(R13)C(=O)N(R13)R14, -C(=O)N(R13)(R14), -C(=O)(C1-6alkyl)N(Rx)(Ry), or 3- to 12-membered N-containing heterocyclyl optionally substituted with one or more R6b. In some embodiments, R6is -N(Rx)(Ry), -N(R13)C(=O)R14, -C(=O)(C1-6alkyl)N(Rx)(Ry), or 3- to 12-membered N-containing heterocyclyl optionally substituted with one or more R6b. In some embodiments, R6is -N(Rx)(Ry), -N(R13)C(=O)R14, -C(=O)(C1-6alkyl)N(Rx)(Ry), azetidinyl, or piperazinyl, wherein the azetidinyl or piperazinyl of R6is optionally substituted with one or Attorney Docket No.: 185992002240 more R6b. In some embodiments, R6is -N(Rx)(Ry). In some embodiments, R6is -N(R13)C(=O)R14, -N(R13)C(=O)OR14, -N(R13)C(=O)N(R13)R14, -C(=O)N(R13)(R14), or -C(=O)(C1-6alkyl)N(Rx)(Ry). In some embodiments, R6is -N(R13)C(=O)R14or -C(=O)(C1-6alkyl)N(Rx)(Ry). In some embodiments, R6 is 3- to 12-membered N-containing heterocyclyloptionally substituted with one or more R6b. In some embodiments, R6 is azetidinyl,pyrrolidinyl, or piperazinyl, wherein the azetidinyl, pyrrolidinyl, or piperazinyl is optionallysubstituted with one or more R6b. In some embodiments, R6 is azetidinyl or piperazinyl,wherein the azetidinyl or piperazinyl is optionally substituted with one or more R6b. In some embodiments, R6is -OR12, -N(Rx)(Ry), -N(R13)C(=O)R14, - N(R13)C(=O)OR14, -N(R13)C(=O)N(R13)R14, -C(=O)N(R13)(R14), -C(=O)(C1-6alkyl)N(Rx)(Ry), or 3- to 12-membered N-containing heterocyclyl optionally substituted withone or more R6b. In some embodiments, R6 is -OR12, -N(Rx)(Ry), -N(R13)C(=O)R14, -N(R13)C(=O)OR14, -N(R13)C(=O)N(R13)R14, -C(=O)N(R13)(R14), -C(=O)(C1-6alkyl)N(Rx)(Ry), or 3- to 8-membered N-containing heterocyclyl optionally substituted withone or more R6b. In some embodiments of a compound of formula (I), or any variation or embodiment thereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, orsolvate of any of the foregoing, L is a bond and R6 is 3- to 12-membered N-containingheterocyclyl optionally substituted with one or more R6b. In some embodiments, L is a bondand R6is azetidinyl or piperazinyl, wherein the azetidinyl or piperazinyl is optionally substituted with one or more R6b. In some embodiments of a compound of formula (I), or any variation or embodimentthereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, orsolvate of any of the foregoing, R6 is selected from the group consisting of , Attorney Docket No.: 185992002240 some embodiments,R6 is selected from the group consisting of . In some In some embodiments of a compound of formula (I), or any variation or embodiment thereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, orsolvate of any of the foregoing, R8 and R9 are each independently H, halo, -N(Rx)(Ry), -OR11,-N(R13)C(O)R14, or -N(R13)C(O)OR14. In some embodiments, R8 and R9 are eachindependently H, halo, -NH2, -N(C1-6alkyl)(C1-6alkyl), -O(C1-6alkyl), -NHC(O)(5- to 6-membered aryl), or -NHC(O)O(C1-6alkyl), wherein the 5- to 6-membered aryl of -NHC(O)(5-to 6-membered aryl) is optionally substituted with -N(C1-6alkyl)(C1-6alkyl). In someembodiments, R8and R9are each independently H, F, Cl, -NH2, -N(CH3)(CH3), -OCH3, -NHC(O)(phenyl), or -NHC(O)O(CH2CH3), wherein the phenyl of -NHC(O)(phenyl) issubstituted with -N(CH3)(CH3). In some embodiments, R8and R9are each H. In some embodiments, each R12 is independently H, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, or 5- to 10-membered heteroaryl, wherein the C1-6alkyl is optionallysubstituted with one or more halo, deuterium, -O(C1-6alkyl), or -N(Rx)(Ry). In someembodiments, each R12 is independently H, C1-6alkyl, C3-8cycloalkyl, or 5- to 10-memberedheteroaryl, wherein the C1-6alkyl is optionally substituted with one or more halo, deuterium, Attorney Docket No.: 185992002240or -N(Rx)(Ry). In some embodiments, each R12 is independently H, C1-6alkyl, or C3-8cycloalkyl, wherein the C1-6alkyl is optionally substituted with one or more halo, deuterium,or -N(Rx)(Ry). In some embodiments of a compound of formula (I), or any variation or embodimentthereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, orsolvate of any of the foregoing, R14 is selected from the group consisting aforementioned R14 groups have the (R)- configuration. In some embodiments, theaforementioned R14 groups have the (S)- configuration.

[0002] Attorney Docket No.: 185992002240 In some embodiments of a compound of formula (I), the compound is a compound of formula (II): any variation or embodiment thereof, orstereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate ofany of the foregoing, wherein X1 is N or CH, and n is 0, 1, 2, or 3, and R1, R2, R4, R6, R7, R8,R9, R10 and L are as defined elsewhere herein. In another variation, X1 is N or CH, and n is 0,1, 2, or 3, and R1, R2, R4, R6, R7, R8, R9, R10and L are as defined for a compound of formula(I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of theforegoing, or any variation or embodiment thereof. In some embodiments of a compound offormula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt,hydrate, or solvate of any of the foregoing, the compound is a compound of formula (II), or astereoisomer or tautomer thereof, or a pharmaceutically acceptable salt any of the foregoing. In some embodiments of formula (II), X1 is N. In some embodiments, X1 is CH.In some embodiments of formula (II), n is 0, 1, or 2. In some embodiments In someembodiments, n is 0 or 1. In some embodiments, n is 0. In some embodiments, n is 1. In someembodiments, n is 2. In some embodiments of a compound of formula (I), the compound is a compound of formula (II-A): any variation or embodiment thereof, orstereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate ofany of the foregoing, wherein X1 is N or CH, and R1, R2, R6, R8, R9, and L are as definedelsewhere herein. In another variation, X1 is N or CH, and R1, R2, R6, R8, R9, and L are asdefined for a compound of formula (I), or a stereoisomer or tautomer thereof, or a Attorney Docket No.: 185992002240 pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof. In some of the foregoing embodiments, provided herein is a compound of formula (II-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt any of the foregoing. In some embodiments of a compound of formula (I), the compound is a compound of formula (II-B): any variation or embodiment thereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, wherein R1, R2, R4, R6, R7, R8, R9, R10and L are as defined elsewhereherein. In another variation, R1, R2, R4, R6, R7, R8, R9, R10 and L are as defined for acompound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceuticallyacceptable salt of any of the foregoing, or any variation or embodiment thereof. In someembodiments of a compound of formula (II-B), or a stereoisomer or tautomer thereof, or apharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, the compound isa compound of formula (II-B), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt any of the foregoing. In some embodiments of a compound of formula (I), the compound is a compound offormula (II-C): any variation or embodiment thereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, wherein R1, R2, R4, R6, R7, R8, R9, R10and L are as defined elsewhereherein. In another variation, R1, R2, R4, R6, R7, R8, R9, R10 and L are as defined for acompound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically Attorney Docket No.: 185992002240acceptable salt of any of the foregoing, or any variation or embodiment thereof. In someembodiments of a compound of formula (II-C), or a stereoisomer or tautomer thereof, or apharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, the compound isa compound of formula (II-C), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt any of the foregoing. In some embodiments of a compound of formula (I), the compound is a compound of formula (II-D) any variation or embodiment thereof, orstereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate ofany of the foregoing, wherein X1 is N or CH; n is 0, 1, 2, or 3; R3c is H or C1-4alkyl; p is 0, 1,2, 3, 4, 5, or 6; and R4, R6, R7, R8, R9, R10and L are as defined elsewhere herein. In another variation, X1is N or CH; n is 0, 1, 2, or 3; R3cis H or C1-4alkyl; p is 0, 1, 2, 3, 4, 5, or 6; andR4, R6, R7, R8, R9, R10 and L are as defined for a compound of formula (I), or a stereoisomeror tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or anyvariation or embodiment thereof. In some embodiments of a compound of formula (II-D), ora stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvateof any of the foregoing, the compound is a compound of formula (II-D), or a stereoisomer ortautomer thereof, or a pharmaceutically acceptable salt any of the foregoing. In some embodiments of formula (II-D), X1 is N. In some embodiments, X1 is CH.In some embodiments of formula (II-D), n is 0, 1, or 2. In some embodiments, n is 0or 1. In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is2. In some embodiments of formula (II-D), R3c is H or methyl. In some embodiments,R3c is H. In some embodiments, R3c is C1-4alkyl. In some embodiments, R3cis methyl. Attorney Docket No.: 185992002240 In some embodiments of formula (II-D), p is 0, 1, 2, 3, or 4. In some embodiments, pis 0, 1, or 2. In some embodiments, p is 0 or 1. In some embodiments, p is 0. In someembodiments, p is 1. In some embodiments, p is 2.In some embodiments of a compound of formula (I), the compound is a compound of formula (II-D-1) any variation or embodiment thereof,or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, wherein X1is N or CH; R3cis H or C1-4alkyl; p is 0, 1, 2, 3, 4, 5, or 6; and R3, R7, R8, R9, R10, and L are as defined elsewhere herein. In another variation, X1is N or CH; p is 0, 1, 2, 3, 4, 5, or 6; and R3, R7, R8, R9, R10, and L are as defined for a compound offormula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt ofany of the foregoing, or any variation or embodiment thereof. In some embodiments of acompound of formula (II-D-1), or a stereoisomer or tautomer thereof, or a pharmaceuticallyacceptable salt, hydrate, or solvate of any of the foregoing, the compound is a compound offormula (II-D-1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt any of the foregoing. In some embodiments of formula (II-D-1), R3c is H or methyl. In some embodiments,R3c is H. In some embodiments, R3c is C1-4alkyl. In some embodiments, R3cis methyl. In some embodiments of formula (II-D-1), p is 0, 1, 2, 3, or 4. In some embodiments,p is 0, 1, or 2. In some embodiments, p is 0 or 1. In some embodiments, p is 0. In someembodiments, p is 1. In some embodiments, p is 2. Attorney Docket No.: 185992002240 In some embodiments of a compound of formula (I), the compound is a compound of formula (II-D-2) any variation or embodiment thereof,or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, wherein X1is N or CH; R3cis H or C1-4alkyl; p is 0, 1, 2, 3, 4, 5, or 6; and R3, R8, R9, and L are as defined elsewhere herein. In another variation, X1is N or CH; p is 0, 1, 2, 3, 4, 5, or 6; and R3, R8, R9, and L are as defined for a compound of formula (I), ora stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of theforegoing, or any variation or embodiment thereof. In some embodiments of a compound offormula (II-D-2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt,hydrate, or solvate of any of the foregoing, the compound is a compound of formula (II-D-2),or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt any of the foregoing. In some embodiments of formula (II-D-2), R3c is H or methyl. In some embodiments,R3c is H. In some embodiments, R3c is C1-4alkyl. In some embodiments, R3cis methyl. In some embodiments of formula (II-D-2), p is 0, 1, 2, 3, or 4. In some embodiments,p is 0, 1, or 2. In some embodiments, p is 0 or 1. In some embodiments, p is 0. In someembodiments, p is 1. In some embodiments, p is 2. Attorney Docket No.: 185992002240 In some embodiments of a compound of formula (I), the compound is a compound of formula (III): any variation or embodiment thereof, orstereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate ofany of the foregoing, wherein X1 is N or CH; n is 0, 1, 2, or 3; and R1, R2, R4, R6, R7, R8, R9,R10 and L are as defined elsewhere herein. In another variation, X1 is N or CH; n is 0, 1, 2, or3; and R1, R2, R4, R6, R7, R8, R9, R10and L are as defined for a compound of formula (I), or astereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of theforegoing, or any variation or embodiment thereof. In some embodiments of a compound offormula (III), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt,hydrate, or solvate of any of the foregoing, the compound is a compound of formula (III), or astereoisomer or tautomer thereof, or a pharmaceutically acceptable salt any of the foregoing. In some embodiments of a compound of formula (I), the compound is a compound of formula (III-A): any variation or embodiment thereof, orstereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate ofany of the foregoing, wherein X1 is N or CH; and R1, R2, R6, R8, R9, and L are as definedelsewhere herein. In another variation, X1 is N or CH; and R1, R2, R6, R8, R9, and L are asdefined for a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodimentthereof. In some embodiments of a compound of formula (III-A), or a stereoisomer ortautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate of any of the Attorney Docket No.: 185992002240foregoing, the compound is a compound of formula (III-A), or a stereoisomer or tautomerthereof, or a pharmaceutically acceptable salt any of the foregoing. In some embodiments of a compound of formula (I), the compound is a compound of formula (III-B): any variation or embodiment thereof, orstereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate ofany of the foregoing, wherein R1, R2, R4, R6, R7, R8, R9, R10 and L are as defined elsewhereherein. In another variation, R1, R2, R4, R6, R7, R8, R9, R10 and L are as defined for acompound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceuticallyacceptable salt of any of the foregoing, or any variation or embodiment thereof. In someembodiments of a compound of formula (III-B), or a stereoisomer or tautomer thereof, or apharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, the compound isa compound of formula (III-B), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt any of the foregoing. In some embodiments of a compound of formula (I), the compound is a compound offormula (IV): any variation or embodiment thereof, orstereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate ofany of the foregoing, wherein X2, X4 and X5 are each independently C, N, O or S; X3 and X6are each independently C or N; n is 0, 1, 2, or 3, and R1, R2, R4, R6, R7, R8, R9, R10and L areas defined elsewhere herein. In another variation, X2, X4 and X5 are each independently C, N,O or S; X3 and X6 are each independently C or N; n is 0, 1, 2, or 3, and R1, R2, R4, R6, R7, R8, Attorney Docket No.: 185992002240 R9, R10and L are as defined for a compound of formula (I), or a stereoisomer or tautomerthereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation orembodiment thereof. In some embodiments of a compound of formula (IV), or a stereoisomeror tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate of any of theforegoing, the compound is a compound of formula (IV), or a stereoisomer or tautomerthereof, or a pharmaceutically acceptable salt any of the foregoing. In some embodiments of a compound of formula (I), the compound is a compound offormula (IV-A): any variation or embodiment thereof, orstereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, wherein R1, R2, R6, R7, R8, R9, R10and L are as defined elsewhereherein. In another variation, R1, R2, R6, R7, R8, R9, R10 and L are as defined for a compoundof formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt ofany of the foregoing, or any variation or embodiment thereof. In some embodiments of acompound of formula (IV-A), or a stereoisomer or tautomer thereof, or a pharmaceuticallyacceptable salt, hydrate, or solvate of any of the foregoing, the compound is a compound offormula (IV-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt any of the foregoing. In some embodiments, the compounds of formula (I), or any variation or embodimentthereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any ofthe foregoing, selectively modulate TDP-43. In some embodiments, the compounds offormula (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, ora pharmaceutically acceptable salt of any of the foregoing, reduce TDP-43 cytoplasmicinclusions, improve nuclear TDP-43 function, or reduce neurodegeneration. In someembodiments, the compounds of formula (I), or any variation or embodiment thereof, or astereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of theforegoing, reduce TDP-43 cytoplasmic inclusions. In some embodiments, the compounds offormula (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or Attorney Docket No.: 185992002240a pharmaceutically acceptable salt of any of the foregoing, improve nuclear TDP-43 function.In some embodiments, the compounds of formula (I), or any variation or embodimentthereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any ofthe foregoing, reduce neurodegeneration. In some embodiments, the compounds of formula(I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or apharmaceutically acceptable salt of any of the foregoing, mitigate TDP-43 cytoplasmiccondensates in motor neurons. In some embodiments, the motor neurons are iPSC-derivedmotor neurons. In some embodiments, STMN2 and POLDIP3 splicing in iPSC-derivedmotor neurons is restored. In some embodiments of a compound of formula (I), or any variation or embodiment thereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, orsolvate of any of the foregoing, the compound is selected from Table 1. In someembodiments of a compound of formula (I), or any variation or embodiment thereof, orstereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate ofany of the foregoing, the compound is selected from examples 1-68 of Table 1. In someembodiments of a compound of formula (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, the compound is selected from Table 1, or a pharmaceuticallyacceptable salt of any of the foregoing. In some embodiments of a compound of formula (I),or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or apharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, the compound isselected from compounds 1-68 of Table 1, or a pharmaceutically acceptable salt of any of theforegoing. In some embodiments of a compound of formula (I), or any variation orembodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptablesalt, hydrate, or solvate of any of the foregoing, the compound is selected from compounds 1-43, or 45-68 of Table 1, or a pharmaceutically acceptable salt of any of the foregoing. Insome embodiments of a compound of formula (I), or any variation or embodiment thereof, ora stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvateof any of the foregoing, the compound is selected from compounds 1-43, 45-361, 363-367,370-399, and 404-405 of Table 1, or a pharmaceutically acceptable salt of any of theforegoing. Attorney Docket No.: 185992002240 Table 1 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 Attorney Docket No.: 185992002240 In some embodiments, provided herein is a compound of formula (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, wherein the compound is selected from the group consisting of Attorney Docket No.: 185992002240 1-(4-(5-(6,7-dimethoxy-4-(pyrrolidin-1-yl) quinolin-2-yl) pyridin-2-yl) piperazin-1-yl) ethan-1-one; (1-(2-(6-(azetidin-1-yl) pyridin-3-yl)-6-fluoro-7-methoxyquinolin-4-yl) pyrrolidin-3- yl) methanol; 2-(4-(5-(6-fluoro-4-(3-(hydroxymethyl) pyrrolidin-1-yl)-7-methoxyquinolin-2-yl) pyridin-2-yl) piperazin-1-yl) ethan-1-ol; (1-(2-(2-(azetidin-1-yl) thiazol-5-yl)-6-fluoro-7-methoxyquinolin-4-yl) pyrrolidin-3- yl) methanol; (1-(2-(6-(azetidin-1-yl) pyridin-3-yl)-7-(dimethylamino)-6-fluoroquinolin-4-yl) pyrrolidin-3-yl) methanol; 2-(2-(6-(dimethylamino) pyridin-3-yl)-7-methoxyquinolin-4-yl) octahydro-6H- pyrrolo[3,4-c] pyridin-6-one; 6,7-dimethoxy-2-(6-(piperazin-1-yl) pyridin-3-yl)-4-(pyrrolidin-1-yl) quinoline; 2-(4-(5-(6,7-dimethoxy-4-(pyrrolidin-1-yl) quinolin-2-yl) pyridin-2-yl) piperazin-1-yl) ethan-1-ol; 1-(7-methoxy-2-(6-(piperazin-1-yl) pyridin-3-yl) quinolin-4-yl)-3-methylpyrrolidin-3- ol; (1-(7-methoxy-2-(6-(piperazin-1-yl) pyridin-3-yl) quinolin-4-yl) pyrrolidin-3-yl) methanol; 2-(7-methoxy-2-(6-(piperazin-1-yl) pyridin-3-yl) quinolin-4-yl)-2,7-diazaspiro [4.5] decane; 4-(2-methylpyrrolidin-1-yl)-2-(6-(piperazin-1-yl) pyridin-3-yl) quinoline; 2-(6-(piperazin-1-yl) pyridin-3-yl)-4-(pyrrolidin-1-yl) quinoline; 2-(2-(6-(azetidin-3-yl) pyridin-3-yl)-7-methoxyquinolin-4-yl)-2,7-diazaspiro [4.5] decane; 6-methoxy-4-(3-methoxypyrrolidin-1-yl)-N, N-dimethyl-2-(4-(2-(methylamino) ethoxy) phenyl) quinolin-7-amine; 4-(3-methoxypyrrolidin-1-yl)-N, N-dimethyl-2-(6-(2-(methylamino) ethoxy) pyridin- 3-yl) quinolin-7-amine; 2-(6-fluoro-7-methoxy-2-(6-(piperazin-1-yl) pyridin-3-yl) quinolin-4-yl)-2,7- diazaspiro [4.5] decane; (1-(6-fluoro-7-methoxy-2-(6-(methylamino) pyridin-3-yl) quinolin-4-yl) pyrrolidin-3- yl) methanol; Attorney Docket No.: 185992002240 5-(6-fluoro-7-methoxy-4-(2,7-diazaspiro [4.5] decan-2-yl) quinolin-2-yl)-N- methylpyridin-2-amine; 2-(6-(piperazin-1-yl)pyridin-3-yl)-4-(2,6-diazaspiro[3.4]octan-6-yl)quinoline; (1-(2-(6-(piperazin-1-yl) pyridin-3-yl) quinolin-4-yl) pyrrolidin-3-yl) methanol; 2-(7-methoxy-2-(6-(piperazin-1-yl) pyridin-3-yl) quinolin-4-yl)-7-methyl-2,7- diazaspiro [4.5] decane; 7-methoxy-2-(6-(piperazin-1-yl) pyridin-3-yl)-4-(2,6-diazaspiro [3.4] octan-6-yl) quinoline; 2-(7-methoxy-2-(4-(piperazin-1-yl) phenyl) quinolin-4-yl)-2,7-diazaspiro [4.5] decane; 2-(4-(7-methoxy-4-(octahydro-2H-pyrrolo[3,4-c] pyridin-2-yl) quinolin-2-yl) phenoxy)-N-methylethan-1-amine; 6-fluoro-7-methoxy-4-(octahydro-2H-pyrrolo[3,4-c] pyridin-2-yl)-2-(6-(piperazin-1- yl) pyridin-3-yl) quinoline; 6-fluoro-N, N-dimethyl-2-(6-(piperazin-1-yl) pyridin-3-yl)-4-(2,7-diazaspiro [4.5] decan-2-yl) quinolin-7-amine; 2-(4-(6-fluoro-7-methoxy-4-(octahydro-2H-pyrrolo[3,4-c] pyridin-2-yl) quinolin-2-yl) phenoxy)-N-methylethan-1-amine; 5-(7-methoxy-4-(octahydro-2H-pyrrolo[3,4-c] pyridin-2-yl) quinolin-2-yl)-N, N- dimethylpyridin-2-amine; (1-(2-(6-(2-(cyclopropylamino) ethoxy) pyridin-3-yl)-6-fluoro-7-methoxyquinolin-4- yl) pyrrolidin-3-yl) methanol; 2-amino-1-(5-(6-fluoro-4-(3-(hydroxymethyl) pyrrolidin-1-yl)-7-methoxyquinolin-2- yl) pyridin-2-yl) propan-1-one; 2-(2-(6-(azetidin-1-yl) pyridin-3-yl)-6-fluoro-7-methoxyquinolin-4-yl)-2,7-diazaspiro [4.5] decane; 2-amino-1-(4-(5-(7-methoxy-4-(2,7-diazaspiro [4.5] decan-2-yl) quinolin-2-yl) pyridin-2-yl) piperazin-1-yl) propan-1-one; 4-hexahydropyrrolo[3,4-c] pyrrol-2(1H)-yl)-2-(6-(piperazin-1-yl) pyridin-3-yl) quinoline; 1-(4-(5-(4-(3,6-diazabicyclo [3.2.0] heptan-3-yl) quinolin-2-yl) pyridin-2-yl) piperazin-1-yl)-2-aminopropan-1-one; 2-(6-(piperazin-1-yl) pyridin-3-yl)-4-(1,6-diazaspiro [3.4] octan-6-yl) quinoline; Attorney Docket No.: 185992002240 2-(6-(piperazin-1-yl) pyridin-3-yl)-4-(2,7-diazaspiro [4.4] nonan-2-yl) quinoline; 4-(hexahydropyrrolo[3,4-c] pyrrol-2(1H)-yl)-2-(6-(piperazin-1-yl) pyridin-3-yl) quinoline; 4-(3,6-diazabicyclo [3.2.0] heptan-3-yl)-2-(6-(piperazin-1-yl) pyridin-3-yl) quinoline; 4-(3,6-diazabicyclo [3.2.0] heptan-6-yl)-2-(6-(piperazin-1-yl) pyridin-3-yl) quinoline; 2-(6-fluoro-7-methoxy-2-(6-(piperazin-1-yl) pyridin-3-yl) quinolin-4-yl)-2,7- diazaspiro [4.5] decane; 2-amino-1-(4-(4-(7-methoxy-4-(2,7-diazaspiro [4.5] decan-2-yl) quinolin-2-yl) phenyl) piperazin-1-yl) propan-1-one; 4-(1,4-diazepan-1-yl)-6-fluoro-7-methoxy-2-(6-(piperazin-1-yl) pyridin-3-yl) quinoline; 2-amino-1-(4-(4-(7-methoxy-4-(3-methoxypyrrolidin-1-yl) quinolin-2-yl) phenyl) piperazin-1-yl) propan-1-one; 2-amino-1-(4-(5-(7-(dimethylamino)-4-(3-methoxypyrrolidin-1-yl) quinolin-2-yl) pyridin-2-yl) piperazin-1-yl) propan-1-one; ethyl (2-(6-(methylamino) pyridin-3-yl)-4-(2,7-diazaspiro [4.5] decan-2-yl) quinolin- 7-yl) carbamate; 2-amino-N-(4-(6-fluoro-7-methoxy-4-(octahydro-2H-pyrrolo[3,4-c] pyridin-2-yl) quinolin-2-yl) phenyl)-3-methylbutanamide; 2-amino-1-(4-(5-(6-fluoro-7-methoxy-4-(octahydro-2H-pyrrolo[3,4-c] pyridin-2-yl) quinolin-2-yl) pyridin-2-yl) piperazin-1-yl)-2-methylpropan-1-one; 5-[4-(2, 9-diazaspiro[4.5]decan-2-yl) -7-methoxy-2-quinolyl]-N, N-dimethyl-pyridin- 2-amine; 2-(4-(piperazin-1-yl) phenyl)-4-(pyrrolidin-1-yl) quinoline; (1-(2-(6-(piperazin-1-yl) pyridin-3-yl) quinolin-4-yl) pyrrolidin-3-yl) methanol; (1-(6-amino-7-methoxy-2-(6-(piperazin-1-yl) pyridin-3-yl) quinolin-4-yl) pyrrolidin- 3-yl) methanol; 2-amino-1-(5-(6-fluoro-7-methoxy-4-(2,7-diazaspiro[4.5]decan-2-yl)quinolin-2- yl)pyridin-2-yl)propan-1-one; [4-[5-[4-[3-(hydroxymethyl) pyrrolidin-1-yl]-7-methoxy-2-quinolyl]-2-pyridyl] piperazin-1-yl]-pyrrolidin-2-yl-methanone; 2-(6-(piperazin-1-yl) pyridin-3-yl)-4-(2,7-diazaspiro [4.4] nonan-2-yl) quinoline; 6-(2-(6-(piperazin-1-yl) pyridin-3-yl) quinolin-4-yl)-2-oxa-6-azaspiro [3.4] octane; Attorney Docket No.: 185992002240 2-((5-(7-methoxy-4-(2,7-diazaspiro [4.5] decan-2-yl) quinolin-2-yl) pyridin-2-yl) oxy)-N-methylethan-1-amine; 2-amino-1-(4-(5-(6-fluoro-7-methoxy-4-(octahydro-2H-pyrrolo[3,4-c]pyridin-2- yl)quinolin-2-yl)pyridin-2-yl)piperazin-1-yl)propan-1-one; 2-amino-1-[5-[4-(2,9-diazaspiro [4.5]decan-2-yl)-7-(dimethylamino)-6-fluoro-2- quinolyl]-2-pyridyl]propan-1-one; 2-((5-(6-fluoro-4-(octahydro-2H-pyrrolo[3,4-c]pyridin-2-yl)quinolin-2-yl)pyridin-2- yl)oxy)-N-methylethan-1-amine; 2-((5-(6,7-difluoro-4-(octahydro-2H-pyrrolo[3,4-c]pyridin-2-yl)quinolin-2-yl)pyridin- 2-yl)oxy)-N-methylethan-1-amine; N-[4-[4-(2, 9-diazaspiro[4.5]decan-2-yl) -6-fluoro-7-methoxy-2- quinolyl]phenyl]acetamide; 5-[7-chloro-4-(2, 9-diazaspiro[4.5]decan-2-yl)-2-quinolyl]-N-methyl-pyridin-2-amine; 2-(6-piperazin-1-yl-3-pyridyl)-4-[3,6-diazabicyclo [3.2.0] heptan-6-yl] quinoline; 2-amino-1-(4-(5-(4-(3-(hydroxymethyl) pyrrolidin-1-yl)-7-methoxyquinolin-2-yl) pyridin-2-yl) piperazin-1-yl)-3-methylbutan-1-one; 2-amino-1-[4-[5-[4-[3-(hydroxymethyl) pyrrolidin-1-yl]-7-methoxy-2-quinolyl]-2- pyridyl] piperazin-1-yl]-4-methyl-pentan-1-one; and 2-(azetidin-1-yl)-5-[4-(2,9-diazaspiro [4.5]decan-2-yl)-7-methoxy-2-quinolyl]thiazole. In some embodiments, the compound is selected from the group consisting of 1-(4-(5-(6,7-dimethoxy-4-(pyrrolidin-1-yl) quinolin-2-yl) pyridin-2-yl) piperazin-1- yl) ethan-1-one; (1-(2-(6-(azetidin-1-yl) pyridin-3-yl)-6-fluoro-7-methoxyquinolin-4-yl) pyrrolidin-3- yl) methanol; 2-(4-(5-(6-fluoro-4-(3-(hydroxymethyl) pyrrolidin-1-yl)-7-methoxyquinolin-2-yl) pyridin-2-yl) piperazin-1-yl) ethan-1-ol; (1-(2-(2-(azetidin-1-yl) thiazol-5-yl)-6-fluoro-7-methoxyquinolin-4-yl) pyrrolidin-3- yl) methanol; (1-(2-(6-(azetidin-1-yl) pyridin-3-yl)-7-(dimethylamino)-6-fluoroquinolin-4-yl) pyrrolidin-3-yl) methanol; 2-(2-(6-(dimethylamino) pyridin-3-yl)-7-methoxyquinolin-4-yl) octahydro-6H- pyrrolo[3,4-c] pyridin-6-one; Attorney Docket No.: 185992002240 6,7-dimethoxy-2-(6-(piperazin-1-yl) pyridin-3-yl)-4-(pyrrolidin-1-yl) quinoline; 2-(4-(5-(6,7-dimethoxy-4-(pyrrolidin-1-yl) quinolin-2-yl) pyridin-2-yl) piperazin-1- yl) ethan-1-ol; 1-(7-methoxy-2-(6-(piperazin-1-yl) pyridin-3-yl) quinolin-4-yl)-3-methylpyrrolidin-3- ol; (1-(7-methoxy-2-(6-(piperazin-1-yl) pyridin-3-yl) quinolin-4-yl) pyrrolidin-3-yl) methanol; 2-(7-methoxy-2-(6-(piperazin-1-yl) pyridin-3-yl) quinolin-4-yl)-2,7-diazaspiro [4.5] decane; 4-(2-methylpyrrolidin-1-yl)-2-(6-(piperazin-1-yl) pyridin-3-yl) quinoline; 2-(6-(piperazin-1-yl) pyridin-3-yl)-4-(pyrrolidin-1-yl) quinoline; 2-(2-(6-(azetidin-3-yl) pyridin-3-yl)-7-methoxyquinolin-4-yl)-2,7-diazaspiro [4.5] decane; 6-methoxy-4-(3-methoxypyrrolidin-1-yl)-N, N-dimethyl-2-(4-(2-(methylamino) ethoxy) phenyl) quinolin-7-amine; 4-(3-methoxypyrrolidin-1-yl)-N, N-dimethyl-2-(6-(2-(methylamino) ethoxy) pyridin- 3-yl) quinolin-7-amine; 2-(6-fluoro-7-methoxy-2-(6-(piperazin-1-yl) pyridin-3-yl) quinolin-4-yl)-2,7- diazaspiro [4.5] decane; (1-(6-fluoro-7-methoxy-2-(6-(methylamino) pyridin-3-yl) quinolin-4-yl) pyrrolidin-3- yl) methanol; 5-(6-fluoro-7-methoxy-4-(2,7-diazaspiro [4.5] decan-2-yl) quinolin-2-yl)-N- methylpyridin-2-amine; 2-(6-(piperazin-1-yl)pyridin-3-yl)-4-(2,6-diazaspiro[3.4]octan-6-yl)quinoline; (1-(2-(6-(piperazin-1-yl) pyridin-3-yl) quinolin-4-yl) pyrrolidin-3-yl) methanol; 2-(7-methoxy-2-(6-(piperazin-1-yl) pyridin-3-yl) quinolin-4-yl)-7-methyl-2,7- diazaspiro [4.5] decane; 7-methoxy-2-(6-(piperazin-1-yl) pyridin-3-yl)-4-(2,6-diazaspiro [3.4] octan-6-yl) quinoline; 2-(7-methoxy-2-(4-(piperazin-1-yl) phenyl) quinolin-4-yl)-2,7-diazaspiro [4.5] decane; 2-(4-(7-methoxy-4-(octahydro-2H-pyrrolo[3,4-c] pyridin-2-yl) quinolin-2-yl) phenoxy)-N-methylethan-1-amine; Attorney Docket No.: 185992002240 6-fluoro-7-methoxy-4-(octahydro-2H-pyrrolo[3,4-c] pyridin-2-yl)-2-(6-(piperazin-1- yl) pyridin-3-yl) quinoline; 6-fluoro-N, N-dimethyl-2-(6-(piperazin-1-yl) pyridin-3-yl)-4-(2,7-diazaspiro [4.5] decan-2-yl) quinolin-7-amine; 2-(4-(6-fluoro-7-methoxy-4-(octahydro-2H-pyrrolo[3,4-c] pyridin-2-yl) quinolin-2-yl) phenoxy)-N-methylethan-1-amine; 5-(7-methoxy-4-(octahydro-2H-pyrrolo[3,4-c] pyridin-2-yl) quinolin-2-yl)-N, N- dimethylpyridin-2-amine; (1-(2-(6-(2-(cyclopropylamino) ethoxy) pyridin-3-yl)-6-fluoro-7-methoxyquinolin-4- yl) pyrrolidin-3-yl) methanol; 2-amino-1-(5-(6-fluoro-4-(3-(hydroxymethyl) pyrrolidin-1-yl)-7-methoxyquinolin-2- yl) pyridin-2-yl) propan-1-one; 2-(2-(6-(azetidin-1-yl) pyridin-3-yl)-6-fluoro-7-methoxyquinolin-4-yl)-2,7-diazaspiro [4.5] decane; 2-amino-1-(4-(5-(7-methoxy-4-(2,7-diazaspiro [4.5] decan-2-yl) quinolin-2-yl) pyridin-2-yl) piperazin-1-yl) propan-1-one; 4-hexahydropyrrolo[3,4-c] pyrrol-2(1H)-yl)-2-(6-(piperazin-1-yl) pyridin-3-yl) quinoline; 1-(4-(5-(4-(3,6-diazabicyclo [3.2.0] heptan-3-yl) quinolin-2-yl) pyridin-2-yl) piperazin-1-yl)-2-aminopropan-1-one; 2-(6-(piperazin-1-yl) pyridin-3-yl)-4-(1,6-diazaspiro [3.4] octan-6-yl) quinoline; 2-(6-(piperazin-1-yl) pyridin-3-yl)-4-(2,7-diazaspiro [4.4] nonan-2-yl) quinoline; 4-(3,6-diazabicyclo [3.2.0] heptan-6-yl)-2-(6-(piperazin-1-yl) pyridin-3-yl) quinoline; 4-(3,6-diazabicyclo [3.2.0] heptan-3-yl)-2-(6-(piperazin-1-yl) pyridin-3-yl) quinoline; 2-(6-fluoro-7-methoxy-2-(6-(piperazin-1-yl) pyridin-3-yl) quinolin-4-yl)-2,7- diazaspiro [4.5] decane; 2-amino-1-(4-(4-(7-methoxy-4-(2,7-diazaspiro [4.5] decan-2-yl) quinolin-2-yl) phenyl) piperazin-1-yl) propan-1-one; 4-(1,4-diazepan-1-yl)-6-fluoro-7-methoxy-2-(6-(piperazin-1-yl) pyridin-3-yl) quinoline; 2-amino-1-(4-(4-(7-methoxy-4-(3-methoxypyrrolidin-1-yl) quinolin-2-yl) phenyl) piperazin-1-yl) propan-1-one; Attorney Docket No.: 185992002240 2-amino-1-(4-(5-(7-(dimethylamino)-4-(3-methoxypyrrolidin-1-yl) quinolin-2-yl) pyridin-2-yl) piperazin-1-yl) propan-1-one; ethyl (2-(6-(methylamino) pyridin-3-yl)-4-(2,7-diazaspiro [4.5] decan-2-yl) quinolin- 7-yl) carbamate; 2-amino-N-(4-(6-fluoro-7-methoxy-4-(octahydro-2H-pyrrolo[3,4-c] pyridin-2-yl) quinolin-2-yl) phenyl)-3-methylbutanamide; 2-amino-1-(4-(5-(6-fluoro-7-methoxy-4-(octahydro-2H-pyrrolo[3,4-c] pyridin-2-yl) quinolin-2-yl) pyridin-2-yl) piperazin-1-yl)-2-methylpropan-1-one; 5-[4-(2, 9-diazaspiro[4.5]decan-2-yl) -7-methoxy-2-quinolyl]-N, N-dimethyl-pyridin- 2-amine; 2-(4-(piperazin-1-yl) phenyl)-4-(pyrrolidin-1-yl) quinoline; (1-(2-(6-(piperazin-1-yl) pyridin-3-yl) quinolin-4-yl) pyrrolidin-3-yl) methanol; (1-(6-amino-7-methoxy-2-(6-(piperazin-1-yl) pyridin-3-yl) quinolin-4-yl) pyrrolidin- 3-yl) methanol; 2-amino-1-(5-(6-fluoro-7-methoxy-4-(2,7-diazaspiro[4.5]decan-2-yl)quinolin-2- yl)pyridin-2-yl)propan-1-one; [4-[5-[4-[3-(hydroxymethyl) pyrrolidin-1-yl]-7-methoxy-2-quinolyl]-2-pyridyl] piperazin-1-yl]-pyrrolidin-2-yl-methanone; 2-(6-(piperazin-1-yl) pyridin-3-yl)-4-(2,7-diazaspiro [4.4] nonan-2-yl) quinoline; 6-(2-(6-(piperazin-1-yl) pyridin-3-yl) quinolin-4-yl)-2-oxa-6-azaspiro [3.4] octane; 2-((5-(7-methoxy-4-(2,7-diazaspiro [4.5] decan-2-yl) quinolin-2-yl) pyridin-2-yl) oxy)-N-methylethan-1-amine; 2-amino-1-(4-(5-(6-fluoro-7-methoxy-4-(octahydro-2H-pyrrolo[3,4-c]pyridin-2- yl)quinolin-2-yl)pyridin-2-yl)piperazin-1-yl)propan-1-one; 2-amino-1-[5-[4-(2,9-diazaspiro [4.5]decan-2-yl)-7-(dimethylamino)-6-fluoro-2- quinolyl]-2-pyridyl]propan-1-one; 2-((5-(6-fluoro-4-(octahydro-2H-pyrrolo[3,4-c]pyridin-2-yl)quinolin-2-yl)pyridin-2- yl)oxy)-N-methylethan-1-amine; 2-((5-(6,7-difluoro-4-(octahydro-2H-pyrrolo[3,4-c]pyridin-2-yl)quinolin-2-yl)pyridin- 2-yl)oxy)-N-methylethan-1-amine; N-[4-[4-(2, 9-diazaspiro[4.5]decan-2-yl) -6-fluoro-7-methoxy-2- quinolyl]phenyl]acetamide; 5-[7-chloro-4-(2, 9-diazaspiro[4.5]decan-2-yl)-2-quinolyl]-N-methyl-pyridin-2-amine; Attorney Docket No.: 185992002240 2-(6-piperazin-1-yl-3-pyridyl)-4-[3,6-diazabicyclo [3.2.0] heptan-6-yl] quinoline; 2-amino-1-(4-(5-(4-(3-(hydroxymethyl) pyrrolidin-1-yl)-7-methoxyquinolin-2-yl) pyridin-2-yl) piperazin-1-yl)-3-methylbutan-1-one; 2-amino-1-[4-[5-[4-[3-(hydroxymethyl) pyrrolidin-1-yl]-7-methoxy-2-quinolyl]-2- pyridyl] piperazin-1-yl]-4-methyl-pentan-1-one; 2-(azetidin-1-yl)-5-[4-(2,9-diazaspiro [4.5]decan-2-yl)-7-methoxy-2- quinolyl]thiazole; 4-(3-methoxypyrrolidin-1-yl)-N,N-dimethyl-2-(2-(piperazin-1-yl)thiazol-5- yl)quinolin-7-amine; 2-(4-(5-(6-fluoro-4-(3-(hydroxymethyl)pyrrolidin-1-yl)-7-methoxyquinolin-2- yl)pyridin-2-yl)piperazin-1-yl)ethan-1-ol; 2-amino-1-(5-(6-fluoro-7-methoxy-4-(octahydro-2H-pyrrolo[3,4-c]pyridin-2- yl)quinolin-2-yl)pyridin-2-yl)propan-1-one; 2-amino-1-(4-(5-(4-(3-(hydroxymethyl)pyrrolidin-1-yl)-7-methoxyquinolin-2- yl)pyridin-2-yl)piperazin-1-yl)propan-1-one; 2-(4-(6-fluoro-7-(methoxy-d3)-4-(octahydro-2H-pyrrolo[3,4-c]pyridin-2-yl)quinolin- 2-yl)phenoxy)-N-methylethan-1-amine; (1-(2-(6-(5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)pyridin-3-yl)-7- methoxyquinolin-4-yl)pyrrolidin-3-yl)methanol; (1-(7-(dimethylamino)-2-(6-(piperazin-1-yl)pyridin-3-yl)quinolin-4-yl)pyrrolidin-3- yl)methanol; 2-(7-(methoxy-d3)-2-(4-(piperazin-1-yl)phenyl)quinolin-4-yl)-2,7- diazaspiro[4.5]decane; (1-(7-methoxy-2-(6-(2-(methylamino)ethoxy)pyridin-3-yl)quinolin-4-yl)pyrrolidin-3- yl)methanol; 2-amino-N-(5-(6-fluoro-7-methoxy-4-(octahydro-2H-pyrrolo[3,4-c]pyridin-2- yl)quinolin-2-yl)pyridin-2-yl)-N-methylpropanamide; ethyl (2-(2-(azetidin-1-yl)thiazol-5-yl)-4-(octahydro-2H-pyrrolo[3,4-c]pyridin-2- yl)quinolin-7-yl)carbamate; 2-amino-1-(4-(7-(methoxy-d3)-4-(2,7-diazaspiro[4.5]decan-2-yl)quinolin-2- yl)phenyl)propan-1-one; 2-amino-1-(4-(7-(methoxy-d3)-4-(octahydro-2H-pyrrolo[3,4-c]pyridin-2-yl)quinolin- 2-yl)phenyl)propan-1-one; Attorney Docket No.: 185992002240 2-amino-1-(4-(6-fluoro-7-(methoxy-d3)-4-(octahydro-2H-pyrrolo[3,4-c]pyridin-2- yl)quinolin-2-yl)phenyl)propan-1-one; 2-amino-1-(4-(7-(dimethylamino)-6-fluoro-4-(octahydro-2H-pyrrolo[3,4-c]pyridin-2- yl)quinolin-2-yl)phenyl)propan-1-one; 2-(4-(6-fluoro-4-(octahydro-2H-pyrrolo[3,4-c]pyridin-2-yl)-7-(pent-4-yn-1- yloxy)quinolin-2-yl)phenoxy)-N-methylethan-1-amine; 2-(6-(azetidin-1-yl)pyridin-3-yl)-7-methoxy-4-(octahydro-2H-pyrrolo[3,4-c]pyridin- 2-yl)quinoline; 2-(6-(azetidin-1-yl)pyridin-3-yl)-6-fluoro-7-methoxy-4-(octahydro-2H-pyrrolo[3,4- c]pyridin-2-yl)quinoline; 2-(4-(6-fluoro-7-methoxy-4-(2,7-diazaspiro[4.5]decan-2-yl)quinolin-2-yl)phenoxy)- N-methylethan-1-amine; 2-(2-(4-(azetidin-1-yl)phenyl)-6-fluoro-7-methoxyquinolin-4-yl)-2,7- diazaspiro[4.5]decane; 2-amino-N-(5-(6-fluoro-7-methoxy-4-(octahydro-2H-pyrrolo[3,4-c]pyridin-2- yl)quinolin-2-yl)pyridin-2-yl)-2-methylpropanamide; (1-(2-(4-(2-(methylamino)ethoxy)phenyl)quinolin-4-yl)pyrrolidin-3-yl)methanol; (1-(7-methoxy-2-(4-(piperazin-1-yl)phenyl)quinolin-4-yl)pyrrolidin-3-yl)methanol; 4-(3-methoxypyrrolidin-1-yl)-N,N-dimethyl-2-(4-(2- (methylamino)ethoxy)phenyl)quinolin-7-amine; 2-(6-(piperazin-1-yl)pyridin-3-yl)-4-(2,6-diazaspiro[3.4]octan-2-yl)quinoline; 2-amino-N-(5-(6-fluoro-7-methoxy-4-(octahydro-2H-pyrrolo[3,4-c]pyridin-2- yl)quinolin-2-yl)pyridin-2-yl)propanamide; 2-(2-(6-(azetidin-1-yl)pyridin-3-yl)-6-fluoro-7-methoxyquinolin-4-yl)-2,7- diazaspiro[4.5]decan-8-one; (1-(6-fluoro-7-methoxy-2-(6-(methyl(2-(methylamino)ethyl)amino)pyridin-3- yl)quinolin-4-yl)pyrrolidin-3-yl)methanol; (1-(6-fluoro-7-methoxy-2-(6-(piperazin-1-yl)pyridin-3-yl)quinolin-4-yl)pyrrolidin-3- yl)methanol; [1-[7-(dimethylamino)-2-[6-[2-(methylamino)ethoxy]-3-pyridyl]-4- quinolyl]pyrrolidin-3-yl]methanol; [1-[6-fluoro-7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]pyrrolidin- 3-yl]methanol; Attorney Docket No.: 185992002240 [1-[6-fluoro-2-[4-[2-(methylamino)ethoxy]phenyl]-7-(trideuteriomethoxy)-4- quinolyl]pyrrolidin-3-yl]methanol; 2-[4-[4-(2,9-diazaspiro[4.5]decan-2-yl)-6-fluoro-7-(trideuteriomethoxy)-2- quinolyl]phenoxy]-N-methyl-ethanamine; 2-[4-[6-fluoro-7-methoxy-4-(9-methyl-2,9-diazaspiro[4.5]decan-2-yl)-2- quinolyl]phenoxy]-N-methyl-ethanamine; 5-[7-methoxy-4-(5-methyl-3,3a,4,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridin-2-yl)-2- quinolyl]-N,N-dimethyl-pyridin-2-amine; 7-[7-methoxy-2-(4-piperazin-1-ylphenyl)-4-quinolyl]-2-oxa-7-azaspiro[3.4]octane; [1-[6-fluoro-7-methoxy-2-[5-[2-(methylamino)ethoxy]-2-pyridyl]-4- quinolyl]pyrrolidin-3-yl]methanol; [1-[7-chloro-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]pyrrolidin-3- yl]methanol; 2-[2-[6-(dimethylamino)-3-pyridyl]-7-methoxy-4-quinolyl]-3,3a,5,6,7,7a-hexahydro- 1H-pyrrolo[3,4-c]pyridin-4-one; 2-(2-(4-(azetidin-3-yloxy)phenyl)-7-methoxyquinolin-4-yl)octahydro-4H-pyrrolo[3,4- c]pyridin-4-one; 2-[4-[7-methoxy-4-(9-methyl-2,9-diazaspiro[4.5]decan-2-yl)-2-quinolyl]phenoxy]-N- methyl-acetamide; 2-[7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-3,3a,5,6,7,7a- hexahydro-1H-pyrrolo[3,4-c]pyridin-4-one; 2-[7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-2,7- diazaspiro[4.5]decan-6-one; 2-[4-[4-(2,9-diazaspiro[4.5]decan-2-yl)-7-methoxy-2-quinolyl]phenoxy]-N-methyl- acetamide; [1-[7-(dimethylamino)-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]pyrrolidin-3- yl]methanol; ethyl N-[4-[3-(hydroxymethyl)pyrrolidin-1-yl]-2-[4-[2-(methylamino)ethoxy]phenyl]- 7-quinolyl]carbamate; [1-[2-(4-piperazin-1-ylphenyl)-4-quinolyl]pyrrolidin-3-yl]methanol; [1-[7-methoxy-2-(4-piperazin-1-ylphenyl)-4-quinolyl]azetidin-3-yl]methanol; [1-[7-[2-(dimethylamino)ethoxy]-2-(4-pyrrolidin-1-ylphenyl)-4-quinolyl]pyrrolidin-3- yl]methanol; Attorney Docket No.: 185992002240 [1-[7-(dimethylamino)-2-[4-(methylamino)phenyl]-4-quinolyl]pyrrolidin-3- yl]methanol; N,N-dimethyl-2-[6-[2-(methylamino)ethoxy]-3-pyridyl]-4-(2-oxa-7- azaspiro[3.4]octan-7-yl)quinolin-7-amine; N,N-dimethyl-4-(5-methyl-3,3a,4,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridin-2-yl)-2- [6-[2-(methylamino)ethoxy]-3-pyridyl]quinolin-7-amine; N,N-dimethyl-2-[6-[2-(methylamino)ethoxy]-3-pyridyl]-4-pyrrolidin-1-yl-quinolin-7- amine; 2-(4-(4-(3,3-difluoro-4-methoxypyrrolidin-1-yl)-7-methoxyquinolin-2-yl)phenoxy)- N-methylethan-1-amine; [1-[7-(dimethylamino)-2-[6-[2-(methylamino)ethoxy]-3-pyridyl]-4-quinolyl]azetidin- 3-yl]methanol; 2-[[5-[7-methoxy-4-(2-oxa-7-azaspiro[3.4]octan-7-yl)-2-quinolyl]-2-pyridyl]oxy]-N- methyl-ethanamine; N,N-dimethyl-2-[6-[2-(methylamino)ethoxy]-3-pyridyl]-4-(6-methyl-2,6- diazaspiro[3.3]heptan-2-yl)quinolin-7-amine; 2-[4-[7-methoxy-4-(2-oxa-7-azaspiro[3.4]octan-7-yl)-2-quinolyl]phenoxy]-N-methyl- ethanamine; 7-[2-(6-piperazin-1-yl-3-pyridyl)-4-quinolyl]-2λ6-thia-7-azaspiro[3.4]octane 2,2- dioxide; N-methyl-2-[[5-[7-morpholino-4-(2-oxa-7-azaspiro[3.4]octan-7-yl)-2-quinolyl]-2- pyridyl]oxy]ethanamine; [1-[7-(dimethylamino)-2-[5-[2-(methylamino)ethoxy]-2-pyridyl]-4- quinolyl]pyrrolidin-3-yl]methanol; 2-(5-methoxy-2-pyridyl)-N,N-dimethyl-4-(2-oxa-7-azaspiro[3.4]octan-7-yl)quinolin- 7-amine; [1-[2-[6-[2-(methylamino)ethoxy]-3-pyridyl]-7-morpholino-4-quinolyl]pyrrolidin-3- yl]methanol; N,N-dimethyl-2-[5-[2-(methylamino)ethoxy]-2-pyridyl]-4-(2-oxa-7- azaspiro[3.4]octan-7-yl)quinolin-7-amine; N,N-dimethyl-2-[6-[2-(methylamino)ethoxy]-3-pyridyl]-4-(7-methyl-2,7- diazaspiro[4.4]nonan-2-yl)quinolin-7-amine; 7-methoxy-4-(3-methoxypyrrolidin-1-yl)-2-(4-piperazin-1-ylphenyl)quinoline; Attorney Docket No.: 185992002240 ethyl N-[4-(5-methyl-3,3a,4,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridin-2-yl)-2-[6- (methylamino)-3-pyridyl]-7-quinolyl]carbamate; 4-(3-methoxypyrrolidin-1-yl)-N,N-dimethyl-2-(6-piperazin-1-yl-3-pyridyl)quinolin-7- amine; [1-[7-(dimethylamino)-2-(5-methoxy-2-pyridyl)-4-quinolyl]pyrrolidin-3-yl]methanol; N-methyl-1-[1-[2-(6-piperazin-1-yl-3-pyridyl)-4-quinolyl]azetidin-3-yl]methanamine; [1-[7-methoxy-2-(5-piperazin-1-yl-2-pyridyl)-4-quinolyl]pyrrolidin-3-yl]methanol; 7-methoxy-4-(5-methyl-3,3a,4,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridin-2-yl)-2-(4- piperazin-1-ylphenyl)quinoline; N,N-dimethyl-4-(5-methyl-3,3a,4,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridin-2-yl)-2- [4-[2-(methylamino)ethoxy]phenyl]quinolin-7-amine; N-methyl-2-[[6-[7-morpholino-4-(2-oxa-7-azaspiro[3.4]octan-7-yl)-2-quinolyl]-3- pyridyl]oxy]ethanamine; N,N-dimethyl-2-[6-[2-(methylamino)ethoxy]-3-pyridyl]-4-[3- (trifluoromethoxy)pyrrolidin-1-yl]quinolin-7-amine; 4-(3-ethoxypyrrolidin-1-yl)-N,N-dimethyl-2-[6-[2-(methylamino)ethoxy]-3- pyridyl]quinolin-7-amine; 2-[[5-[4-(3-methoxypyrrolidin-1-yl)-7-pyrrolidin-1-yl-2-quinolyl]-2-pyridyl]oxy]-N- methyl-ethanamine; 4-(3-methoxypyrrolidin-1-yl)-N,N-dimethyl-2-[6-(2-pyrrolidin-1-ylethoxy)-3- pyridyl]quinolin-7-amine; 2-[[5-[4-(3-methoxypyrrolidin-1-yl)-7-morpholino-2-quinolyl]-2-pyridyl]oxy]-N- methyl-ethanamine; [1-[6-fluoro-7-methoxy-2-[6-[2-(methylamino)ethoxy]-3-pyridyl]-4- quinolyl]pyrrolidin-3-yl]methanol; 7-methoxy-4-(5-methyl-3,3a,4,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridin-2-yl)-2-(5- pyrrolidin-1-yl-2-pyridyl)quinoline; 2-[[5-[6-fluoro-7-methoxy-4-(5-methyl-3,3a,4,6,7,7a-hexahydro-1H-pyrrolo[3,4- c]pyridin-2-yl)-2-quinolyl]-2-pyridyl]oxy]-N-methyl-ethanamine; 4-(1,3,3a,4,5,6,7,7a-octahydropyrrolo[3,4-c]pyridin-2-yl)-7-methoxy-2-(6-pyrrolidin- 1-yl-3-pyridyl)quinoline; 6-(7-methoxy-2-(4-(2-(methylamino)ethoxy)phenyl)quinolin-4- yl)octahydropyrrolo[3,4-e][1,2]thiazine 1,1-dioxide; Attorney Docket No.: 185992002240 1-[6-fluoro-7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-N-methyl- pyrrolidine-3-carboxamide; 6-fluoro-N,N-dimethyl-2-[6-[2-(methylamino)ethoxy]-3-pyridyl]-4-(7-methyl-2,7- diazaspiro[4.4]nonan-2-yl)quinolin-7-amine; N-methyl-1-[1-[2-(6-piperazin-1-yl-3-pyridyl)-4-quinolyl]pyrrolidin-3- yl]methanamine; 4-[3-(difluoromethoxy)pyrrolidin-1-yl]-N,N-dimethyl-2-[6-[2-(methylamino)ethoxy]- 3-pyridyl]quinolin-7-amine; 2-[7-methoxy-2-(6-piperazin-1-yl-3-pyridyl)-4-quinolyl]-3,3a,5,6,7,7a-hexahydro-1H- pyrrolo[3,4-c]pyridin-4-one; 2-[[5-[7-methoxy-4-(5-methyl-3,3a,4,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridin-2- yl)-2-quinolyl]-2-pyridyl]oxy]-N-methyl-ethanamine; 2-[6-fluoro-7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]- 3,3a,5,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridin-4-one; 2-[6-fluoro-7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-2,7- diazaspiro[4.5]decan-6-one; 5-[6-fluoro-7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]- 1,2,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-3-one; 2-[[5-[4-(2,2-dioxo-2λ6-thia-7-azaspiro[3.4]octan-7-yl)-6-fluoro-7-methoxy-2- quinolyl]-2-pyridyl]oxy]-N-methyl-ethanamine; 2-[4-[4-(2,2-dioxo-2λ6-thia-7-azaspiro[3.4]octan-7-yl)-6-fluoro-7-methoxy-2- quinolyl]phenoxy]-N-methyl-ethanamine; N'-[5-[6-fluoro-7-methoxy-4-(5-methyl-3,3a,4,6,7,7a-hexahydro-1H-pyrrolo[3,4- c]pyridin-2-yl)-2-quinolyl]-2-pyridyl]-N,N'-dimethyl-ethane-1,2-diamine; 2-[6-fluoro-7-methoxy-2-[6-[2-(methylamino)ethoxy]-3-pyridyl]-4-quinolyl]- 3,3a,5,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridin-4-one; 2-[4-[6-fluoro-7-methoxy-4-(5-methyl-3,3a,4,6,7,7a-hexahydro-1H-pyrrolo[3,4- c]pyridin-2-yl)-2-quinolyl]phenoxy]-N-methyl-ethanamine; 2-[2-[6-(azetidin-1-yl)-3-pyridyl]-6-fluoro-7-methoxy-4-quinolyl]-5-methyl- 1,3,3a,6,7,7a-hexahydropyrrolo[3,4-c]pyridin-4-one; 2-[6-fluoro-7-methoxy-2-(6-pyrrolidin-1-yl-3-pyridyl)-4-quinolyl]-5-methyl- 1,3,3a,6,7,7a-hexahydropyrrolo[3,4-c]pyridin-4-one; Attorney Docket No.: 185992002240 2-[6-fluoro-7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-70methyl- 1,3,3a,6,7,7a-hexahydropyrrolo[3,4-c]pyridin-4-one; 2-[7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-5-methyl- 1,3,3a,6,7,7a-hexahydropyrrolo[3,4-c]pyridin-4-one; 2-[6-fluoro-7-methoxy-2-[6-[2-(methylamino)ethoxy]-3-pyridyl]-4-quinolyl]-5- methyl-1,3,3a,6,7,7a-hexahydropyrrolo[3,4-c]pyridin-4-one; 2-[2-[4-(azetidin-1-yl)phenyl]-6-fluoro-7-methoxy-4-quinolyl]-3,3a,5,6,7,7a- hexahydro-1H-pyrrolo[3,4-c]pyridin-4-one; 2-[2-[6-(dimethylamino)-3-pyridyl]-6-fluoro-7-methoxy-4-quinolyl]-5-methyl- 1,3,3a,6,7,7a-hexahydropyrrolo[3,4-c]pyridin-4-one; N-[4-[4-(2,2-dioxo-2λ6-thia-7-azaspiro[3.4]octan-7-yl)-6-fluoro-2-quinolyl]phenyl]- 2-pyrrolidin-1-yl-acetamide; 1-[6-fluoro-7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-N,N- dimethyl-pyrrolidine-3-carboxamide; 2-[7-(dimethylamino)-2-[6-[2-(methylamino)ethoxy]-3-pyridyl]-4-quinolyl]-5- methyl-1,3,3a,6,7,7a-hexahydropyrrolo[3,4-c]pyridin-4-one; 7-[2-[6-(azetidin-1-yl)-3-pyridyl]-6-fluoro-7-methoxy-4-quinolyl]-2λ6-thia-7- azaspiro[4.4]nonane 2,2-dioxide; 2-[4-[4-(2,2-dioxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-c]pyrrol-5-yl)-6-fluoro-7- methoxy-2-quinolyl]phenoxy]-N-methyl-ethanamine; 6-[6-fluoro-7-methoxy-2-(6-pyrrolidin-1-yl-3-pyridyl)-4-quinolyl]-2λ6-thia-6- azaspiro[3.3]heptane 2,2-dioxide; 2-[2-[4-(azetidin-3-yloxy)phenyl]-6-fluoro-7-methoxy-4-quinolyl]-3,3a,5,6,7,7a- hexahydro-1H-pyrrolo[3,4-c]pyridin-4-one; 2-[6-fluoro-7-methoxy-2-(4-pyrrolidin-3-yloxyphenyl)-4-quinolyl]-3,3a,5,6,7,7a- hexahydro-1H-pyrrolo[3,4-c]pyridin-4-one; 1-[6-fluoro-7-methoxy-2-[6-[2-(methylamino)ethoxy]-3-pyridyl]-4-quinolyl]-N- methyl-pyrrolidine-3-carboxamide; 2-[6-fluoro-7-methoxy-2-[4-[pyrrolidin-3-yl]oxyphenyl]-4-quinolyl]-5-methyl- 1,3,3a,6,7,7a-hexahydropyrrolo[3,4-c]pyridin-4-one; 7-[2-[6-(azetidin-1-yl)-3-pyridyl]-6-fluoro-7-methoxy-4-quinolyl]-2λ6-thia-3,7- diazaspiro[4.4]nonane 2,2-dioxide; Attorney Docket No.: 185992002240 6-[2-[6-(azetidin-1-yl)-3-pyridyl]-6-fluoro-7-methoxy-4-quinolyl]-2-methyl- 3,4,4a,5,7,7a-hexahydropyrrolo[3,4-e]thiazine 1,1-dioxide; 2-[6-fluoro-7-methoxy-2-[4-[pyrrolidin-3-yl]oxyphenyl]-4-quinolyl]-5-methyl- 1,3,3a,6,7,7a-hexahydropyrrolo[3,4-c]pyridin-4-one; 2-[4-[4-(7,7-difluoro-5-methyl-1,3,3a,4,6,7a-hexahydropyrrolo[3,4-c]pyridin-2-yl)-6- fluoro-7-methoxy-2-quinolyl]phenoxy]-N-methyl-ethanamine; 2-[6-(2,6-diazaspiro[3.3]heptan-2-yl)-3-pyridyl]-6-fluoro-7-methoxy-4-(5-methyl- 3,3a,4,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridin-2-yl)quinoline; 2-[6-(1,6-diazaspiro[3.3]heptan-6-yl)-3-pyridyl]-6-fluoro-7-methoxy-4-(5-methyl- 3,3a,4,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridin-2-yl)quinoline; 2-[6-(azetidin-3-ylmethoxy)-3-pyridyl]-6-fluoro-7-methoxy-4-(5-methyl- 3,3a,4,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridin-2-yl)quinoline; 2-[6-(azetidin-2-ylmethoxy)-3-pyridyl]-6-fluoro-7-methoxy-4-(5-methyl- 3,3a,4,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridin-2-yl)quinoline; 2-[4-(azetidin-3-yloxy)phenyl]-6-fluoro-7-methoxy-4-(5-methyl-3,3a,4,6,7,7a- hexahydro-1H-pyrrolo[3,4-c]pyridin-2-yl)quinoline; 6-fluoro-7-methoxy-4-(5-methyl-3,3a,4,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridin- 2-yl)-2-(4-pyrrolidin-3-yloxyphenyl)quinoline; 2-[4-[6-fluoro-7-methoxy-4-(8-methyl-2,8-diazaspiro[3.5]nonan-2-yl)-2- quinolyl]phenoxy]-N-methyl-ethanamine; 2-[4-[6-fluoro-7-methoxy-4-(2-methyl-2,6-diazaspiro[3.4]octan-6-yl)-2- quinolyl]phenoxy]-N-methyl-ethanamine; 2-[[5-[6-fluoro-7-methoxy-4-(2-methyl-2,6-diazaspiro[3.4]octan-6-yl)-2-quinolyl]-2- pyridyl]oxy]-N-methyl-ethanamine; 2-[6-fluoro-7-methoxy-2-(6-pyrrolidin-1-yl-3-pyridyl)-4-quinolyl]-9-methyl-2,6,9- triazaspiro[4.5]decan-8-one; 2-[4-[4-(2,2-dioxo-2λ6-thia-7-azaspiro[3.4]octan-7-yl)-6,7-difluoro-2- quinolyl]phenoxy]-N-methyl-ethanamine; 2-[6,7-difluoro-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-3,3a,5,6,7,7a- hexahydro-1H-pyrrolo[3,4-c]pyridin-4-one; 7-[2-[6-(azetidin-1-yl)-3-pyridyl]-6-fluoro-7-methoxy-4-quinolyl]-3-methyl-2λ6-thia- 3,7-diazaspiro[4.4]nonane 2,2-dioxide; Attorney Docket No.: 185992002240 6-[6-fluoro-7-methoxy-2-(6-pyrrolidin-1-yl-3-pyridyl)-4-quinolyl]-2-methyl-2,6- diazaspiro[3.4]octan-3-one; 2-[[5-[4-(7,7-difluoro-5-methyl-1,3,3a,4,6,7a-hexahydropyrrolo[3,4-c]pyridin-2-yl)-6- fluoro-7-methoxy-2-quinolyl]-2-pyridyl]oxy]-N-methyl-ethanamine; 4-[5-(2,2-difluoroethyl)-3,3a,4,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridin-2-yl]-6- fluoro-7-methoxy-2-(6-pyrrolidin-1-yl-3-pyridyl)quinoline; 2-[6-fluoro-7-methoxy-2-(6-pyrrolidin-1-yl-3-pyridyl)-4-quinolyl]-9-methyl-2,6,9- triazaspiro[4.5]decan-7-one; 2-[4-[6-fluoro-7-methoxy-4-(5-methyl-3,3a,4,6,7,7a-hexahydro-1H-pyrrolo[3,4- c]pyridin-2-yl)-2-quinolyl]phenyl]sulfanyl-N-methyl-ethanamine; 6-fluoro-2-[4-(1H-imidazol-4-yloxy)phenyl]-7-methoxy-4-(5-methyl-3,3a,4,6,7,7a- hexahydro-1H-pyrrolo[3,4-c]pyridin-2-yl)quinoline; 2-[6-fluoro-7-methoxy-2-(6-piperazin-1-yl-3-pyridyl)-4-quinolyl]-3,3a,5,6,7,7a- hexahydro-1H-pyrrolo[3,4-c]pyridin-4-one; 2-[4-[4-(2,2-dioxo-2λ6-thia-7-azaspiro[3.4]octan-7-yl)-2-quinolyl]phenoxy]-N- methyl-ethanamine; 6-fluoro-4-(3-methoxypyrrolidin-1-yl)-N,N-dimethyl-2-[4-[2- (methylamino)ethoxy]phenyl]quinolin-7-amine; 2-[[5-(6-fluoro-7-methoxy-4-pyrrolidin-1-yl-2-quinolyl)-2-pyridyl]oxy]-N-methyl- ethanamine; 2-[4-[4-(2,2-dioxo-2λ6-thia-7-azaspiro[3.4]octan-7-yl)-6-fluoro-7-pent-4-ynoxy-2- quinolyl]phenoxy]-N-methyl-ethanamine; 1-[6-fluoro-7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]pyrrolidin- 3-one; 2-[4-[4-(2,3,3a,4,6,6a-hexahydrofuro[2,3-c]pyrrol-5-yl)-6-fluoro-7-methoxy-2- quinolyl]phenoxy]-N-methyl-ethanamine; 2-[4-[4-(1,3,3a,4,6,6a-hexahydrofuro[3,4-c]pyrrol-5-yl)-6-fluoro-7-methoxy-2- quinolyl]phenoxy]-N-methyl-ethanamine; 2-[[5-[4-(1,3,3a,4,6,6a-hexahydrofuro[3,4-c]pyrrol-5-yl)-6-fluoro-7-methoxy-2- quinolyl]-2-pyridyl]oxy]-N-methyl-ethanamine; 7-[6-fluoro-2-[4-(1H-imidazol-4-yloxy)phenyl]-7-methoxy-4-quinolyl]-2λ6-thia-7- azaspiro[3.4]octane 2,2-dioxide; Attorney Docket No.: 185992002240 5-[6-fluoro-7-methoxy-2-(4-pyrrolidin-1-ylphenyl)-4-quinolyl]-1,3,3a,4,6,6a- hexahydrothieno[3,4-c]pyrrole 2,2-dioxide; 6-fluoro-N,N-dimethyl-4-(5-methyl-3,3a,4,6,7,7a-hexahydro-1H-pyrrolo[3,4- c]pyridin-2-yl)-2-[4-[2-(methylamino)ethoxy]phenyl]quinolin-7-amine; 6-fluoro-N,N-dimethyl-2-[4-[2-(methylamino)ethoxy]phenyl]-4-(2-oxa-7- azaspiro[3.4]octan-7-yl)quinolin-7-amine; 2-[4-[6-fluoro-7-methoxy-4-(2-oxa-7-azaspiro[3.4]octan-7-yl)-2-quinolyl]phenoxy]- N-methyl-ethanamine; 6-fluoro-7-methoxy-4-(5-methyl-3,3a,4,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridin- 2-yl)-2-(4-piperazin-1-ylphenyl)quinoline; 6-fluoro-N,N-dimethyl-2-[4-[2-(methylamino)ethoxy]phenyl]-4-(7-methyl-2,7- diazaspiro[4.4]nonan-2-yl)quinolin-7-amine; 2-[2-[6-(azetidin-1-yl)-3-pyridyl]-6-fluoro-7-methoxy-4-quinolyl]-3,3a,4,6,7,7a- hexahydro-1H-thiopyrano[3,4-c]pyrrole 5,5-dioxide; 2-[[6-[4-(2,9-diazaspiro[4.5]decan-2-yl)-6-fluoro-7-(trideuteriomethoxy)-2-quinolyl]- 3-pyridyl]oxy]-N-methyl-ethanamine; [1-[6-fluoro-2-[5-[2-(methylamino)ethoxy]-2-pyridyl]-7-(trideuteriomethoxy)-4- quinolyl]pyrrolidin-3-yl]methanol; 2-[[5-[4-(2,2-dioxo-2λ6-thia-7-azaspiro[3.4]octan-7-yl)-6-fluoro-7-methoxy-2- quinolyl]-2-pyridyl]oxy]-N,N-dimethyl-ethanamine; 2-[4-[6-fluoro-4-(5-methyl-3,3a,4,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridin-2-yl)-7- (trideuteriomethoxy)-2-quinolyl]phenoxy]-N-methyl-ethanamine; 6-fluoro-7-methoxy-4-(5-methyl-3,3a,4,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridin- 2-yl)-2-(6-piperazin-1-yl-3-pyridyl)quinoline; 5-[6-fluoro-7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]- 1,3,3a,4,6,6a-hexahydropyrrolo[2,3-c]pyrrol-2-one; 2-[[5-[4-(9,9-difluoro-7-methyl-2,7-diazaspiro[4.4]nonan-2-yl)-6-fluoro-7-methoxy- 2-quinolyl]-2-pyridyl]oxy]-N-methyl-ethanamine; 2-[4-[4-(9,9-difluoro-7-methyl-2,7-diazaspiro[4.4]nonan-2-yl)-6-fluoro-7-methoxy-2- quinolyl]phenoxy]-N-methyl-ethanamine; 2-[6-fluoro-7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-5-methyl- 1,3,3a,6,7,7a-hexahydropyrrolo[3,4-c]pyridin-4-one; Attorney Docket No.: 185992002240 2-[2-[4-[2-(dimethylamino)ethoxy]phenyl]-6-fluoro-7-methoxy-4-quinolyl]-5-methyl- 1,3,3a,6,7,7a-hexahydropyrrolo[3,4-c]pyridin-4-one; 2-[4-[4-(2,2-dioxo-2λ6-thia-7-azaspiro[3.4]octan-7-yl)-6-fluoro-7-methoxy-2- quinolyl]phenoxy]-N,N-dimethyl-ethanamine; 5-[6-fluoro-7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-2-methyl- 3a,4,6,6a-tetrahydro-1H-pyrrolo[3,4-c]pyrrol-3-one; 2-[2-[4-(azetidin-3-yloxy)phenyl]-6-fluoro-7-methoxy-4-quinolyl]-5-methyl- 1,3,3a,6,7,7a-hexahydropyrrolo[3,4-c]pyridin-4-one; 2,2-difluoro-N-[2-[4-[6-fluoro-7-methoxy-4-(5-methyl-3,3a,4,6,7,7a-hexahydro-1H- pyrrolo[3,4-c]pyridin-2-yl)-2-quinolyl]phenoxy]ethyl]ethanamine; 6-fluoro-N,N-dimethyl-2-[6-[2-(methylamino)ethoxy]-3-pyridyl]-4-(2-methyl-2,6- diazaspiro[3.4]octan-6-yl)quinolin-7-amine; 2-[[5-[6-fluoro-7-methoxy-4-(2-oxa-7-azaspiro[3.4]octan-7-yl)-2-quinolyl]-2- pyridyl]oxy]-N-methyl-ethanamine; 2-[4-[6-fluoro-7-methoxy-4-(7-methyl-2,7-diazaspiro[4.4]nonan-2-yl)-2- quinolyl]phenoxy]-N-methyl-ethanamine; 2-[6-fluoro-7-methoxy-2-[4-[2-24(methylamino)ethoxy]phenyl]-4-quinolyl]-6- methyl-2,6-diazaspiro[3.5]nonan-5-one; 4,4-difluoro-7-[6-fluoro-7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4- quinolyl]-2-methyl-2,7-diazaspiro[4.4]nonan-1-one; 2-(4-(4-(3,3-difluoro-4-methoxypyrrolidin-1-yl)-7-methoxyquinolin-2-yl)phenoxy)- N-methylethan-1-amine; 2-[4-[6-fluoro-7-methoxy-4-(1-methyl-2,3,3a,5,6,6a-hexahydropyrrolo[3,2-b]pyrrol- 4-yl)-2-quinolyl]phenoxy]-N-methyl-ethanamine; 3-[4-[6-fluoro-7-methoxy-4-(7-methyl-2,7-diazaspiro[4.4]nonan-2-yl)-2- quinolyl]phenoxy]-N-methyl-propan-1-amine; 2-[4-(azetidin-3-ylmethoxy)phenyl]-6-fluoro-7-methoxy-4-(7-methyl-2,7- diazaspiro[4.4]nonan-2-yl)quinoline; 2-[4-[4-[3-[(dimethylamino)methyl]pyrrolidin-1-yl]-6-fluoro-7-methoxy-2- quinolyl]phenoxy]-N-methyl-ethanamine; 2-[2-[4-(azetidin-3-ylmethoxy)phenyl]-6-fluoro-7-methoxy-4-quinolyl]-5-methyl- 1,3,3a,6,7,7a-hexahydropyrrolo[3,4-c]pyridin-4-one; Attorney Docket No.: 185992002240 1-[5-[6-fluoro-7-methoxy-4-(5-methyl-3,3a,4,6,7,7a-hexahydro-1H-pyrrolo[3,4- c]pyridin-2-yl)-2-quinolyl]-2-pyridyl]pyrrolidin-3-ol; 2-[6-fluoro-7-methoxy-2-(4-piperazin-1-ylphenyl)-4-quinolyl]-5-methyl- 1,3,3a,6,7,7a-hexahydropyrrolo[3,4-c]pyridin-4-one; 2-[7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-5-methyl- 1,3,3a,6,7,7a-hexahydropyrrolo[3,4-c]pyridin-4-one; 2-[4-[4-[5-(2,2-difluoroethyl)-3,3a,4,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridin-2- yl]-7-methoxy-2-quinolyl]phenoxy]-N-methyl-ethanamine; 2-[[5-[7-methoxy-4-(7-methyl-2,7-diazaspiro[4.4]nonan-2-yl)-2-quinolyl]-2- pyridyl]oxy]-N-methyl-ethanamine; 2-[7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-7-methyl-2,7- diazaspiro[4.4]nonan-8-one; 2-[4-[7-methoxy-4-(7-methyl-2,7-diazaspiro[4.4]nonan-2-yl)-2-quinolyl]phenoxy]-N- methyl-ethanamine; 1-[7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-N-methyl- pyrrolidine-3-carboxamide; 7-[6-fluoro-7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-2,7- diazaspiro[4.4]nonan-1-one; 2-[4-[4-(3,3-difluoropyrrolidin-1-yl)-6-fluoro-7-methoxy-2-quinolyl]phenoxy]-N- methyl-ethanamine; 2-[4-[7-methoxy-4-(3-methyl-2,2-dioxo-2λ6-thia-3,7-diazaspiro[4.4]nonan-7-yl)-2- quinolyl]phenoxy]-N-methyl-ethanamine; 2-[4-[4-(1,3-dimethyl-2,2-dioxo-2λ6-thia-3,7-diazaspiro[4.4]nonan-7-yl)-7-methoxy- 2-quinolyl]phenoxy]-N-methyl-ethanamine; 2-[6-fluoro-7-methoxy-2-[4-(2-methoxyethoxy)phenyl]-4-quinolyl]-3,3a,5,6,7,7a- hexahydro-1H-pyrrolo[3,4-c]pyridin-4-one; 2-[6-fluoro-7-methoxy-2-[4-[2-(trideuteriomethoxy)ethoxy]phenyl]-4-quinolyl]- 3,3a,5,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridin-4-one; 2-[1-[6-fluoro-7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4- quinolyl]pyrrolidin-3-yl]-N-methyl-acetamide; 2-[2-[4-[2-(dimethylamino)ethoxy]phenyl]-7-methoxy-4-quinolyl]-3,3a,5,6,7,7a- hexahydro-1H-pyrrolo[3,4-c]pyridin-4-one; Attorney Docket No.: 185992002240 2-[6-fluoro-7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-2,7- diazaspiro[4.4]nonan-8-one; 2-[2-[4-(azetidin-3-yloxy)phenyl]-7-methoxy-4-quinolyl]-3,3a,5,6,7,7a-hexahydro- 1H-pyrrolo[3,4-c]pyridin-4-one; 2-[7-methoxy-2-[4-[pyrrolidin-3-yl]oxyphenyl]-4-quinolyl]-3,3a,5,6,7,7a-hexahydro- 1H-pyrrolo[3,4-c]pyridin-4-one; N-methyl-2-[4-[7-morpholino-4-(2-oxa-7-azaspiro[3.4]octan-7-yl)-2- quinolyl]phenoxy]ethanamine; 2-[2-[4-[2-(methylamino)ethoxy]phenyl]-7-(trideuteriomethoxy)-4-quinolyl]- 3,3a,5,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridin-4-one; 2-[7-methoxy-2-[5-[2-(methylamino)ethoxy]-2-pyridyl]-4-quinolyl]-3,3a,5,6,7,7a- hexahydro-1H-pyrrolo[3,4-c]pyridin-4-one; 2-[1-[7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]pyrrolidin-3-yl]- N-methyl-acetamide; 2-[7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-2,7- diazaspiro[4.4]nonan-8-one; 2-[2-[4-[2-(cyclopropylamino)ethoxy]phenyl]-7-methoxy-4-quinolyl]-3,3a,5,6,7,7a- hexahydro-1H-pyrrolo[3,4-c]pyridin-4-one; 2-[4-[7-methoxy-4-(3-methoxypyrrolidin-1-yl)-2-quinolyl]phenoxy]-N-methyl- ethanamine; 2-[7-ethoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-3,3a,5,6,7,7a- hexahydro-1H-pyrrolo[3,4-c]pyridin-4-one; 7-[7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-2,7- diazaspiro[4.4]nonan-1-one; 1-[[4-[4-(5-azaspiro[2.4]heptan-5-yl)-6-fluoro-7-methoxy-2- quinolyl]phenoxy]methyl]-N-methyl-cyclopropanamine; 2-[7-methoxy-2-[4-[[1-(methylamino)cyclopropyl]methoxy]phenyl]-4-quinolyl]-5- methyl-1,3,3a,6,7,7a-hexahydropyrrolo[3,4-c]pyridin-4-one; 2-[7-chloro-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-3,3a,5,6,7,7a- hexahydro-1H-pyrrolo[3,4-c]pyridin-4-one; 1-[4-[7-methoxy-4-(5-methyl-3,3a,4,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridin-2- yl)-2-quinolyl]phenyl]pyrrolidin-3-ol; Attorney Docket No.: 185992002240 2-[7-methyl-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-3,3a,5,6,7,7a- hexahydro-1H-pyrrolo[3,4-c]pyridin-4-one; 2-[7-cyclopropyl-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-3,3a,5,6,7,7a- hexahydro-1H-pyrrolo[3,4-c]pyridin-4-one; 5-[7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-1,3,3a,4,6,6a- hexahydropyrrolo[2,3-c]pyrrol-2-one; 2-[2-[4-[3-hydroxypyrrolidin-1-yl]phenyl]-7-methoxy-4-quinolyl]-3,3a,5,6,7,7a- hexahydro-1H-pyrrolo[3,4-c]pyridin-4-one; 6-[7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-3,4,4a,5,7,7a- hexahydro-1H-pyrrolo[3,4-b]pyridin-2-one; 7-[7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-1,7- diazaspiro[4.4]nonan-2-one; 2-[7-(2-methoxyethoxy)-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]- 3,3a,5,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridin-4-one; 2-[7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-5-methyl- 3,3a,4,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridin-7-ol; 2-[7-(difluoromethoxy)-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]- 3,3a,5,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridin-4-one; 2-[4-[7-methoxy-4-[3-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]-2-quinolyl]phenoxy]- N-methyl-ethanamine; 2-[4-[4-(3,3-difluoro-4-methoxy-pyrrolidin-1-yl)-7-methoxy-2-quinolyl]phenoxy]-N- methyl-ethanamine; 2-[4-[7-methoxy-4-(7-methyl-2,7-diazaspiro[4.4]nonan-2-yl)-2-quinolyl]phenoxy]- N,N-dimethyl-ethanamine; 2-[8-fluoro-7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]- 3,3a,5,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridin-4-one; 2-[4-[4-[3-[(dimethylamino)methyl]pyrrolidin-1-yl]-7-methoxy-2-quinolyl]phenoxy]- N-methyl-ethanamine; 7-[7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-3-methyl-1,7- diazaspiro[4.4]nonan-2-one; 2-[7-methoxy-2-[4-[3-(methylamino)propoxy]phenyl]-4-quinolyl]-3,3a,5,6,7,7a- hexahydro-1H-pyrrolo[3,4-c]pyridin-4-one; Attorney Docket No.: 185992002240 2-[7-methoxy-2-[5-[2-(methylamino)ethoxy]-2-pyridyl]-4-quinolyl]-3,3a,5,6,7,7a- hexahydro-1H-pyrrolo[3,4-c]pyridin-4-one; 3a-fluoro-2-[7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]- 1,3,5,6,7,7a-hexahydropyrrolo[3,4-c]pyridin-4-one; 5-[7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-1,3,3a,4,6,6a- hexahydropyrrolo[3,4-b]pyrrol-2-one; 5-[7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-1,2,3a,4,6,6a- hexahydropyrrolo[3,4-c]pyrrol-3-one; 2-[7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-2,7- diazaspiro[4.4]nonan-8-one; 3-[4-[7-methoxy-4-(1-methyl-1,7-diazaspiro[4.4]nonan-7-yl)-2-quinolyl]phenoxy]-N- methyl-propan-1-amine; 2-(7-methoxy-2-(4-(piperazin-1-yl)phenyl)quinolin-4-yl)octahydro-4H-pyrrolo[3,4- c]pyridin-4-one; N-(1-(7-methoxy-2-(4-(2-(methylamino)ethoxy)phenyl)quinolin-4-yl)pyrrolidin-3- yl)acetamide; 6-fluoro-7-methoxy-4-(5-methyloctahydro-2H-pyrrolo[3,4-c]pyridin-2-yl)-2-(6- (pyrrolidin-1-yl)pyridin-3-yl)quinoline; 4-(3-methoxypyrrolidin-1-yl)-N,N-dimethyl-2-(5-(2-(methylamino)ethoxy)pyridin-2- yl)quinolin-7-amine; 6-(7-methoxy-2-(6-(piperazin-1-yl)pyridin-3-yl)quinolin-4-yl)-2-thia-6- azaspiro[3.4]octane 2,2-dioxide; 2-(1-(7-methoxy-2-(4-(2-(methylamino)ethoxy)phenyl)quinolin-4-yl)pyrrolidin-3-yl)- N-methylacetamide; ethyl (1-(7-methoxy-2-(4-(2-(methylamino)ethoxy)phenyl)quinolin-4-yl)pyrrolidin-3- yl)carbamate; 2-(7-methoxy-2-(6-(2-(methylamino)ethoxy)pyridin-3-yl)quinolin-4-yl)octahydro- 4H-pyrrolo[3,4-c]pyridin-4-one; 6-(7-methoxy-2-(4-(2-(methylamino)ethoxy)phenyl)quinolin-4-yl)-2-thia-6- azaspiro[3.4]octane 2,2-dioxide; 1-(7-methoxy-2-(4-(2-(methylamino)ethoxy)phenyl)quinolin-4-yl)pyrrolidine-3- carbonitrile; Attorney Docket No.: 185992002240 1-(7-methoxy-2-(4-(2-(methylamino)ethoxy)phenyl)quinolin-4-yl)-N,N- dimethylpyrrolidine-3-carboxamide; 1-(7-methoxy-2-(4-(2-(methylamino)ethoxy)phenyl)quinolin-4-yl)pyrrolidin-3-yl methylcarbamate; 2-(4-(7-methoxy-4-(3-((methylamino)methyl)pyrrolidin-1-yl)quinolin-2-yl)phenoxy)- N-methylethan-1-amine; 5-(7-methoxy-2-(4-(2-(methylamino)ethoxy)phenyl)quinolin-4-yl)hexahydro-1H- thieno[3,4-c]pyrrole 2,2-dioxide; 2-(dimethylamino)-N-(4-(7-methoxy-4-(4-oxooctahydro-2H-pyrrolo[3,4-c]pyridin-2- yl)quinolin-2-yl)phenyl)acetamide; 2-(2-(4-(2-(1H-pyrazol-1-yl)ethoxy)phenyl)-7-methoxyquinolin-4-yl)octahydro-4H- pyrrolo[3,4-c]pyridin-4-one; 1-(7-methoxy-2-(4-(2-(methylamino)ethoxy)phenyl)quinolin-4-yl)-N,N- dimethylpyrrolidin-3-amine; 6-(7-methoxy-2-(4-(2-(methylamino)ethoxy)phenyl)quinolin-4-yl)-2-thia-6- azaspiro[3.3]heptane 2,2-dioxide; 5-(6-fluoro-7-methoxy-2-(4-(2-(methylamino)ethoxy)phenyl)quinolin-4- yl)hexahydropyrrolo[3,4-b]pyrrol-2(1H)-one; 2-[7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-3,3a,5,6,7,7a- hexahydro-1H-pyrrolo[3,4-c]pyridin-4-one; 6-[7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-2-methyl-2,6- diazaspiro[3.4]octan-3-one; 2-[4-[7-methoxy-4-(2-methyl-2,6-diazaspiro[3.4]octan-6-yl)-2-quinolyl]phenoxy]-N- methyl-ethanamine; 2-[7-methoxy-2-(5-methoxy-2-pyridyl)-4-quinolyl]-3,3a,5,6,7,7a-hexahydro-1H- pyrrolo[3,4-c]pyridin-4-one; N-[[1-[7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]pyrrolidin-3- yl]methyl]-N-methyl-acetamide; 2-[[6-[4-(2,9-diazaspiro[4.5]decan-2-yl)-6-fluoro-7-methoxy-2-quinolyl]-3- pyridyl]oxy]-N-methyl-ethanamine; N-[1-[7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]pyrrolidin-3- yl]methanesulfonamide; Attorney Docket No.: 185992002240 1-[7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-N,3-dimethyl- pyrrolidine-3-carboxamide; 2-(7-methoxy-2-(4-(2-(methylamino)cyclopropoxy)phenyl)quinolin-4-yl)octahydro- 4H-pyrrolo[3,4-c]pyridin-4-one; 2-[7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-2,6- diazaspiro[3.4]octan-5-one; 2-[[1-[7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]pyrrolidin-3- yl]amino]etanol; 1-(7-methoxy-2-(4-(3-(methylamino)cyclobutoxy)phenyl)quinolin-4-yl)-N- methylpyrrolidine-3-carboxamide; 2-[4-[7-methoxy-4-[3-(methylaminomethyl)azetidin-1-yl]-2-quinolyl]phenoxy]-N- methyl-ethanamine; N-methyl-2-[4-[4-[3-(methylaminomethyl)azetidin-1-yl]-2- quinolyl]phenoxy]ethanamine; 1-[7-methoxy-2-(4-piperazin-1-ylphenyl)-4-quinolyl]-N-methyl-pyrrolidine-3- carboxamide; 6-[7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-3,4,4a,5,7,7a- hexahydro-1H-pyrrolo[3,4-b]pyridin-2-one; 1-[7-methoxy-2-[4-[3-(methylamino)propyl]phenyl]-4-quinolyl]-N-methyl- pyrrolidine-3-carboxamide; 1-[2-[4-[2-(dimethylamino)ethoxy]phenyl]-7-methoxy-4-quinolyl]-N-methyl- pyrrolidine-3-carboxamide; [1-[7-(dimethylamino)-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]pyrrolidin- 3-yl]methanol; 1-[7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-N-methyl- pyrrolidine-3-sulfonamide; 1-[4-[4-[3-[(dimethylamino)methyl]pyrrolidin-1-yl]-7-methoxy-2-quinolyl]phenoxy]- 3-(methylamino)propan-2-ol; 5-[7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-1,2,3a,4,6,6a- hexahydropyrrolo[3,4-c]pyrrol-3-one; N-ethyl-1-[7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]pyrrolidine- 3-carboxamide; Attorney Docket No.: 185992002240 2-[4-[7-methoxy-4-[3-morpholinopyrrolidin-1-yl]-2-quinolyl]phenoxy]-N-methyl- ethanamine; N-(2-methoxyethyl)-1-[7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4- quinolyl]pyrrolidine-3-carboxamide; N-cyclopropyl-1-[7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4- quinolyl]pyrrolidine-3-carboxamide; 1-[7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-N-methyl-azetidine- 3-carboxamide; 2-[4-[4-(2,2-dioxo-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c][1,2,5]thiadiazol-5-yl)-7- methoxy-2-quinolyl]phenoxy]-N-methyl-ethanamine; 1-[2-[4-(3,3-difluorobutoxy)phenyl]-7-methoxy-4-quinolyl]-N-methyl-pyrrolidine-3- carboxamide; 4-(hydroxymethyl)-1-[7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4- quinolyl]pyrrolidin-3-ol; 1-[7-methoxy-2-[4-(3,3,3-trifluoropropoxy)phenyl]-4-quinolyl]-N-methyl- pyrrolidine-3-carboxamide; 1-[7-methoxy-2-(4-morpholinophenyl)-4-quinolyl]-N-methyl-pyrrolidine-3- carboxamide; 1-[1-[7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]pyrrolidin-3- yl]ethanone; 1-[7-methoxy-2-[4-(2-methoxyethylamino)phenyl]-4-quinolyl]-N-methyl-pyrrolidine- 3-carboxamide; 6-[7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-1,4,4a,5,7,7a- hexahydropyrrolo[3,4-d][1,3]oxazin-2-one; 1-[7-cyclopropyl-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-N-methyl- pyrrolidine-3-carboxamide; 1-[7-(dimethylamino)-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-N-methyl- pyrrolidine-3-carboxamide; 1-[7-methoxy-2-[4-(2-methylsulfinylethoxy)phenyl]-4-quinolyl]-N-methyl- pyrrolidine-3-carboxamide; 1-[7-methoxy-2-[4-[2-methoxyethyl(methyl)amino]phenyl]-4-quinolyl]-N-methyl- pyrrolidine-3-carboxamide; Attorney Docket No.: 185992002240 1-[7-methoxy-6-methyl-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-N-methyl- pyrrolidine-3-carboxamide; 1-[6-cyclopropyl-7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-N- methyl-pyrrolidine-3-carboxamide; 1-[2-[4-[2-(cyclopropylamino)ethoxy]phenyl]-7-methoxy-4-quinolyl]-N-methyl- pyrrolidine-3-carboxamide; 1-[7-methoxy-2-[4-[2-(2-methoxyethylamino)ethoxy]phenyl]-4-quinolyl]-N-methyl- pyrrolidine-3-carboxamide; 1-[7-methoxy-2-[4-(2-morpholinoethoxy)phenyl]-4-quinolyl]-N-methyl-pyrrolidine- 3-carboxamide; N-methyl-1-[2-[4-[2-(methylamino)ethoxy]phenyl]-7-(trideuteriomethoxy)-4- quinolyl]pyrrolidine-3-carboxamide; 2-[4-[7-methoxy-4-[3-[methylsulfinyl]pyrrolidin-1-yl]-2-quinolyl]phenoxy]-N- methyl-ethanamine; 5-[6-fluoro-7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]- 1,2,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-3-one; 1-[7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-N-methyl- pyrrolidine-3-carboxamide; 1-[7-methoxy-2-[4-[2-(methylamino)ethoxy]phenyl]-4-quinolyl]-N-methyl- pyrrolidine-3-carboxamide; 2-[4-[4-(2,2-dioxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-c]pyrrol-5-yl)-7-methoxy-2- quinolyl]phenoxy]-N,N-dimethyl-ethanamine; 7-[7-methoxy-2-(4-methoxyphenyl)-4-quinolyl]-2λ6-thia-7-azaspiro[3.4]octane 2,2- dioxide; 1-[2-[4-[2-(isopropylamino)ethoxy]phenyl]-7-methoxy-4-quinolyl]-N-methyl- pyrrolidine-3-carboxamide; 1-[2-[4-[2-hydroxyethyl(methyl)amino]phenyl]-7-methoxy-4-quinolyl]-N-methyl- pyrrolidine-3-carboxamide; 1-[2-[4-[2-(isobutylamino)ethoxy]phenyl]-7-methoxy-4-quinolyl]-N-methyl- pyrrolidine-3-carboxamide; 1-[7-methoxy-2-[5-[2-(methylamino)ethoxy]-2-pyridyl]-4-quinolyl]-N-methyl- pyrrolidine-3-carboxamide; Attorney Docket No.: 185992002240 2-(7-methoxy-2-(4-(2-(methylamino)ethoxy)phenyl)quinolin-4-yl)-2,6- diazaspiro[3.5]nonan-5-one; 5-(7-methoxy-2-(4-(2-(methylamino)ethoxy)phenyl)quinolin-4-yl)hexahydro-1H- pyrrolo[3,4-c]isothiazole 2,2-dioxide; 1-(7-methoxy-2-(4-(2-(methylamino)propoxy)phenyl)quinolin-4-yl)-N- methylpyrrolidine-3-carboxamide; 4-(hydroxymethyl)-1-(7-methoxy-2-(4-(2-(methylamino)ethoxy)phenyl)quinolin-4- yl)pyrrolidin-3-ol; 2,2,2-trifluoro-1-(1-(7-methoxy-2-(4-(2-(methylamino)ethoxy)phenyl)quinolin-4- yl)pyrrolidin-3-yl)-N-methylethan-1-amine; 2,2,2-trifluoro-1-(1-(7-methoxy-2-(4-(2-(methylamino)ethoxy)phenyl)quinolin-4- yl)pyrrolidin-3-yl)-N-methylethan-1-amine; N-(2-hydroxyethyl)-1-(7-methoxy-2-(4-(2-(methylamino)ethoxy)phenyl)quinolin-4- yl)pyrrolidine-3-carboxamide; 5-(2-(4-(3-hydroxypyrrolidin-1-yl)phenyl)-7-methoxyquinolin-4-yl)hexahydro-1H- thieno[3,4-c]pyrrole 2,2-dioxide; 2-(4-(7-methoxy-4-(3-methoxypyrrolidin-1-yl)quinolin-2-yl)phenoxy)-N- (trifluoromethyl)ethan-1-amine; 7-(7-methoxy-2-(4-(2-(methylamino)ethoxy)phenyl)quinolin-4-yl)-2-thia-3,7- diazaspiro[4.4]nonane 2,2-dioxide; 1-(4-(7-methoxy-4-(3-methoxypyrrolidin-1-yl)quinolin-2-yl)phenoxy)-3- (methylamino)propan-2-ol; and 2-(4-(7-methoxy-4-(5-methyloctahydro-2H-pyrrolo[3,4-c]pyridin-2-yl)quinolin-2- yl)phenoxy)-N-methylethan-1-amine. PHARMACEUTICAL COMPOSITIONS Provided herein are pharmaceutical compositions comprising a compound of formula(I), or any variation or embodiment thereof or a stereoisomer or tautomer thereof, such as (II),(II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (IV), or (IV-A), or apharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, as described elsewhere herein. In some embodiments, provided herein is a pharmaceutical compositioncomprising (i) a compound of formula (I), or any variation or embodiment thereof, or astereoisomer or tautomer thereof, such as (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2),(III), (III-A), (IV), or (IV-A), or a pharmaceutically acceptable salt, hydrate, or solvate of Attorney Docket No.: 185992002240any of the foregoing, and (ii) one or more pharmaceutically acceptable excipients. In anothervariation, provided herein is a pharmaceutical composition comprising (i) a compound offormula (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof,such as (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (IV), or (IV-A), ora pharmaceutically acceptable salt of any of the foregoing, and (ii) one or morepharmaceutically acceptable excipients. In some embodiments, the composition comprises atherapeutically effective amount of the compound, or a stereoisomer or tautomer thereof, or apharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing. In someembodiments, the composition comprises a therapeutically effective amount of thecompound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt ofany of the foregoing. In some embodiments, provided herein are pharmaceutical compositions comprising(i) a compound of formula (I), stereoisomer or tautomer thereof, or apharmaceutically acceptable salt thereof, and (ii) one or more pharmaceutically acceptableexcipients, whereinR1 and R2 are taken together with the N to which they are attached to form a saturated 4- to 5-membered monocyclic heterocyclyl, saturated 7- to 10-membered fused heterocyclyl, orsaturated 7- to 10-membered spirocyclic heterocyclyl, whereinthe saturated 4- to 5-membered monocyclic heterocyclyl, saturated 7- to 9-memberedfused heterocyclyl, or saturated 7- to 10-membered spirocyclic heterocyclyl isoptionally substituted with one or more R3;each R3 is independently halo, C1-6alkyl, oxo, -OR12, -N(Rx)(Ry), or -C(=O)N(R13)(R14), wherein the C1-6alkyl of R3is optionally substituted with R3a;Ring A is 4- to 8-membered cycloalkenyl, 4- to 8-membered unsaturated heterocyclyl,phenyl, or 5- to 6-membered heteroaryl, wherein Attorney Docket No.: 185992002240 the 4- to 8-membered cycloalkenyl, 4- to 8-membered unsaturated heterocyclyl, phenyl, or 5- to 6-membered heteroaryl of Ring A is optionally substituted by one or more R4, and the 4- to 8-membered unsaturated heterocyclyl or 5- to 6-membered heteroaryl of Ring A comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S; each R4is independently halo, C1-6alkyl, or -OR12; L is a bond, C1-6alkyl, -O-(C1-6alkyl)-, -S-(C1-6alkyl)-, or -N(R5)(C1-6alkyl)-; R5is H, C1-6alkyl, or C3-8cycloalkyl, wherein the C1-6alkyl of R5is optionally substituted with one or more halo, -N(Rx)(Ry), or - OR12, and the C3-8cycloalkyl is optionally substituted with one or more R5b; R6is -OR12, -O-(3- to 12-membered N-containing heterocyclyl), -O-(5- to 6-membered N- containing heteroaryl), -N(Rx)(Ry), -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, - N(R13)C(=O)OR14, -OC(=O)N(R13)R14, -C(=O)(C1-6alkyl)N(Rx)(Ry), -C(=O)N(R13)(R14), - N(R13)S(=O)2R14, -S(=O)N(R13)R14, -S(=O)2N(R13)(R14), -(C3-8cycloalkyl)N(Rx)(Ry), or 3- to 8-membered N-containing heterocyclyl, wherein the -O-(3- to 8-membered N-containing heterocyclyl), -O-(5- to 6-membered N- containing heteroaryl), or 3- to 8-membered N-containing heterocyclyl of R6is optionally substituted with one or more R6b, -C(=O)R14, -C(=O)N(R13)(R14), or - C(=O)OR14, and the 3- to 8-membered N-containing heterocyclyl of R6optionally further comprises 1 or 2 atoms selected from the group consisting of N, O, and S; R7is H or halo; R8and R9are each independently H, halo, C1-6alkyl, -OR12, -N(Rx)(Ry), -N(R13)C(O)R14, - N(R13)C(O)OR14, -N(R13)C(O)N(R13)R14, -OC(O)R14, -OC(O)OR14, -OC(O)N(R13)R14, - C(O)R14, -C(O)OR14, -C(O)N(R13)(R14), C3-8cycloalkyl, or 3- to 8-membered heterocyclyl, wherein the C1-6alkyl of R8or R9is optionally substituted by one or more R7a, the 3- to 8-membered heterocyclyl of R8is optionally substituted with one or more R7b, and the 3- to 8-membered heterocyclyl of R8comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S; R10is H; each R1a, R3a, R4a, R6a, or R7ais independently -OR12or -N(Rx)(Ry); Attorney Docket No.: 185992002240each R1b, R3b, R4b, R5b, R6b, or R7b is independently halo, C1-6alkyl, -OR11, or -N(Rx)(Ry), wherein the C1-6alkyl of R1b, R3b, R4b, R5b, R6b, or R7b is optionally substituted by -OR12, -N(Rx)(Ry), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 6-membered heteroaryl; each R11is independently H or C1-6alkyl;each R12 is independently H, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, or 5- to 10-membered heteroaryl, wherein the C1-6alkyl is optionally substituted with one or more halo, deuterium, -O(C1-6alkyl), or -N(Rx)(Ry);each R13 is independently H, C1-6alkyl, or C3-8cycloalkyl;each R14 is independently H, C1-6alkyl, C2-6alkenyl, C3-8cycloalkyl, 6- to 10-membered aryl,5- to 10-membered heteroaryl, or 3- to 12-membered heterocyclyl, whereinthe C1-6alkyl of R14 is optionally substituted by one or more halo, -OH, -O(C1-6alkyl),-SH, -S(C1-6alkyl), -(C=O)NH2, -(C=O)OH, -O(C=O)C1-8alkyl), -NH(C=NH)NH2, -N(Rx)(Ry), C3-8cycloalkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, or3- to 12-membered heterocyclyl, whereinthe 6- to 10-membered aryl of R14 is optionally substituted by -OH, andthe C3-8cycloalkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, or 3- to12-membered heterocyclyl of R14 is optionally substituted with halo, C1-6alkyl, -OH,or -N(Rx)(Ry); each R15is independently H or C1-6alkyl; andeach Rx and Ry is independently H, C1-6alkyl, C3-8cycloalkyl, -C(=O)(C1-6alkyl), or -C(=O)O(C1-6alkyl), wherein the C1-6alkyl of Rx or Ry is optionally substituted with halo, 6- to 10-membered aryl,5- to 10-membered heteroaryl, -NH2, NH(C1-6alkyl), or -N(C1-6alkyl)(C1-6alkyl), andthe C1-6alkyl of -C(=O)(C1-6alkyl) or -C(=O)O(C1-6alkyl) is optionally substituted with-O(C=O)C1-8alkyl), wherein when Ring A is phenyl, then -L-R6is not -NH2 or -OCH3. Suitable pharmaceutically acceptable excipients may include, for example, fillers, diluents, sterile aqueous solutions and various organic solvents, permeation enhancers, solubilizers, and adjuvants. Various substances may be embraced by the term excipient, including without limitation any substance used as a binder, disintegrant, coating, Attorney Docket No.: 185992002240 compression / encapsulation aid, cream or lotion, lubricant, solutions for parenteral administration, materials for chewable tablets, sweetener or flavoring, suspending / gelling agent, or wet granulation agent. Examples of suitable excipients are well-known to those skilled in the art. See, e.g., Handbook of Pharmaceutical Excipients, Pharmaceutical Press (2017), which is incorporated herein by reference in its entirety. Such compositions are prepared in a manner well known in the pharmaceutical art. See, e.g., Remington’s Pharmaceutical Sciences, Academic Press, 23rded. (2020), which is incorporated herein byreference in its entirety.METHODS OF TREATMENT Traumatic brain injury (TBI) is a risk factor for ALS as demonstrated by the significantly higher incidence of disease in professional athletes and military veterans [See,e.g., Lehman et al. Neurology 79, 1970-1974 (2012); McKee et al. J. Neuropathol. Exp.Neurol. 69, 989-929 (2010); Chio et al. Brain 128, 472-476 (2005), and Sagiraju et al. Mil.Med. 185 e501-e509 (2020), each of which is incorporated herein by reference in its entirety].Cytoplasmic accumulation of TDP-43 has been shown in ~80% brains of patients withrepeated head traumas [McKee et al. J. Neuropathol. Exp. Neurol. 69, 989-929 (2010), whichis incorporated herein by reference in its entirety]. TDP-43 proteinopathy and loss-of- function has been shown to be a driver of neurodegeneration and pathology in preclinicalmodels of brain injury and ALS [Lai et al. Cell Stem Cell 31, 519-536 (2024); Dogan et al.Acta Neuropathol Commun 11, 206 (2023); and Kahriman et al. Brain 146, 5139-5152(2023), each of which is incorporated herein by reference in its entirety]. Neurofilament lightchain (NfL) and glial fibrillary acid protein (GFAP) are prognostic neurodegeneration biomarkers for both TBI [Shahim et al. Neurology 95, e610-e622 (2020); Shahim et al. SciRep 6, 36791 (2016) and Abdelhak et al. Nat Rev Neuro 18, 158-172 (2022), each of which isincorporated herein by reference in its entirety] and ALS [Lu et al. Neurology 84, 2247-2257); and Benninger et al. J Clin Neurosci 26, 75-78 (2016), each of which is incorporatedherein by reference in its entirety]. In one aspect, provided is a method for treating a disease or condition mediated byTDP-43, comprising administering to an individual in need thereof a compound of formula(I) or any variation or embodiment thereof, such as (II), (II-A), (II-B), (II-C), (II-D), (II-D-1),(II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or a stereoisomer or tautomer thereof, or apharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, or apharmaceutical composition comprising a compound of formula (I) or any variation or Attorney Docket No.: 185992002240 embodiment thereof, such as (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, and one or more pharmaceutically acceptable excipients. In some embodiments, provided is a method for treating a disease or condition mediated by TDP-43, comprising administering to an individual in need thereof a compound of formula (I) or any variation or embodiment thereof, such as (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition comprising a compound of formula (I) or any variation or embodiment thereof, such as (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients. In some embodiments, a therapeutically effective amount of a compound of formula (I) or any variation or embodiment thereof, such as (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, or a pharmaceutical composition comprising a compound of formula (I) or any variation or embodiment thereof, such as (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, and one or more pharmaceutically acceptable excipients is administered. In some embodiments, a therapeutically effective amount of a compound of formula (I) or any variation or embodiment thereof, such as (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition comprising a compound of formula (I) or any variation or embodiment thereof, such as (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients is administered. In some embodiments, the methods selectively modulate TDP-43. In some embodiments, the methods reduce TDP-43 cytoplasmic inclusions, improve nuclear TDP-43 function, or reduce neurodegeneration. In some embodiments, the methods reduce TDP-43 cytoplasmic inclusions. In some embodiments, the methods improve nuclear TDP-43 function. In some embodiments, the methods reduce neurodegeneration. In some embodiments, the methods mitigate TDP-43 cytoplasmic Attorney Docket No.: 185992002240 condensates in motor neurons. In some embodiments, the motor neurons are iPSC-derivedmotor neurons. In some embodiments, STMN2 and POLDIP3 splicing in iPSC-derivedmotor neurons is restored. In some embodiments, provided herein is a method for treating a disease or conditionmediated by TDP-43, comprising administering to an individual in need thereof a compoundof formula (I), stereoisomer or tautomer thereof, or apharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising acompound of formula (I) or a stereoisomer or tautomer thereof, or a pharmaceuticallyacceptable salt thereof, whereinR1 and R2 are taken together with the N to which they are attached to form a saturated 4- to 5-membered monocyclic heterocyclyl, saturated 7- to 10-membered fused heterocyclyl, orsaturated 7- to 10-membered spirocyclic heterocyclyl, whereinthe saturated 4- to 5-membered monocyclic heterocyclyl, saturated 7- to 9-memberedfused heterocyclyl, or saturated 7- to 10-membered spirocyclic heterocyclyl isoptionally substituted with one or more R3;each R3 is independently halo, C1-6alkyl, oxo, -OR12, -N(Rx)(Ry), or -C(=O)N(R13)(R14), wherein the C1-6alkyl of R3is optionally substituted with R3a;Ring A is 4- to 8-membered cycloalkenyl, 4- to 8-membered unsaturated heterocyclyl,phenyl, or 5- to 6-membered heteroaryl, whereinthe 4- to 8-membered cycloalkenyl, 4- to 8-membered unsaturated heterocyclyl,phenyl, or 5- to 6-membered heteroaryl of Ring A is optionally substituted by one ormore R4, and the 4- to 8-membered unsaturated heterocyclyl or 5- to 6-membered heteroaryl ofRing A comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S;each R4 is independently halo, C1-6alkyl, or -OR12; L is a bond, C1-6alkyl, -O-(C1-6alkyl)-, -S-(C1-6alkyl)-, or -N(R5)(C1-6alkyl)-; Attorney Docket No.: 185992002240 R5is H, C1-6alkyl, or C3-8cycloalkyl, wherein the C1-6alkyl of R5is optionally substituted with one or more halo, -N(Rx)(Ry), or - OR12, and the C3-8cycloalkyl is optionally substituted with one or more R5b; R6is -OR12, -O-(3- to 12-membered N-containing heterocyclyl), -O-(5- to 6-membered N- containing heteroaryl), -N(Rx)(Ry), -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, - N(R13)C(=O)OR14, -OC(=O)N(R13)R14, -C(=O)(C1-6alkyl)N(Rx)(Ry), -C(=O)N(R13)(R14), - N(R13)S(=O)2R14, -S(=O)N(R13)R14, -S(=O)2N(R13)(R14), -(C3-8cycloalkyl)N(Rx)(Ry), or 3- to 8-membered N-containing heterocyclyl, wherein the -O-(3- to 8-membered N-containing heterocyclyl), -O-(5- to 6-membered N- containing heteroaryl), or 3- to 8-membered N-containing heterocyclyl of R6is optionally substituted with one or more R6b, -C(=O)R14, -C(=O)N(R13)(R14), or - C(=O)OR14, and the 3- to 8-membered N-containing heterocyclyl of R6optionally further comprises 1 or 2 atoms selected from the group consisting of N, O, and S; R7is H or halo; R8and R9are each independently H, halo, C1-6alkyl, -OR12, -N(Rx)(Ry), -N(R13)C(O)R14, - N(R13)C(O)OR14, -N(R13)C(O)N(R13)R14, -OC(O)R14, -OC(O)OR14, -OC(O)N(R13)R14, - C(O)R14, -C(O)OR14, -C(O)N(R13)(R14), C3-8cycloalkyl, or 3- to 8-membered heterocyclyl, wherein the C1-6alkyl of R8or R9is optionally substituted by one or more R7a, the 3- to 8-membered heterocyclyl of R8is optionally substituted with one or more R7b, and the 3- to 8-membered heterocyclyl of R8comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S; R10is H; each R1a, R3a, R4a, R6a, or R7ais independently -OR12or -N(Rx)(Ry); each R1b, R3b, R4b, R5b, R6b, or R7bis independently halo, C1-6alkyl, -OR11, or -N(Rx)(Ry), wherein the C1-6alkyl of R1b, R3b, R4b, R5b, R6b, or R7bis optionally substituted by -OR12, - N(Rx)(Ry), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 6- membered heteroaryl; each R11is independently H or C1-6alkyl; Attorney Docket No.: 185992002240each R12 is independently H, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, or 5- to 10-membered heteroaryl, wherein the C1-6alkyl is optionally substituted with one or more halo, deuterium, -O(C1-6alkyl), or -N(Rx)(Ry);each R13 is independently H, C1-6alkyl, or C3-8cycloalkyl;each R14 is independently H, C1-6alkyl, C2-6alkenyl, C3-8cycloalkyl, 6- to 10-membered aryl,5- to 10-membered heteroaryl, or 3- to 12-membered heterocyclyl, whereinthe C1-6alkyl of R14 is optionally substituted by one or more halo, -OH, -O(C1-6alkyl),-SH, -S(C1-6alkyl), -(C=O)NH2, -(C=O)OH, -O(C=O)C1-8alkyl), -NH(C=NH)NH2, -N(Rx)(Ry), C3-8cycloalkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, or3- to 12-membered heterocyclyl, whereinthe 6- to 10-membered aryl of R14 is optionally substituted by -OH, andthe C3-8cycloalkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, or 3- to12-membered heterocyclyl of R14 is optionally substituted with halo, C1-6alkyl, -OH,or -N(Rx)(Ry); each R15is independently H or C1-6alkyl; andeach Rx and Ry is independently H, C1-6alkyl, C3-8cycloalkyl, -C(=O)(C1-6alkyl), or -C(=O)O(C1-6alkyl), wherein the C1-6alkyl of Rx or Ry is optionally substituted with halo, 6- to 10-membered aryl,5- to 10-membered heteroaryl, -NH2, NH(C1-6alkyl), or -N(C1-6alkyl)(C1-6alkyl), andthe C1-6alkyl of -C(=O)(C1-6alkyl) or -C(=O)O(C1-6alkyl) is optionally substituted with-O(C=O)C1-8alkyl), wherein when Ring A is phenyl, then -L-R6is not -NH2 or -OCH3. In some embodiments, the disease or condition is a neurological disease or condition. In some embodiments, the disease or condition is selected from the group consisting of Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, traumatic brain injury (TBI), chronic traumatic encephalopathy (CTE), frontotemporal dementia (FTD), inclusion bodymyositis, Perry syndrome, corticobasal degeneration, spinocerebellar ataxia type 3, andamyotrophic lateral sclerosis (ALS). In some embodiments, the disease or condition is traumatic brain injury (TBI).In some embodiments, the disease or condition is frontotemporal dementia (FTD).In some embodiments, the disease or condition is amyotrophic lateral sclerosis (ALS).In some variations, the amyotrophic lateral sclerosis is sporadic amyotrophic lateral sclerosisor C9ORF72 amyotrophic lateral sclerosis. Attorney Docket No.: 185992002240 In some embodiments, the individual is a human.In one aspect, provided herein is a method of reducing neurodegeneration, comprisingadministering to an individual in need thereof a compound of formula (I) or any variation orembodiment thereof, such as (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A),(III-B), (IV), or (IV-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, or a pharmaceutical compositioncomprising a compound of formula (I) or any variation or embodiment thereof, such as (II),(II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or astereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate ofany of the foregoing, and one or more pharmaceutically acceptable excipients. In someembodiments, provided herein is a method of reducing neurodegeneration, comprisingadministering to an individual in need thereof a compound of formula (I) or any variation orembodiment thereof, such as (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A),(III-B), (IV), or (IV-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition comprising acompound of formula (I) or any variation or embodiment thereof, such as (II), (II-A), (II-B),(II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or a stereoisomer ortautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one ormore pharmaceutically acceptable excipients. In some embodiments, the individual has aneurological disease or condition. In some embodiments, the individual has a disease or condition selected from the group consisting of Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, traumatic brain injury (TBI), chronic traumatic encephalopathy (CTE), frontotemporal dementia (FTD), inclusion body myositis, Perry syndrome, corticobasal degeneration, spinocerebellar ataxia type 3, and amyotrophic lateral sclerosis (ALS). In some embodiments, the individual has frontotemporal dementia (FTD). In some embodiments, theindividual has a traumatic brain injury or ALS. In some embodiments, the individual has atraumatic brain injury. In some embodiments, the individual has ALS. In some variations, theamyotrophic lateral sclerosis is sporadic amyotrophic lateral sclerosis or C9ORF72amyotrophic lateral sclerosis. In one aspect, provided herein is a method of reducing neurodegeneration fromtraumatic brain injury, comprising administering to an individual in need thereof a compoundof formula (I) or any variation or embodiment thereof, such as (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or a stereoisomer or tautomerthereof, or a pharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, or a Attorney Docket No.: 185992002240pharmaceutical composition comprising a compound of formula (I) or any variation orembodiment thereof, such as (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A),(III-B), (IV), or (IV-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, and one or more pharmaceuticallyacceptable excipients. In some embodiments, provided herein is a method of reducingneurodegeneration from traumatic brain injury, comprising administering to an individual inneed thereof a compound of formula (I) or any variation or embodiment thereof, such as (II),(II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or astereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of theforegoing, or a pharmaceutical composition comprising a compound of formula (I) or anyvariation or embodiment thereof, such as (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients. In one aspect, provided herein is a method of modulating TDP-43, comprisingcontacting a cell with an effective amount of a compound of formula (I) or any variation orembodiment thereof, such as (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A),(III-B), (IV), or (IV-A), or a stereoisomer or tautomer thereof, or a pharmaceuticallyacceptable salt, hydrate, or solvate of any of the foregoing, or a pharmaceutical compositioncomprising a compound of formula (I) or any variation or embodiment thereof, such as (II),(II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or astereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate ofany of the foregoing, and one or more pharmaceutically acceptable excipients. In someembodiments, provided herein is a method of modulating TDP-43, comprising contacting acell with an effective amount of a compound of formula (I) or any variation or embodimentthereof, such as (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B),(IV), or (IV-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition comprising a compound of formula(I) or any variation or embodiment thereof, such as (II), (II-A), (II-B), (II-C), (II-D), (II-D-1),(II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or a stereoisomer or tautomer thereof, or apharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceuticallyacceptable excipients. In some embodiments, modulating TDP-43 comprises modulatingTDP-43 incorporation into condensates, modulating TDP-43 binding to RNA in condensates,modulating TDP-43 aggregation, or modulating TDP43 protein-protein interactions. In some Attorney Docket No.: 185992002240embodiments, modulating TDP-43 comprises modulating TDP-43 incorporation intocondensates. In some embodiments, modulating TDP-43 comprises modulating TDP-43binding to RNA in condensates. In some embodiments, modulating TDP-43 comprisesmodulating TDP-43 aggregation. In some embodiments, modulating TDP-43 comprisesmodulating TDP43 protein-protein interactions. In some embodiments, modulating TDP-43comprises mitigating TDP-43 interaction to RNA condensates, mitigating TDP-43aggregation, or mitigating TDP-43 protein-protein interactions. In some embodiments,modulating TDP-43 comprises mitigating TDP-43 interaction to RNA condensates. In some embodiments, modulating TDP-43 comprises mitigating TDP-43 aggregation. In some embodiments, modulating TDP-43 comprises mitigating TDP-43 protein-protein interactions. In one aspect, provided herein is a method of directly modulating TDP-43, comprisingcontacting a cell with an effective amount of a compound of formula (I) or any variation orembodiment thereof, such as (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A),(III-B), (IV), or (IV-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, or a pharmaceutical compositioncomprising a compound of formula (I) or any variation or embodiment thereof, such as (II),(II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or astereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate ofany of the foregoing, and one or more pharmaceutically acceptable excipients. In someembodiments, provided herein is a method of directly modulating TDP-43, comprisingcontacting a cell with an effective amount of a compound of formula (I) or any variation orembodiment thereof, such as (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A),(III-B), (IV), or (IV-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition comprising acompound of formula (I) or any variation or embodiment thereof, such as (II), (II-A), (II-B),(II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or a stereoisomer ortautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one ormore pharmaceutically acceptable excipients. In some embodiments, the methods selectivelymodulate TDP-43. In some embodiments, the methods reduce TDP-43 cytoplasmic inclusions, improve nuclear TDP-43 function, or reduce neurodegeneration. In someembodiments, the methods reduce TDP-43 cytoplasmic inclusions. In some embodiments,the methods improve nuclear TDP-43 function. In some embodiments, the methods reduce neurodegeneration. In some embodiments, the methods mitigate TDP-43 cytoplasmic condensates in motor neurons. In some embodiments, the motor neurons are iPSC-derived Attorney Docket No.: 185992002240motor neurons. In some embodiments, STMN2 and POLDIP3 splicing in iPSC-derivedmotor neurons is restored. In one aspect, provided herein is a method of modulating TDP-43 driven geneexpression levels, comprising contacting a cell with an effective amount of a compound offormula (I) or any variation or embodiment thereof, such as (II), (II-A), (II-B), (II-C), (II-D),(II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or a stereoisomer or tautomerthereof, or a pharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, or apharmaceutical composition comprising a compound of formula (I) or any variation orembodiment thereof, such as (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A),(III-B), (IV), or (IV-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, and one or more pharmaceuticallyacceptable excipients. In some embodiments, provided herein is a method of modulatingTDP-43 driven gene expression levels, comprising contacting a cell with an effective amountof a compound of formula (I) or any variation or embodiment thereof, such as (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or a stereoisomeror tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or apharmaceutical composition comprising a compound of formula (I) or any variation orembodiment thereof, such as (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A),(III-B), (IV), or (IV-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptableexcipients. In some embodiments, the gene expression levels are for STMN2 or POLDIP3. Insome embodiments, the gene expression levels are for STMN2. In some embodiments, thegene expression levels are for POLDIP3. In some embodiments, the methods selectivelymodulate TDP-43. In some embodiments, the methods reduce TDP-43 cytoplasmic inclusions, improve nuclear TDP-43 function, or reduce neurodegeneration. In some embodiments, the methods reduce TDP-43 cytoplasmic inclusions. In some embodiments, the methods improve nuclear TDP-43 function. In some embodiments, the methods reduce neurodegeneration. In some embodiments, the methods mitigate TDP-43 cytoplasmic condensates in motor neurons. In some embodiments, the motor neurons are iPSC-derivedmotor neurons. In some embodiments, STMN2 and POLDIP3 splicing in iPSC-derivedmotor neurons is restored. In one aspect, provided herein is a compound of formula (I), or any variation orembodiment thereof, such as (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A),(III-B), (IV), or (IV-A), or a stereoisomer or tautomer thereof, or a pharmaceutically Attorney Docket No.: 185992002240acceptable salt, hydrate, or solvate of any of the foregoing, or a pharmaceutical compositioncomprising a compound of formula (I), or any variation or embodiment thereof, such as (II),(II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or astereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate ofany of the foregoing, and one or more pharmaceutically acceptable excipients, for use in thetreatment of a disease or condition mediated by TDP-43. In some embodiments, providedherein is a compound of formula (I), or any variation or embodiment thereof, such as (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or astereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of theforegoing, or a pharmaceutical composition comprising a compound of formula (I), or anyvariation or embodiment thereof, such as (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients, for use in the treatment of a disease or condition mediated by TDP-43. In one aspect, provided herein is the use of a compound of formula (I) or anyvariation or embodiment thereof, such as (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or a stereoisomer or tautomer thereof, or apharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, or apharmaceutical composition comprising a compound of formula (I) or any variation orembodiment thereof, such as (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A),(III-B), (IV), or (IV-A), or a stereoisomer or tautomer thereof, or a pharmaceuticallyacceptable salt, hydrate, or solvate of any of the foregoing, and one or more pharmaceuticallyacceptable excipients, in the manufacture a medicament for the treatment of a disease orcondition mediated by TDP-43. In some embodiments, provided herein is the use of acompound of formula (I) or any variation or embodiment thereof, such as (II), (II-A), (II-B),(II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or a stereoisomer ortautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or apharmaceutical composition comprising a compound of formula (I) or any variation orembodiment thereof, such as (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A),(III-B), (IV), or (IV-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients, in the manufacture a medicament for the treatment of a disease or condition mediated by TDP-43. Attorney Docket No.: 185992002240 KITS The present disclosure further provides kits for carrying out the methods disclosedherein. The kits may comprise a compound, or stereoisomer or tautomer thereof, orpharmaceutically acceptable salt, hydrate, or solvate thereof as described herein and suitablepackaging. The kits may comprise one or more containers comprising any compounddescribed herein. In one aspect, a kit includes a compound of the disclosure or stereoisomeror tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and alabel and / or instructions for use of the compound in the treatment of a disease or disorderdescribed herein. The kits may comprise a unit dosage form of the compound. In someembodiments, the kits may comprise a compound, or stereoisomer or tautomer thereof, orpharmaceutically acceptable salt thereof. Provided herein are kits, comprising (i) an effective amount of a compound offormula (I) or any variation or embodiment thereof, such as (II), (II-A), (II-B), (II-C), (II-D),(II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or a stereoisomer or tautomerthereof, or a pharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, and(ii) instructions for use in treating a TDP-43 mediated disease, disorder, or condition in anindividual in need thereof. In some embodiments, the kits comprise (i) a compound offormula (I) or any variation or embodiment thereof, such as (II), (II-A), (II-B), (II-C), (II-D),(II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or a stereoisomer or tautomerthereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) instructions foruse in treating a TDP-43 mediated disease, disorder, or condition in an individual in needthereof. In some embodiments, the kits comprise (i) an effective amount of a compound offormula (I) or any variation or embodiment thereof, such as (II), (II-A), (II-B), (II-C), (II-D),(II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or a stereoisomer or tautomerthereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) instructions foruse in treating a TDP-43 mediated disease, disorder, or condition in an individual in needthereof. Also provided herein are kits, comprising (i) a pharmaceutical compositioncomprising an effective amount of a compound of formula (I) or any variation or embodimentthereof, such as (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B),(IV), or (IV-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt,hydrate, or solvate of any of the foregoing, and one or more pharmaceutically acceptableexcipients; and (ii) instructions for use in treating a TDP-43 mediated disease, disorder, orcondition in an individual in need thereof. In some embodiments, the kits comprise (i) a Attorney Docket No.: 185992002240pharmaceutical composition comprising an effective amount of a compound of formula (I) orany variation or embodiment thereof, such as (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or a stereoisomer or tautomer thereof, or apharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceuticallyacceptable excipients; and (ii) instructions for use in treating a TDP-43 mediated disease,disorder, or condition in an individual in need thereof. In some embodiments, the individual is a human. Articles of manufacture are also provided, wherein the article of manufacturecomprises a compound of formula (I) or any variation or embodiment thereof, such as (II),(II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or astereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate ofany of the foregoing, in a suitable container. In some embodiments, the article of manufacturecomprises a compound of formula (I) or any variation or embodiment thereof, such as (II),(II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or astereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of theforegoing, in a suitable container. Also provided herein are articles of manufacture,comprising a pharmaceutical composition comprising a compound of formula (I) or anyvariation or embodiment thereof, such as (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or a stereoisomer or tautomer thereof, or apharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, in a suitablecontainer. In some embodiments, the articles of manufacture comprise a pharmaceuticalcomposition comprising a compound of formula (I) or any variation or embodiment thereof,such as (II), (II-A), (II-B), (II-C), (II-D), (II-D-1), (II-D-2), (III), (III-A), (III-B), (IV), or (IV-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, in a suitable container. The container may be a vial, jar, ampoule, preloaded syringe, or intravenous bag. METHODS OF PREPARING The present disclosure further provides processes for preparing the compounds of present invention. In some aspects, provided herein are processes of preparing a compound offormula (I), or any variation or embodiment thereof or a stereoisomer or tautomer thereof, ora pharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing. In someembodiments, provided herein are processes of preparing a compound of formula (I), or anyvariation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically Attorney Docket No.: 185992002240 acceptable salt of any of the foregoing. In some embodiments, provided herein are processesof preparing a compound of formula (I), or any variation or embodiment thereof, or astereoisomer or tautomer thereof. The following synthetic reaction schemes, which are detailed in the Schemes and Examples, are merely illustrative of some of the methods by which the compounds of the present disclosure, or an embodiment or aspect thereof, can be synthesized. Various modifications to these synthetic reaction schemes can be made, as will be apparent to those of ordinary skill in the art. As depicted in the Schemes and Examples below, in certain exemplary embodiments, compounds of formula (I), or any variation or embodiment thereof, as described elsewhere herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate,or solvate of any of the foregoing, are prepared according to the general procedures. Thegeneral methods below, and other methods known to synthetic chemists of ordinary skill in the art, can be applied to all formulae, embodiments, and species described herein. The starting materials and the intermediates of the synthetic reaction schemes can be isolated and purified if desired using conventional techniques, including, but not limited to, filtration, distillation, crystallization, chromatography, and the like. Such materials can be characterized using conventional means, including physical constants and spectral data. Although certain exemplary embodiments are depicted and described herein, the compounds of the present disclosure, or any variation or embodiment thereof, may be prepared using appropriate starting materials according to the methods described generally herein and / or by methods available to one of ordinary skill in the art. All the products generated from the following reactions can be isolated and purified employing standard techniques, such as extraction, prep-TLC, ion exchange chromatography, chromatography on silica gel, prep-HPLC. Specific purification steps and methods were set up and will be referred to in the text as follows. Compounds may be prepared by methods known in the art of organic chemistry as set forth in part by the following synthesis schemes. In all the schemes described below, it is well understood that protecting groups for sensitive or reactive groups are employed where necessary in accordance with general principles of chemistry. Protecting groups are manipulated according to standard methods of organic synthesis (T. W. Green and P.G.M. Wuts (1991) Protecting Groups in Organic Synthesis, John Wiley et Sons, hereby incorporated by reference in its entirety). These groups are removed at a convenient stage of the compound synthesis using methods that are readily apparent to those skilled in the art. Attorney Docket No.: 185992002240 The compound may be represented as a mixture of enantiomers, which may be resolved intothe individual pure R- or S-enantiomers.Commercial nitrobenzene and aniline were used as starting material A.1 (Schemes 1,2, 3 and 4) for the synthesis of 6,7-disubstituted 2,4-dichloroquinoline A.4. Commercialmaterials were used as such for cyclization step (step 3) to form the quinolines A.4 orunderwent two former steps: a first step to further substitute compound A.1 in position 3 byreductive amination, aromatic nucleophilic substitution, or methylation to get A.2, and a second step for the reduction of nitro-groups or deacylation of methylamide to get the freeaniline A.3. The derivative 2,4-dichloroquinoline A.4 was then formed by cyclization of A.3with malonic acid in phosphoryl chloride. The 2,4-dichloroquinoline A.4 underwent a Suzuki cross coupling with commerciallyavailable or synthesized boronic ester reagents (Scheme 1). Quinolines A.4 were selectivelysubstituted in position 2 to give compounds A.5. The substitution of position 4 of compoundA.5 was realized by Buchwald cross coupling or by aromatic nucleophilic substitution withcommercial or synthesized amines and allowed the formation of FP (Final Product).SCHEME 1. Similarly to Scheme 1, other FP were synthesized applying first the Buchwaldcoupling or the nucleophilic aromatic substitution of position 4 of quinolines A.4 to givederivatives B.1 (Scheme 2). This step was then followed by a Suzuki coupling to give FP. Attorney Docket No.: 185992002240 SCHEME 2. In some cases, the substituted (hetero)aromatic ring added during the Suzuki couplingon quinolines A.4 contains a PG (Protecting Group, Schemes 3 and 4). In these cases, FPwere obtained after an additional step of deprotection. Scheme 3 describes the synthetic sequence similar to Scheme 1, with a Suzuki cross coupling realized first on quinolines A.4,followed by the substitution of quinolines C.1 using a Buchwald reaction or a nucleophilicaromatic substitution to give compounds C2. Compound C.2 underwent then a deprotectionstep to give FP. SCHEME 3. Scheme 4 describes a synthetic sequence similar to Scheme 2, where derivative B.1 isobtained after a Buchwald or aromatic nucleophilic substitution realized on quinolines A.4and followed by a Suzuki cross coupling, and coupling FP are obtained by deprotection ofcompounds C.2. SCHEME 4. Attorney Docket No.: 185992002240 Scheme 5 describes a synthetic sequence where A.5 was obtained following Scheme 1and where the Buchwald coupling reaction is done with an opened or cyclized amine linkedto a PG. to get D.1 intermediates. FP is obtained after an additional step of deprotection.SCHEME 5. Scheme 6 describes a synthetic sequence where an opened or cyclized amine used for the Buchwald coupling or aromatic substitution on C.1, obtained from Scheme 3, held aprotecting group PG’ to get compound E.1. Compound E.1 is then fully deprotected to giveFP. SCHEME 6. Enumerated Embodiments Enumerated Embodiment 1. A compound of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, orsolvate of any of the foregoing, wherein:R1and R2are each independently C1-6alkyl, C2-6alkenyl, -C(=O)R14, -C(=O)OR14, - C(=O)N(R13)(R14), -S(=O)2R14, -S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 12-memberedheterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl wherein Attorney Docket No.: 185992002240 the C1-6alkyl of R1or R2is optionally substituted with one or more R1a, the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of R1or R2is optionally substituted with one or more R1b, and optionally, two substituents of the C1-6alkyl, C2-6alkenyl, -C(=O)R14, -C(=O)OR14, - C(=O)N(R13)(R14), -S(=O)2R14, -S(=O)2N(R13)(R14), or C3-8cycloalkyl group of R1or R2are taken together with the atoms to which they are attached to form a C3- 8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10- membered heteroaryl, wherein the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R1b; or R1and R2are taken together with the N to which they are attached to form a 3- to 12- membered heterocyclyl or 5- to 10-membered heteroaryl, wherein the 3- to 12-membered heterocyclyl or 5- to 10-membered heteroaryl of R1and R2is optionally substituted with one or more R3; each R3is independently halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, oxo, -OR12, -SR12, -SF5, - N(Rx)(Ry), -NO2, -CN, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, - OC(=O)R14, -OC(=O)N(R13)R14, -OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), - C(=O)OR14, -C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, - N(R13)S(=O)2R14, -S(=O)R14, -S(=O)N(R13)R14, -S(=O)OR14, -S(=NR15)R14, - S(=NR15)N(R13)R14, -S(=NR15)OR14, -S(=O)2R14, -S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C1-6alkyl of R3is optionally substituted with one or more R3a, and optionally, two substituents of R3are taken together with the atoms to which they are attached form a C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10- membered aryl, or 5- to 10-membered heteroaryl is optionally substituted one or more R3b; Ring A is 4- to 12-membered cycloalkenyl, 4- to 12-membered unsaturated heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein Attorney Docket No.: 185992002240 the 4- to 12-membered cycloalkenyl, 4- to 12-membered unsaturated heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of Ring A is optionally substituted by one or more R4, and the 4- to 12-membered unsaturated heterocyclyl or 5- to 10-membered heteroaryl of Ring A comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S; each R4is independently halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, -OR12, -SR12, -SF5, - N(Rx)(Ry), -NO2, -CN, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, - OC(=O)R14, -OC(=O)N(R13)R14, -OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), - C(=O)OR14, -C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, - N(R13)S(=O)2R14, -S(=O)R14, -S(=O)N(R13)R14, -S(=O)OR14, -S(=NR15)R14, - S(=NR15)N(R13)R14, -S(=NR15)OR14, -S(=O)2R14, -S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C1-6alkyl of R4is optionally substituted by one or more R4a, the C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of R4is optionally substituted with one or more R4b, and the 3- to 8-membered heterocyclyl of R4comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S; L is a bond, C1-6alkyl, -O-(C1-6alkyl)-, -S-(C1-6alkyl)-, or -N(R5)(C1-6alkyl)-, wherein the C1-6alkyl, -O-(C1-6alkyl)-, -S-(C1-6alkyl)-, or -N(R5)(C1-6alkyl)- is optionally substituted by one or more RL; each RLis independently halo, -N(Rx)(Ry), -OR12, -SR12, -SF5, -NO2, -CN, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, -OC(=O)R14, -OC(=O)N(R13)R14, - OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), -C(=O)OR14, C3-8cycloalkyl, 3- to 8- membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, or two RLare taken together along with the atoms to which they are attached to form a C3-8cycloalkyl or 3- to 8-membered heterocyclyl; R5is H, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, -C(=O)R14, -S(=O)2R14, -S(=O)2N(R13)(R14), or C3-8cycloalkyl, wherein the C1-6alkyl of R5is optionally substituted with one or more halo, -N(Rx)(Ry), -OR12, -SR12, -SF5, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, - OC(=O)R14, -OC(=O)N(R13)R14, -OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), - C(=O)OR14, -C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, - N(R13)S(=O)2R14, -S(=O)R14, -S(=O)N(R13)R14, -S(=O)OR14, -S(=NR15)R14, - S(=NR15)N(R13)R14, -S(=NR15)OR14, -S(=O)2R14, or -S(=O)2N(R13)(R14), and Attorney Docket No.: 185992002240 the C3-8cycloalkyl is optionally substituted with one or more R5b; R6is H, halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, -OR12, -SR12, -SF5, -N(Rx)(Ry), -NO2, -CN, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, -OC(=O)R14, - OC(=O)N(R13)R14, -OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), -C(=O)OR14, - C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, -N(R13)S(=O)2R14, - S(=O)R14, -S(=O)N(R13)R14, -S(=O)OR14, -S(=NR15)R14, -S(=NR15)N(R13)R14, - S(=NR15)OR14, -S(=O)2R14, -S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C1-6alkyl of R6is optionally substituted by one or more R6a, the C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of R6is optionally substituted with one or more R6b, - C(=O)R14, -C(=O)N(R13)(R14), or -C(=O)OR14, and the 3- to 8-membered heterocyclyl of R6comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S, and optionally, two substituents of R6are taken together with the atoms to which they are attached form a C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R6b; R7, R8, R9, and R10are each independently H, halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, - OR11, -OR12, -SR12, -SF5, -N(Rx)(Ry), -NO2, -CN, -N(R13)C(=O)R14, - N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, -OC(=O)R14, -OC(=O)N(R13)R14, - OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), -C(=O)OR14, -C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, -N(R13)S(=O)2R14, -S(=O)R14, -S(=O)N(R13)R14, - S(=O)OR14, -S(=NR15)R14, -S(=NR15)N(R13)R14, -S(=NR15)OR14, -S(=O)2R14, - S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C1-6alkyl of R7, R8, R9, or R10is optionally substituted by one or more R7a, the 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of R7, R8, R9, or R10is optionally substituted with one or more R7b, and the 3- to 8-membered heterocyclyl of R7, R8, R9, or R10comprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S, and Attorney Docket No.: 185992002240 optionally, two substituents of R7, R8, R9, or R10are taken together with the atoms to which they are attached form a C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R7b; each R1a, R3a, R4a, R6a, or R7ais independently halo, -N(Rx)(Ry), -OR12, -SR12, -SF5, -NO2, - CN, -N(R13)C(=O)R14, -N(R13)C(=O)N(R13)R14, -N(R13)C(=O)OR14, -OC(=O)R14, - OC(=O)N(R13)R14, -OC(=O)OR14, -C(=O)R14, -C(=O)N(R13)(R14), -C(=O)OR14, - C(=NR15)R14, -C(=NOR14)R14, -C(=NR15)N(R13)R14, -C(=NR15)OR14, -N(R13)S(=O)2R14, - S(=O)R14, -S(=O)2R14, -S(=O)N(R13)R14, -S(=O)OR14, -S(=NR15)R14, -S(=NR15)N(R13)R14, - S(=NR15)OR14, -S(=O)2N(R13)(R14), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10- membered aryl, or 5- to 10-membered heteroaryl, wherein the C3-8cycloalkyl, 3- to 12-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl of R1a, R3a, R4a, R6a, or R7ais optionally substituted with one or more R1b, and the 3- to 12-membered heterocyclyl of R1a, R3a, R4a, R6a, or R7acomprises 1, 2, or 3 atoms selected from the group consisting of N, O, and S; each R1b, R3b, R4b, R5b, R6b, or R7bis independently halo, C1-6alkyl, -OR11, -N(Rx)(Ry), oxo, - CN, C3-8cycloalkyl, or 3- to 8-membered heterocyclyl, wherein the C1-6alkyl of R1b, R3b, R4b, R5b, R6b, or R7bis optionally substituted by -OR12, - N(Rx)(Ry), C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl; each R11is independently H, C1-6alkyl, C2-6alkenyl, C3-8cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl, wherein the C1-6alkyl of R11is optionally substituted with 6- to 10-membered aryl, or 5- to 10- membered heteroaryl, wherein the 6- to 10-membered aryl, or 5- to 10-membered heteroaryl is optionally substituted with halo, C1-3alkyl, C1-3alkoxy, or -N(Rx)(Ry), and the 6- to 10-membered aryl, or 5- to 10-membere...

Claims

1. Compound of formula (I) (I), or its stereoisomer or tautomer, or a pharmaceutically acceptable salt of any of the above compounds, where R 1 and R 2 taken together with the N to which they are attached to form a saturated 4-5-membered monocyclic heterocyclyl, a saturated 7-10-membered fused heterocyclyl, or a saturated 7-10-membered spirocyclic heterocyclyl, where saturated 4- to 5-membered monocyclic heterocyclyl, saturated 7- to 9-membered fused heterocyclyl, or saturated 7- to 10-membered spirocyclic heterocyclyl optionally substituted with one or more R 3 ; each R 3 independently represents a halogen, C 1-6 alkyl, oxo, -OR 12 , -N(R x )(R y ), -CN or -C(=O)N(R 13 )(R 14 ), Where C 1-6 alkyl from R 3 optionally substituted by R 3a ; ring A is a 4-8-membered cycloalkenyl, 4-8-membered unsaturated heterocyclyl, phenyl, or 5-6-membered heteroaryl, where 4-8-membered cycloalkenyl, 4-8-membered unsaturated heterocyclyl, phenyl or 5-6-membered heteroaryl of ring A is optionally substituted with one or more R 4 , And 4-8-membered unsaturated heterocyclyl or 5-6-membered heteroaryl ring A contains 1, 2 or 3 atoms selected from the group consisting of N, O and S; each R 4 independently represents a halogen, C 1-6 alkyl or -OR 12 ; L represents a bond, C 1-6 alkyl, -O-(C 1-6 alkyl)-, -S-(C 1-6 alkyl)- or -N(R 5 )(C 1-6 alkyl)-; R 5 represents H, C 1-6 alkyl or C 3-8 cycloalkyl, where C 1-6 alkyl from R 5 optionally substituted with one or more halogen groups, -N(R x )(R y ) or -OR12 , And C 3-8 cycloalkyl optionally substituted with one or more R 5b ; R 6 represents -OR 12 , -O-(3-12-membered N-containing heterocyclyl), -O-(5-6-membered N-containing heterocyclyl), -N(R x )(R y ), -N(R 13 )C(=O)R 14 , -N(R 13 )C(=O)N(R 13 )R 14 , -N(R 13 )C(=O)OR 14 , -OC(=O)N(R 13 )R 14 , -C(=O)(C 1-6 alkyl)N(R x )(R y ), -C(=O)N(R 13 )(R 14 ), -N(R 13 )S(=O)2R 14 , -S(=O)N(R 13 )R 14 , -S(=O)2N(R 13 )(R 14 ), -(C 3-8 cycloalkyl)N(R x )(R y ) or 3-8-membered N-containing heterocyclyl, where -O-(3-8-membered N-containing heterocyclyl), -O-(5-6-membered N-containing heterocyclyl) or 3-8-membered N-containing heterocyclyl from R 6 optionally substituted by one or more R6b , -C(=O)R 14 , -C(=O)N(R 13 )(R 14 ) or -C(=O)OR 14 , And 3-8-membered N-containing heterocyclyl from R 6 optionally further contains 1 or 2 atoms selected from the group consisting of N, O and S; R 7 represents H or halogen; each R 8 and R 9 independently represents H, halogen, C 1-6 alkyl, -OR 12 , -N(R x )(R y ), -N(R 13 )C(=O)R 14 , -N(R 13 )C(=O)OR 14 , -N(R 13 )C(=O)N(R 13 )R 14 , -OC(=O)R 14 , -OC(=O)OR 14 , -OC(=O)N(R 13 )R 14 , -C(=O)R 14 , -C(=O)OR 14 , -C(=O)N(R 13 )(R 14 ), C 3-8 cycloalkyl or 3-8-membered heterocyclyl, where C 1-6 alkyl from R 8 or R 9 optionally substituted by one or more R 7a , 3-8-membered heterocyclyl from R 8 optionally substituted by one or more R 7b , And 3-8-membered heterocyclyl from R 8 contains 1, 2 or 3 atoms selected from the group consisting of N, O and S; R 10 represents H; each R 1a , R 3a , R 4a , R 6a or R 7a independently represents -OR 12 , -N(R x )(R y ), -C(=O)N(R 13 )(R 14 ) or 3-8-membered heterocyclyl; each R 1b , R 3b , R 4b , R 5b , R 6b or R 7b independently represents halogen, C1-6 alkyl, -OR 11 or -N(R x )(R y ), Where C 1-6 alkyl from R 1b , R 3b , R 4b , R 5b , R 6b or R 7b optionally substituted with -OR 12 , -N(R x )(R y ), C 3-8cycloalkyl, 3-8-membered heterocyclyl, phenyl or 5-6-membered heteroaryl; each R 11 independently represents H or C 1-6 alkyl; each R 12 independently represents H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl or 5-10-membered heteroaryl, where C 1-6 alkyl from R 12 optionally substituted with one or more halogen, deuterium, -O(C 1-6 alkyl) or -N(R x )(R y ); each R 13 independently represents H or C 1-6 alkyl; each R 14 independently represents H, C 1-6 alkyl, C 3-8 cycloalkyl, phenyl, 5-6-membered heteroaryl or 3-12-membered heterocyclyl, where C 1-6 alkyl from R 14 optionally substituted with one or more halogen, -OH, -O(C 1-6 alkyl), -N(R x )(R y ), C 3-8cycloalkyl, phenyl, 5-6 membered heteroaryl or 3-12 membered heterocyclyl, and C 3-8 cycloalkyl, phenyl, 5-6-membered heteroaryl or 3-12-membered heterocyclyl from R 14 optionally substituted with halogen, C 1-6 alkyl or -N(R x )(R y ); each R 15 independently represents H or C 1-6 alkyl; and each R x and R y independently represents H, C 1-6 alkyl, C 3-8 cycloalkyl, -C(=O)(C 1-6 alkyl) or -C(=O)O(C 1-6 alkyl), where C 1-6 alkyl from R x or R y optionally substituted with halogen, 6-10-membered aryl, 5-10-membered heteroaryl, -NH2, NH(C 1-6 alkyl) or -N(C 1-6 alkyl)(C 1-6 alkyl), and C 1-6 alkyl from -C(=O)(C 1-6 alkyl) or -C(=O)O(C 1-6 alkyl) optionally substituted with -O(C=O)C 1-8 alkyl), where when ring A is phenyl, then -LR 6 does not represent -NH2 or -OCH3.

2. The compound according to claim 1, which is a compound of formula (II) (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, where X 1 represents N or CH, and n is 0, 1, 2, or 3.

3. The compound of claim 2, wherein the compound is a compound of formula (II-A) (II-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above.

4. The compound of claim 2, wherein the compound is a compound of formula (II-B) (II-B), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above.

5. The compound of claim 2, wherein the compound is a compound of formula (II-C) (II-C), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above.

6. The compound according to claim 1, which is a compound of formula (III) (III), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, where X 1 represents N or CH; and n is 0, 1, 2, or 3.

7. The compound of claim 6, wherein the compound is a compound of formula (III-B) (III-B), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above.

8. A compound according to any one of claims 1 to 7, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, wherein R 8 represents H, halogen, C 1-6 alkyl, -OR 12 , -N(R x )(R y ), -N(R 13 )C(O)R 14 , -N(R 13 )C(O)OR 14, -N(R 13 )C(O)N(R 13 )R 14 , -C(O)N(R 13 )(R 14 ) or C 3-6 cycloalkyl, where C 1-6 alkyl from R 8 optionally substituted by one or more R 7a ; A R 9 represents H, halogen, C 1-6 alkyl, -OR 12 , -CN or C 3-6 cycloalkyl, where C 1-6 alkyl from R 9 optionally substituted by one or more R 7a .

9. The compound according to claim 1, which is a compound of formula (IV): (IV), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, where each X 2 , X 4 and X 5 independently represents C, N, O, or S; each X 3 and X 6 independently represents C or N; and n is 0, 1, 2, or 3.

10. The compound of claim 9, wherein the compound is a compound of formula (IV-A): (IV-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above.

11. The compound of claim 1, wherein ring A is phenyl or 5-6-membered heteroaryl, and the phenyl or 5-6-membered heteroaryl of ring A is optionally substituted with one or more R 4 .

12. The compound of claim 11, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, wherein ring A is selected from the group consisting of phenyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, furan, thiophene, oxazolyl, isoxazolyl, isothiazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyrazinyl and triazinyl.

13. A compound according to claim 12, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, wherein ring A is phenyl, thiazolyl or pyridinyl.

14. A compound according to any one of claims 1-13, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, where R 1 and R 2 taken together with the N to which they are attached to form a saturated 4- to 5-membered monocyclic heterocyclyl, optionally substituted with one or more R 3 .

15. A compound according to any one of claims 1-14, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, where R 1 and R 2 taken together with the N to which they are attached to form azetidinyl or pyrrolidinyl, where the azetidinyl or pyrrolidinyl of R 1 and R 2 optionally substituted by one or more R 3 .

16. The compound according to claim 14 or 15, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, where each R 3 independently represents -OH, C 1-6 alkyl, C 1-6 alkoxy or -N(R x)(R y ), where C 1-6 alkyl from R 3 optionally substituted by R 3a .

17. The compound of claim 16, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, where each R 3 independently represents -OH, C 1-4 alkyl, C 1-4 alkoxy, -NH2, -NH(C 1-4 alkyl), -N(C 1-4 alkyl)(C 1-4 alkyl), -NH(C 3-6 cycloalkyl) or -N(C 1-4 alkyl)(C 3-6 cycloalkyl), where C 1-4 alkyl from R 3 optionally substituted by R 3a .

18. The compound of claim 17, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, wherein each R 3 independently represents -OH, -CH3, -CH2OH, -OCH3, or -NH2.

19. The compound according to claim 14 or 15, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, where R 1 and R 2taken together with the N to which they are attached to form a heterocyclyl selected from the group consisting of , , , , , , , , , , , , , , And 20. A compound according to any one of claims 1-13, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, where R 1 and R 2 taken together with the N to which they are attached to form a saturated 7- to 10-membered fused heterocyclyl, optionally substituted with one or more R 3 .

21. The compound of claim 20, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, where each R 3 independently represents C 1-6 alkyl or oxo.

22. The compound of claim 21, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, where each R 3 independently represents -CH3 or oxo.

23. The compound according to claim 20, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, where R 1 and R 2 taken together with the N to which they are attached to form a heterocyclyl selected from the group consisting of 24. A compound according to any one of claims 1-13, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, where R 1 and R 2 taken together with the N to which they are attached to form a saturated 7- to 10-membered spirocyclic heterocyclyl, optionally substituted with one or more R 3 .

25. The compound of claim 24, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, where each R 3 is a halogen.

26. The compound of claim 25, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, where each R 3 represents F.

27. The compound according to claim 24, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, where R 1 and R 2 taken together with the N to which they are attached to form a heterocyclyl selected from the group consisting of 28. A compound according to any one of claims 1, 2, 6, 9 or 11, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, where each R 4 independently represents halogen or -O-(C 1-6 alkyl).

29. The compound of claim 28, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, wherein each R 4 independently represents halogen or -OCH3.

30. A compound according to any one of paragraphs 1-29, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, where R 5 represents H, C 1-6 alkyl or C 3-8 cycloalkyl, where C 1-6 alkyl from R 5 optionally substituted with one or more halogen groups, -N(R x )(R y ), -OR 12 , And C 3-8 cycloalkyl from R 5 optionally substituted by one or more R 5b .

31. A compound according to any one of claims 1-30, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, where R 5 represents H, C 1-6 alkyl or C 3-8 cycloalkyl.

32. A compound according to any one of paragraphs 1-31, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, where R 5 is H or C 1-6 alkyl.

33. A compound according to any one of paragraphs 1-32, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, where R 5 represents H.

34. A compound according to any one of claims 1-29, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, wherein L is a bond or -O-(C 1-6 alkyl)-.

35. A compound according to any one of claims 1-29 or 34, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, wherein L is a bond or -O-(CH2CH2)-.

36. A compound according to any one of paragraphs 1-35, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, where R 6 represents -N(R x)(R y ).

37. The compound according to paragraphs 1-36, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, where R 6 selected from the group consisting of , , And .

38. A compound according to any one of paragraphs 1-35, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, where R 6 represents -N(R 13 )C(O)R 14 , -N(R 13 )C(O)OR 14 , -N(R 13 )C(O)N(R 13 )R 14 , -C(O)N(R 13 )(R 14 ) or -C(O)(C 1-6 alkyl)N(R 13 )(R 14 ).

39. A compound according to any one of claims 1-35 or 38, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, where R 6 represents -N(R 13 )C(O)R 14 or -C(O)(C 1-6 alkyl)N(R 13 )(R 14 ).

40. A compound according to any one of claims 1-35 or 39, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, where R 6 represents or .

41. A compound according to any one of paragraphs 1-35, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, where R 6 is a 3- to 12-membered N-containing heterocyclyl, optionally substituted with one or more R 6b .

42. A compound according to any one of claims 1-35 or 41, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, wherein L is a bond and R 6 is a 3- to 12-membered N-containing heterocyclyl, optionally substituted with one or more R 6b .

43. A compound according to any one of claims 1-35, 41 or 42, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, where R 6represents azetidinyl, pyrrolidinyl or piperazinyl, wherein azetidinyl, pyrrolidinyl or piperazinyl is optionally substituted by one or more R 6b .

44. A compound according to any one of paragraphs 1-35 or 41-43, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, where R 6 selected from the group consisting of 45. A compound according to any one of claims 1-44, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, wherein each R 8 and R 9 independently represents H, halogen, -N(R x )(R y ), -OR 11 , -N(R 13 )C(O)R 14 or -N(R 13 )C(O)OR 14 .

46. ​​The compound of claim 45, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, where each R 8 and R 9independently represents H, halogen, -NH2, -N(C 1-6 alkyl)(C 1-6 alkyl), -O(C 1-6 alkyl), -NHC(O)(5-6 membered aryl) or -NHC(O)O(C 1-6 alkyl), where 5-6-membered aryl from -NHC(O)(5-6-membered aryl) is optionally substituted with -N(C 1-6 alkyl)(C 1-6 alkyl).

47. The compound of claim 46, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, where each R 8 and R 9 independently represents H, F, Cl, -NH2, -N(CH3)(CH3), -OCH3, -NHC(O)(phenyl), or -NHC(O)O(CH2CH3), where phenyl from -NHC(O)(phenyl) is replaced by -N(CH3)(CH3).

48. A compound according to any one of claims 1-47, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, wherein each R 8 and R 9 represents H.

49. The compound of claim 1, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, wherein the compound is selected from Table 1.

50. The compound of claim 1, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, wherein the compound is selected from compounds 1-68 of Table 1.

51. A pharmaceutical composition comprising a compound according to any one of claims 1-50, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, and one or more pharmaceutically acceptable excipients or carriers.

52. A method of treating a disease or condition mediated by TDP-43, comprising administering to a person in need thereof a compound according to any one of claims 1-50, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, or a pharmaceutical composition according to claim 51.

53. The method of claim 52, wherein said disease or condition mediated by TDP-43 is a neurological disease or condition.

54. The method according to claim 53, characterized in that the neurological disease is selected from the group consisting of Alzheimer's disease, Parkinson's disease, Huntington's disease, traumatic brain injury (TBI), chronic traumatic encephalopathy (CTE), frontotemporal dementia (FTD), inclusion body myositis, Perry syndrome, corticobasal degeneration, spinocerebellar ataxia type 3, and amyotrophic lateral sclerosis (ALS).

55. The method according to claim 53 or 54, wherein the neurological disease or condition is a traumatic brain injury (TBI).

56. The method according to claim 53 or 54, wherein the neurological disease or condition is frontotemporal dementia (FTD).

57. The method according to claim 53 or 54, wherein the neurological disease or condition is amyotrophic lateral sclerosis (ALS).

58. The method according to any one of claims 53, 54 or 57, characterized in that the neurological disease or condition is sporadic amyotrophic lateral sclerosis or C9ORF72-associated amyotrophic lateral sclerosis.

59. The method according to any one of paragraphs 52-58, characterized in that neurodegeneration is reduced.

60. A method for modulating TDP-43, comprising contacting a cell with an effective amount of a compound according to any one of claims 1-50, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, or a pharmaceutical composition according to claim 51, characterized in that TDP-43 modulation includes modulation of TDP-43 incorporation into condensates, modulation of TDP-43 binding to RNA in condensates, modulation of TDP-43 aggregation, or modulation of TDP-43 protein-protein interaction.

61. A method for modulating the expression levels of genes regulated by TDP-43, comprising contacting a cell with an effective amount of a compound according to any one of claims 1-50, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, or a pharmaceutical composition according to claim 51.

62. The method according to claim 61, characterized in that the gene expression levels are intended for STMN2.

63. The method according to claim 61, characterized in that the gene expression levels are intended for POLDIP3.

64. A compound according to any one of claims 1-50, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 51 for use in the treatment of a disease or condition mediated by TDP-43.

65. Use of a compound according to any one of claims 1 to 50, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disease or condition mediated by TDP-43.

66. A kit comprising (i) a compound according to any one of claims 1-50, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the above, or a pharmaceutical composition according to claim 51 and (ii) instructions for use for the treatment of diseases or conditions mediated by the TDP-43 protein in individuals in need thereof.

Images